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Human response to drugs and environmental chemicals is often dramatically 
different from predictions made by conventional cell-based assays. Current in vitro 
methods for testing drug toxicity use a single cell type in a static culture environment, 
treated with a bolus dose. Such experiments do not capture the complex, dynamic 
response of the body to drug absorption, distribution, metabolism and excretion 
(ADME). Integrated pharmacokinetic-pharmacodynamic (PK-PD) models allow 
prediction of pharmacological outcome from a give dosage, but have limitations in 
building realistic models. A micro cell culture analog (µCCA) is a microfluidic device 
based on a physiologically-based pharmacokinetic (PBPK) model, with multiple 
chambers each representing an organ or tissue on a silicon chip, with these chambers 
connected to emulate the blood circulation.  
 This thesis work describes the combined approach of a PK-PD modeling and a 
µCCA platform, for testing the toxicity of chemotherapeutic agents. A PK-PD model 
was developed to predict tumor growth in a rat, treated with the chemotherapeutic 
agent, Tegafur. Various dosing scenarios and the effect of metabolizing enzyme levels 
were tested. As an experimental approach, the µCCA was improved in design, to 
accommodate 3-D hydrogel cell cultures and to enable a long-term operation. Using 
the µCCA, metabolism-dependent toxicity of Tegafur was observed. A PK-PD model 
for a µCCA was developed, and differential responses of three cell lines (representing 
the liver, tumor, and marrow) to the drugs in static and dynamic conditions were 
analyzed. A major challenge in developing microfluidic systems is prevention of 
 bubble formation. A microscale bubble trap was developed, and it was demonstrated 
that the presence of a bubble trap significantly alleviated the bubble interference. To 
address the issue of detection and analysis in a microfluidic device, an in situ, 
fluorescence optical detection system was developed and integrated with a µCCA, and 
a real-time detection of cell viability and metabolic activity was demonstrated.  
This thesis work demonstrates the use of a microfluidic device, µCCA for a 
pharmacokinetic-based drug toxicity study and its combination with a mathematical 
modeling for a quantitative analysis of cell death kinetics. We envision that the 
combined approach will be useful in improving the productivity of drug development 
process by supplementing animal and human studies.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 Motivation 
 
Drug development is a complex process, requiring knowledge from 
pharmacology, cell and molecular biology, chemistry and mathematics. Completion of 
a drug development process takes many years, and only one in ten drugs entering 
clinical trials reaches the market, making the drug discovery process a high-risk 
enterprise (Dingemanse and Appel-Dingemanse 2007). These aspects render drug 
development expensive, both in terms of cost and time. It is estimated that the cost of 
drug development is approximately $US 900 million per new drug (Kola and Landis 
2004). In addition, pharmaceutical companies are suffering from decreasing 
productivity with a decreasing number of new drugs each year. Based on a report by 
Kola and Landis, the average success rate in all therapeutic areas is approximately 
11%, and success rates in some therapeutic areas are even lower, such as 5% success 
rate for oncology drugs (Kola and Landis 2004). In this report, the analysis on the 
underlying causes of attrition reveals that a significant portion of drug candidates fail 
due to lack of efficacy or unforeseen toxicity. 
Typically, the drug development process consists of three main stages; 
preclinical in vitro testing, animal testing, and human clinical trials. In vitro testing 
typically involves a cell-based multi-well plate system (96-well plate or 384-well 
plate), where cells are exposed to drug candidates and the response is analyzed. A cell-
based assay system can provide human cell-specific responses to the drug candidate, 
but is an incomplete model as it does not provide the responses due to multi-organ 
interactions. In addition, cell lines cultured in vitro often do not provide the same 
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responses as the cells in vivo, which makes the human cultured cell model incomplete. 
While the whole body response to a drug can be obtained from clinical trials, testing 
drug candidates in humans is met with serious challenges in resources such as time 
and cost. Animal models have been used as an alternative approach to human clinical 
trials, such as rodents and nonhuman primates. However, animal models are also 
expensive and carry ethical issues. More importantly, the extrapolation of animal to 
human model does not always guarantee successful prediction of human response to a 
drug candidate. Therefore, it is of paramount importance to develop an improved in 
vitro model system that is predictive of human response. This is especially true with 
oncology drugs, where animal models are known to have a high unpredictability for 
human response (Booth et al. 2003). 
A mathematical modeling approach such as pharmacokinetic-
pharmacodynamic (Agoram et al. 2007) modeling has made significant contributions 
to the drug development process. Pharmacokinetics, which relates the administered 
dose of a drug to its concentration profiles in plasma and at a target site, evaluates 
drug absorption, distribution, metabolism and elimination characteristics, collectively 
known as ADME. On the other hand, pharmacodynamics examines the 
pharmacological effect of a drug at a given concentration at the target site. When 
combined together, PK-PD models aim to predict the time course of pharmacological 
effect after a given dosing regimen. The role of PK-PD models in drug discovery 
process has been emphasized in several review papers (Derendorf and Meibohm 1999; 
Perez-Urizar et al. 2000; Meibohm and Derendorf 2002; Karlsson et al. 2005; 
Dingemanse and Appel-Dingemanse 2007), but the impact of a PK-PD modeling 
approach has been limited due to several obstacles, including the problems of finding 
optimal parameters and inaccurate predictions due to unknown mechanism of action.  
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Recently, the advance in micro and nanofabrication technology has enabled 
development of a new research area called microfluidics (Whitesides 2006), and 
microfluidic systems with novel design have been shown to be ideal for attacking 
problems in cell biology, tissue engineering and drug discovery (Beebe et al. 2002; Li 
et al. 2003; El-Ali et al. 2006; Kang et al. 2008). The microscale nature of such 
systems makes it appropriate for addressing questions more relevant to the 
physiological situation in vivo (Breslauer et al. 2006). Furthermore, microfluidics is 
ideal for building a system with multiple compartments and connecting them to 
reproduce multi-organ interaction. Such a capability can be exploited to develop a 
‘body-on-a-chip’ device, as will be described in this dissertation.  
Although microfluidics is a useful and powerful technology in its own right, it 
has great potential for improving the drug development process when combined with a 
mathematical modeling approach, such as PK-PD models. A carefully designed 
microfluidic system can compensate for some of the drawbacks of PK-PD modeling 
system, and a quantitative mathematical analysis by PK-PD modeling can guide the 
design of a physiologically realistic microfluidic system and help researchers interpret 
the experimental result with greater insight. Currently, a mathematical approach 
combined with microfluidic systems has been primarily applied to the simulation of 
transport phenomenon only (Roy et al. 2001; Mehta and Linderman 2006; Zeng et al. 
2006), and there are few examples of mathematical models for the pharmacological 
effect of a drug on cells in a microfluidic system. We believe that the combined 
approach of PK-PD modeling and microfluidic systems has a great potential for a 
synergistic outcome, and will describe efforts for the realization of a ‘PK-PD model 
on a chip’. 
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1.2 Integrated Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling 
 
The term pharmacokinetics refers to the prediction of time-dependent 
concentrations of a substance in a living system (Gerlowski and Jain 1983). It 
examines drug absorption, distribution, metabolism and elimination, collectively 
known as ADME, which determines the disposition of the drug within an organism. A 
pharmacokinetic model attempts to predict the concentration profile of a drug in the 
blood or at the target site from a given dose, as well as the values of pharmacokinetic 
parameters such as clearance rate and half-life. Predicting pharmacokinetics prior to 
the clinical phase of drug development has been shown to be useful, especially in the 
selection of dosages in the clinical studies, which resulted in significant time-savings 
(Reigner et al. 1997). Several commercial PK modeling software packages are 
available on the market, including GastroPlus, SIMCYP, Cloe PK (Willmann et al. 
2003; Agoram et al. 2007).  
Pharmacodynamics refers to the time course of a drug’s pharmacological 
effect at the target site for a given target concentration. In short, pharmacokinetics 
studies ‘what the body does to the drug’, whereas pharmacodynamics characterizes 
‘what the drug does to the body’ (Holford and Sheiner 1982). The basis of 
pharmacodynamics is that the pharmacological effect of a drug is a function of its 
concentration at the target site. The pharmacological effect of a drug is modeled using 
a drug concentration as a variable, whose exact form will differ depending on the type 
and the pharmacological effect of the drug. Pharmacokinetics and pharmacodynamics 
characterize different realms of pharmacology, but when integrated, PK-PD models 
can provide a description of the time course of a drug’s effects in response to a dosage 
regimen (Derendorf and Meibohm 1999; Dingemanse and Appel-Dingemanse 2007). 
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To develop an integrated PK-PD model, concentration profiles of a drug in 
different organs are computed using a pharmacokinetic model, and the 
pharmacodynamic model is used to predict the pharmacological effect based on the 
concentration profile of a drug in a target organ. For example, if one builds a PK-PD 
model for an oncology drug, the concentration profile of a drug in the tumor 
compartment will serve as an input for a PD model, which simulates the tumor growth 
in the presence of the drug. Therefore, one can predict the growth kinetics of the tumor 
for a given dose of the drug (Simeoni et al. 2004). Integrated PK-PD modeling can be 
versatile and can be applied to dosing and scheduling determination (Friberg et al. 
2000), dosing individualization (Holford 1995), formulation development (Aarons et 
al. 2001) and toxicity assessment (Latz et al. 2006). Currently, use of PK-PD modeling 
is limited to early drug development phase and research applications only. Before PK-
PD models can be utilized more broadly, obstacles both in the area of PK and PD 
modeling must be overcome. A limiting factor for building a realistic model is that 
while some parameters are relatively easy to find either in the literature or 
experimentally, some parameters are extremely difficult to estimate, especially for a 
human model. Although it is possible to optimize the model and find the parameters 
given sufficient data, data for human parameters are sparse. Usually during the drug 
development process, a PBPK model for animal is built first to validate the PK-PD 
modeling approach. An animal model is easier to build than a human model, because 
animal data are more readily available. If the animal model can predict animal 
response with reasonable accuracy, then a human model is considered. However, 
verification in an animal model does not necessarily warrant the development of a 
human model, since extrapolation of an animal model to a human model is not always 
straightforward. 
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1.3 Previous Works in Micro Cell Culture Analog (µCCA) 
 
Initially, the prototype cell culture analog (CCA) device used for a proof-of-
concept study was described by Sweeney (Sweeney 1995). In this prototype, two milk 
dilution bottles and a spinner flask were connected using Teflon FEP tubes, and 
recirculation was achieved using peristaltic pumps. The glass bottles represented the 
lung and liver compartments, and the ‘other tissues’ compartment was represented by 
a glass reaction beaker. The system was the first prototype for a multi-compartment 
system with multiple cell types with fluid recirculation. The major limitations of this 
prototype were the non-physiological residence times in each chamber and an 
unrealistic ratio of liver-to-lung cells (Shuler 1996). Also the difficulty with stable 
operation of the device and obtaining time course data were limitations of the 
prototype system. An improved macroscale system was designed to mimic the 
physiological organ characteristics of a rat more closely than the prototype CCA 
(Ghanem and Shuler 2000). The CCA system used cells attached to microcarrier beads, 
which formed packed beds with cell culture medium recirculating through the beds. 
The main advantage of packed beds rather than a monolayer cell culture was that a 
higher cell density was achievable, providing a more realistic liquid-to-cell ratio, and 
medium residence times were closer to in vivo values. With this second generation, 
packed beds CCA device, several aspects of the device operation was examined, 
including mixing profiles, naphthalene distribution profile and the effect of reactor 
environment on cell viability. These systems were validated using naphthalene as a 
model drug, and the experimental results were shown to match with the prediction by 
a mathematical physiologically-based pharmacokinetic (PBPK) model.   
Although the concept of a cell culture analog (CCA) as a physical realization 
of a PBPK model has been validated, still there were several obstacles to overcome. 
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The liquid-to-cell ratio was about 1000:1 in the first prototype and 5:1 in the second 
generation system compared to the physiological ratio of 1:2. Conventional 2-D 
monolayer culture methods using standard culture flasks or wells also have liquid 
volumes greater than the volume of the cell layer. As the cells are exposed to 
environment that is completely different from their native environment, it is not 
surprising that many cells exhibit a different behavior when separated from their 
native tissue and cultured by conventional methods (Cushing and Anseth 2007). 
Secondly, early versions of CCA devices did not have physiologically realistic 
residence times in organ chambers. For example, the residence time for the liver 
chamber in the packed bed CCA device was 1.9 min, whereas the actual residence 
time for the liver in a rat is about 21.3 seconds (Ghanem and Shuler 2000). A PBPK 
model is based on physiological parameters such as blood flow rates and organ sizes, 
and a faithful realization of the PBPK model is achieved only if the residence times in 
each chamber are close to the actual values, because inaccurate residence times in 
organ chambers could distort a pharmacokinetic-pharmacodynamic response, not 
correctly reflecting physiological responses in the body. 
These limitations of macroscale CCA devices together with advances in 
microfluidic technology spurred the development of a microscale CCA (µCCA), 
which is a miniaturized version of the earlier CCA devices (Sin et al. 2004). It should 
be noted that the term ‘micro (µ)’ has been added to emphasize the microscale nature 
of the device. A cell culture analog device in microscale confers several advantages. 1) 
The natural length scales in tissue are order of 100 μm from capillary blood flow with 
cells on order of 10 – 20 μm in size; these dimensions can be easily mimicked in the 
microscale systems. This allows more realistic residence times and relative organ sizes, 
because the flow rate and the geometry of a microfluidic device can be precisely 
controlled using microfabrication techniques. 2) Being in microscale, fewer cells and 
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less test chemical are required, which enables the use of scarce tissue samples and 
novel compounds. Authentic tissue samples provide more realistic representations of 
in vivo environment. A system requiring small amounts of test chemicals would enable 
high throughput experiments with newly developed, novel molecules. 3) The small 
size of the device facilitates operation of multiple devices concurrently, which enables 
high throughput assays. Miniaturization also allows integration of the system with 
other components necessary for drug testing, such as sample analysis and optical 
detection. 4) Once a master device has been fabricated, subsequent devices can be 
made very cheaply, reducing the cost of fabrication for mass parallelization.  
The µCCA device was tested using naphthalene as a model toxicant 
(Viravaidya et al. 2004). Since the majority of naphthalene toxicity affects the lung, a 
rat lung cell line (L2) was cultured in the lung compartment, and a rat or human 
hepatoma cell line (H4IIE or HepG2/C3A) was cultured in the liver compartment. In 
this study, naphthalene was added to the circulating media in a µCCA device, and the 
viability of L2 (lung) and HepG2/C3A (liver) cells were tested by MCB staining for 
GSH. The results showed that after naphthalene was added to the medium, the GSH 
levels in lung and liver cells continuously decreased for the duration of the experiment, 
demonstrating the toxic effect of naphthalene on the cells. To verify that the 
HepG2/C3A (liver) cells were responsible for the observed cytotoxicity of the 
naphthalene in the µCCA, control experiments were performed where the liver 
chamber was empty. When HepG2/C3A (liver) cells were not present in the µCCA 
device, the cytotoxic effect of naphthalene was not observed, as manifested by high 
level of GSH in L2 (lung) cells. Further experiments with several metabolites of 
naphthalene including naphthoquinone, naphthol, and naphthalene dihydrodiol 
revealed that naphthoquinone was responsible for the toxicity of naphthalene in the 
µCCA with a dose-dependent response (Viravaidya et al. 2004). 
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1.4 Specific Goals and Outlines 
 
The ultimate goal of this thesis work is to develop an integrated system that 
combines a mathematical pharmacokinetic-pharmacodynamic (PK-PD) model and an 
experimental platform (µCCA), with a specific focus on a chemotherapeutic agent for 
colon cancer. As will be discussed throughout this thesis work, achieving this goal 
requires combination of different research disciplines, and this thesis work is divided 
into five chapters, which are organized as follows. In the second chapter, the 
development of a mathematical model will be described, which predicts the growth of 
tumor in the rat after administration of a drug for colon cancer. A physiologically-
based pharmacokinetic (PBPK) model is developed first, and combined with a 
pharmacodynamic (PD) model which describes the growth of tumor in a rat in the 
presence of a drug. The developed model is validated by comparing with experimental 
data from existing literature, and different dosing regimens are tested using the model. 
In the third chapter, a micro cell culture analog (µCCA) is developed to test the 
cytotoxic effect of a drug. The µCCA described in this chapter is based on the 
previous work by Sin and Viravaidya (Sin et al. 2004; Viravaidya et al. 2004), with 
two major modifications. First, the three-chamber µCCA is designed for specifically 
assessing the toxicity of a drug for colon cancer. Secondly, instead of 2-D monolayer 
cell cultures, cells are encapsulated in hydrogel, Matrigel or alginate, inside the 
chambers. The µCCA is used to quantify the cytotoxic effect of the drug on colon 
cancer cell line, hepatoma cell line, and myeloblasts, representing tumor, liver, and 
bone marrow, respectively. One of the requirements for testing the cytotoxic effect of 
a cancer drug is that cells need to be cultured for a relatively long-term (several days), 
as opposed to a short-term culture used in the previous naphthalene study (several 
hours). Several issues need to be overcome to achieve the operation of a µCCA for 
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several days, such as prevention of bacterial contamination, complete sealing of the 
device, and prevention of air bubble formation. The fourth chapter describes a 
microscale bubble trap to prevent the formation of air bubbles inside a µCCA. It is 
designed to trap bubbles with a large enough size to cause blockage of channels in a 
µCCA, and dramatically enhanced the operation of a µCCA. Devices in a microscale 
offer several advantages, but also results in limitations in detection and analysis of the 
system. The fifth chapter describes an in situ, fluorescence optical detection system 
(ISFODS), which is designed to be integrated with a µCCA for real-time measurement 
of cell viability or cell metabolic activity. The last chapter depicts development of a 
new µCCA, with specific purpose of incorporating 3-D hydrogel cell cultures in the 
device. Several improvements have been made over the original µCCA described in 
the third chapter, including elimination of bubble formation, better consistency in the 
operation, and easier implementation of high-throughput experiment. It is 
demonstrated that the µCCA can used for assessing the toxicity of a chemotherapeutic 
agent, and a corresponding PK-PD model is developed to describe the action of the 
drug in the device. 
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CHAPTER 2 
COMBINED PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) 
MODEL FOR TUMOR GROWTH IN THE RAT AFTER UFT 
ADMINISTRATION1 
 
2.1 Introduction 
 
Drug development is an expensive, time-consuming process. According to 
Adams et al., drug development cost ranges from $500 million to $2,000 million per 
new drug, depending on the therapy and the developing firm (Adams and Brantner). 
Even after the development and approval of drug to the market, the optimal dosing 
schedule and regimen remain uncertain. For example, the chemotherapeutic drug 5-
fluorouracil (5-FU) was developed several decades ago and has been widely used, but 
the optimal method of using this drug is still in debate (Goyle and Maraveyas 2005; 
Kelder et al. 2006). Finding an optimal dosing strategy is a difficult, expensive task 
that involves a large number of patients and a long period of time, especially for 
oncology drugs. In addition, the inherent metabolic and physiologic variations in 
patients result in patients responding differently to the same dosing regimen (Deeken 
et al. 2007). Pharmacogenetics, which studies the effect of genetic variations on 
responses of patients to drugs and attempts to tailor the dosing strategy for each 
individual patient, attempts to address this issue (Relling and Dervieux 2001; Park et 
al. 2003). Considering this individual genetic variation further complicates the 
problem of dose optimization because it is virtually impossible to perform such a large 
number of tests on each individual.  
                                                 
1  This chapter has been modified from an article Sung, J. H., et al. (2009). "A combined 
pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT 
administration." J Pharm Sci 98(5): 1885-904, with permission of Wiley Interscience. 
 15 
A mathematical approach such as a pharmacokinetic-pharmacodynamic (PK-
PD) model is a feasible alternative as it can link the administration regimen to patient 
response in terms of tumor growth (Simeoni et al. 2004). In this chapter, a PBPK 
model is developed to describe the concentration profiles of a chemotherapeutic drug 
administered in a rat, and a PD model is developed to describe the tumor growth 
kinetics in the presence of the drug. The PBPK model and the PD model are then 
combined together to predict the growth of tumor in a rat. The combined PK-PD 
model is used to find the optimal combination ratio of the drugs, and to test the effect 
of variation in the metabolizing enzyme level. Also a new dosing strategy to maximize 
the drug efficacy is tested. Such a model should be an effective guide towards rapid 
evaluation of treatment strategies and can be a useful tool for patient specific 
chemotherapy if levels of key enzymes in an individual are known. 
 
2.2 Methods 
2.2.1 Experimental Background for Model Development 
 
Colorectal cancer ranks second as a cause of cancer related deaths (Pasetto et 
al. 2006). Since the discovery by C. Heidelberger in 1957 (Heidelberger et al. 1957), 
5-fluorouracil (5-FU) has been the most widely accepted chemotherapeutic agent for 
colorectal cancer. 5-FU was developed based on the study conducted by Rutman et al. 
that rat hepatomas used the pyrimidine uracil more rapidly than other normal tissues 
(Rutman et al. 1954), implying that uracil metabolism can be a target for 
chemotherapeutic agents (Gill et al. 2003). 5-FU can be classified as an antimetabolite 
drug that is synthesized by substitution of fluorine for hydrogen in uracil. The 
mechanism of cytotoxicity of 5-FU has been ascribed to several factors including the 
misincorporation of fluoronucleotides into RNA and DNA, and to the inhibition of 
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nucleotide synthetic enzyme thymidylate synthase (TS). Although it is not clear which 
mechanism of action mainly contributes to the cytotoxic effect of 5-FU, the 
mechanism of action depends on 5-FU concentration, and other factors (Yoshikawa et 
al. 2001). It has been reported that the dysfunction of RNA can be achieved only when 
5-FU concentration is high (10-100μM) (Spiegelman et al. 1980), while DNA 
synthesis can be inhibited at lower 5-FU concentration (0.5-1.0μM) (Parker and Cheng 
1990). 
The catabolism of 5-FU is achieved mainly through the enzyme called 
dihydropyrimidine dehydrogenase (DPD), which is located primarily in the liver. DPD 
catalyzes the conversion of 5-FU to fluoro-5,6-dihydrouracil, and is the rate limiting 
step in the catabolism of 5-FU (Lu et al. 1993). About 80% of the administered 5-FU 
is degraded by DPD (Heggie et al. 1987). Since DPD plays such an important role in 
the catabolism of 5-FU, the relationship between the activity of DPD enzyme and the 
response of patients to 5-FU related chemotherapy has been studied extensively, in the 
expectation of using the DPD enzyme activity as a predictive marker for 5-FU related 
chemotherapy. It has been found that DPD expression is inversely related to the 
efficacy of 5-FU, that is 5-FU was less effective with higher DPD expression level 
(Ichikawa et al. 2003; Kornmann et al. 2003). 5-FU related toxicity has also been 
found to be closely related to the DPD activity. Mutations and single nucleotide 
polymorphisms (SNPs) can cause deficiencies in DPD enzymatic activity, and patients 
with DPD deficiencies have a reduced capacity to metabolize 5-FU and are at risk of 
developing severe toxic reactions (Wei et al. 1996; van Kuilenburg 2004; Deeken et al. 
2007). Based on these findings, individualization of 5-FU chemotherapy has been 
proposed (Park et al. 2003; Ploylearmsaeng et al. 2006). For example, the expression 
level of DPD enzyme can be tested and the dose can be reduced in case of patients 
with low levels of DPD activity. 
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The bioavailability of 5-FU has been shown to be unpredictable, especially 
after oral administration (Hahn et al. 1975). In addition, administered 5-FU is rapidly 
degraded into F-β-alanine by DPD, and the half-life time of the administered 5-FU in 
vivo has been reported to be only 10-20 minutes (Pinedo and Peters 1988). An oral 
prodrug of 5-FU such as Tegafur (tetrahydrofuranyl-5-fluorouracil, Ftorafur, FT) has 
been developed to achieve a better bioavailability and a more stable concentration 
profile of 5-FU after oral administration. Tegafur has no cytotoxic effects in vitro, but 
when it is administered in vivo, it is converted to 5-FU by the cytochrome p450 
enzyme system mainly in the liver (de Bono and Twelves 2001). The metabolic 
pathway of Tegafur and 5-FU is shown in Figure 2.1. Several isozymes of CYP450 
enzymes are known to be responsible for the conversion, including 1A2, 2A6 and 3A5 
(Komatsu et al. 2000). In addition, Tegafur can be converted to 5-FU by thymidine 
phosphorylase (TP) in the liver, small intestine and tumor tissues, or can be converted 
into 5-FU spontaneously in vivo (Tanaka et al. 2000). To enhance the therapeutic 
index of the drug, UFT was developed, which is a combination of uracil and Tegafur 
in a molar ratio of 4 to 1. Uracil is a natural substrate of DPD enzyme, therefore it 
competes with 5-FU and acts as a modulator of 5-FU catabolism (Malet-Martino and 
Martino 2002). The molar ratio of 4 to 1 was chosen because this ratio gave the best 
tumor selectivity in rats in a preclinical test (Fujii et al. 1979). 
 
2.2.2 Physiologically-based Pharmacokinetic (PBPK) Model Structure 
 
The PBPK model in Figure 2.2 consists of seven compartments, which are 
assumed to be homogeneously well-mixed and equilibrated with exiting blood. The 
only exception is the liver compartment for uracil, where the vascular and the tissue 
space were separated to describe the distinctively low uracil concentration in the liver. 
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Figure 2.1 Mechanism of Tegafur and 5-fluorouracil (5-FU) metabolism. 
Tegafur (FT) is metabolized to 5-FU mainly by P450 enzymes in the liver. 5-FU is 
further metabolized and exerts cytotoxic effect via RNA inhibition and DNA 
inhibition. 5-FU is mainly degraded by dihydropyrimidine dehydrogenase (DPD). 
Uracil, which is a natural substrate of DPD, inhibits the degradation. UFT is a 
combination of uracil with Tegafur in a molar ratio of 4 to 1. 
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Figure 2.2 Structure of a PBPK model 
Tegafur is converted to 5-FU mainly by P450 enzyme in the liver and the tumor 
compartment. Uracil and 5-FU are degraded by DPD enzyme and compete with each 
other. UFT is taken orally, therefore uracil and Tegafur starts in the lumen 
compartment in the model. 
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Tegafur and uracil are administered orally and the model starts with GI lumen 
compartment. It was assumed that Tegafur is converted to 5-FU in the liver and the 
tumor compartments (de Bono and Twelves 2001). Conversion in the gastrointestinal 
tract was assumed to be negligible since the main P450 enzyme responsible for the 
conversion is known to be active mainly in the liver (Yamazaki et al. 2001; Kajita et al. 
2003). 5-FU and uracil were assumed to be metabolized by DPD in the liver, tumor, 
and the blood compartment (de Bono and Twelves 2001; Ichikawa et al. 2003; van 
Kuilenburg 2004). 
Ordinary differential equations were used to describe the mass balance for each 
compound in compartments. The mass transfer between the blood and the organs was 
assumed to be limited by perfusion to the organs. It has been reported that 5-FU and 
uracil share a saturable transport system capable of rapid equilibration of these 
substrates across the cell membrane (Wohlhueter et al. 1980). Less is known about the 
transport of Tegafur across the cell membrane, but since Tegafur has a similar 
structure to 5-FU and uracil, we assumed that the transport of Tegafur was also rapid, 
and tested the hypothesis by evaluating the ability of the constructed model to fit to the 
concentration profiles of Tegafur.  
The enzymatic conversion of Tegafur by cytochrome P450, the degradation of 
5-FU by DPD and the metabolism of uracil were assumed to follow Michaelis-Menten 
kinetics. The degradation of 5-FU by DPD is inhibited by uracil by competitive 
inhibition, thus the equation that describes competitive inhibition was used to describe 
the inhibition kinetics (Adjei 1999). A software program, coded in C++, was written to 
solve the differential equations, implementing a 4th order Runge-Kutta algorithm. The 
same equations were also solved using ode45 function in Matlab (Mathworks, Natick, 
MA). 
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2.2.3 PBPK Model Parameters 
 
Physiological parameters such as the volume of organs and blood flow rates 
were taken from the literature, with the weight of a rat assumed to be 220 grams 
(Davies and Morris 1993; Quick and Shuler 1999). All other major organs that were 
not modeled specifically in the PBPK model were lumped into either the well-
perfused organ or the poorly-perfused organ compartments. The size of the tumor was 
assumed to be 1 gram, which was close to the average size of tumors in the study by 
Kawaguchi et al. (Kawaguchi et al. 1980), and 0.25 ml/min/g tissue of blood flow rate 
was calculated from Farris et al. (Farris et al. 1985), which is also close to the value 
found in Vaupel et al. (Vaupel et al. 1989). Physiological parameters used in the 
simulation are listed in Table 2.1. 
The tissue-to-blood partition coefficients were calculated by the method of 
Poulin and Theil, which predicts partition coefficients based on n-octanol-water 
partition coefficients and the tissue composition (Poulin and Theil 2002). Rat tissue 
composition data used in the calculations were also taken from Poulin and Theil 
(Poulin and Theil 2002). A homogeneous distribution was assumed when partition 
coefficients were used to describe the distribution of the drugs. An effort was made to 
make as few changes as possible to the values of calculated partition coefficients. 
However, it was necessary in some cases to make some modifications to the values of 
partition coefficients to achieve an acceptable fit. The partition coefficient values used 
in the simulation are listed in Table 2.2. 
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Table 2.1 Physiological values 
All values were taken from Quick,(Quick and Shuler 1999) except the values for the 
tumor.  
a. Tumor weight is assumed to be 1.0 gram, taken from the average tumor size 
from Kawaguchi (Kawaguchi et al. 1980).   
b. 0.25 ml/min/g tissue was assumed, from Farris et al. (Farris et al. 1985).  
c. In case of uracil in liver, 10% vascular space was assumed (Jain 1988). 
d.  Well perfused organs include kidney and lung 
e. Poorly perfused organs include muscle, bone and skin. 
 
 
 
 
 
 
 Organ weighta Blood flow rate (ml/min)a
Blood 13.2 76.45 
Gut 7.92 17.1 
Liver 8.8 19 
Tumor 1.0b 0.25 c 
Fat 15.4 38.9 
Well perfused organse 8.5 38.9 
Poorly perfused organsf 165 11.4 
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Table 2.2 Partition coefficientsa 
a. In case where the parameter was adjusted, the adjusted values are shown in the 
parenthesis 
b. Partition coefficients for tumor were adjusted to fit to data. 
 
 
 
 
 
 
 
 
 5-FU Tegafur uracil 
Gut 0.794 0.808 (0.6) 0.793 
Liver 0.759 (1.635) 0.768 (0.326) N/A 
Tumor b 0.5 0.895 0.793 
Fat 0.169 0.336 0.153 
Well perfused organs 0.826 0.834 0.825 
Poorly perfused 
organs 
0.795 0.800 0.795 
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Biochemical parameters such as Vm and Km for reactions based on Michaelis-
Menten kinetics could be obtained from studies using rat liver homogenates or 
microsomes. However Vm parameters measured in vitro are often not representative of 
in vivo parameters. Our approach was to use the literature to make initial estimates of 
parameters and then to modify the kinetic parameters based on optimization routines 
to make a good fit to existing experimental animal data. The rate of absorption into 
gastrointestinal tract was estimated under the assumption that the drug was absorbed 
completely within 30 minutes (Borner et al. 2002). IC50 (concentration of uracil that 
shows 50% inhibition) values for the degradation of 5-FU is known to be about 18 μM 
(Tatsumi et al. 1987), but the Ki value for competitive inhibition of uracil was not 
available from the literature. Therefore, the inhibition constant was made adjustable to 
fit the experimental data, using 18μM as the starting value for the optimization. Since 
uracil and 5-FU compete for the same DPD enzyme, they inhibit the activity of DPD 
on each other. Appropriate inhibition terms were added to the equations describing the 
kinetics of both 5-FU and uracil. 
 
2.2.4 Curve Fitting Procedure 
 
Concentration profiles of three different compounds (5-FU, Tegafur and uracil) 
in four different organs (gut, liver, tumor and blood) for two different dosing 
conditions were fitted to the experimental data from literature (Kawaguchi et al. 1980). 
Curve fitting procedure was done by a standard weighted least square method (Jacobs 
and Institute of Mathematics and Its Applications. 1977) and a lsqnonlin routine of the 
optimization toolbox in the Matlab software (Mathworks, Natick, MA) was used. The 
weight of 1/yi was given, where yi is the model solution at time point i. Since we tried 
to fit the concentration profiles of three different compounds in several different 
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organs, a systematic approach was required. In the first step, we took the data for the 
case where only uracil was administered. The parameters that were made adjustable 
were Vm and Km values for uracil metabolism, and the absorption constant for the 
absorption of uracil in the gut. After the fitting, uracil clearance from the tumor 
compartment was ignored since the adjusted value of Vm was low and clearance from 
the tumor compartment was negligible. In the second step, we took the data for the 
case where only Tegafur was administered (without uracil), and parameters related to 
the metabolism of Tegafur were optimized. In this step the parameters that were made 
adjustable were Vm values of CYP450 enzymes in the liver and the tumor, the 
absorption constant for Tegafur in the gut, and the partition coefficients of Tegafur in 
the gut and the liver. The third step was to take 5-FU concentration profiles from the 
same condition (administration of Tegafur only), and use them to fit the parameters for 
the metabolism of 5-FU. The adjustable parameters were Vm values of DPD enzyme, 
and partition coefficients of 5-FU in the gut and the liver. Clearance of 5-FU from the 
blood was ignored since the adjusted value was low and contribution of 5-FU 
clearance from the blood was negligible. Having optimized the parameters involved in 
the metabolism of uracil, Tegafur and 5-FU, the only parameters left were those that 
are involved in the interaction between 5-FU and uracil via inhibition of DPD enzyme. 
In the fourth step, the uracil concentration profiles from administration of UFT 
(combination of uracil and Tegafur) were used to optimize the value of the inhibition 
constant for uracil degradation (ki_u). Subsequently 5-FU concentration profiles were 
taken and used to optimize the inhibition constant for 5-FU degradation (ki). The 
optimization of the inhibition constants was done in an iterative manner, where after 
the fifth step we went back to the fourth step and re-did the optimization until the 
optimization results were consistent. The resulting optimized kinetic parameters are 
summarized in table 2.3. 
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Table 2.3 Kinetic parameters 
Parameter Value Description 
Vm, CYP, liver (nmol/min/g tissue)  
997 
(52.1) 
Vmax for CYP450 enzyme in liver a 
Km, CYP, liver (nmol/ml) 2700 Michaelis Menten constant b 
Vm, CYP, tumor (nmol/min/g tissue)  504 Vmax for TP enzyme in tumor 
Km, CYP, tumor (nmol/ml) 2700 Michaelis Menten constant 
Vm, DPD, liver (nmol/min/g tissue)  
250.7 
(192) 
Vmax for DPD enzyme in liver c 
Km,DPD, liver (nmol/ml) 40 Michaelis Menten constant d 
Vm, DPD, tumor (nmol/min/g tissue)  16.2  Vmax for DPD enzyme in tumor 
Km,DPD, tumor (nmol/ml) 40 Michaelis Menten constant 
kabs,FT (g/min)  1.29  Absorption coefficient for FT 
kabs,Uracil (g/min)  0.0164 Absorption coefficient for uracil 
Ki (nmol/ml)  20 Inhibition constant of 5-FU in liver 
Ki_U (nmol/ml)  10 Inhibition constant for uracil in liver 
Ki_T 5 Inhibition constant for 5-FU in tumor 
CLFT (ml/min)  1 Systemic clearance rate of FT 
CLFU (ml/min)  0.1 Systemic clearance rate of 5-FU 
Vm,Uracil,L (nmol/min/g tissue)  45 Vmax for uracil clearance in liver 
Km,Uracil,L (nmol/g tissue)  2 Michaelis Menten constant 
Vm,Uracil,B (nmol/min/g tissue)  10 Vmax for uracil clearance in blood 
Km,Uracil_B (nmol/g tissue)  2 Michaelis Menten constant 
ku_out(nmol/min) 100 
Transfer coefficient from tissue space 
to vascular spacee 
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Table 2.3 (Continued) 
ku_int(nmol/min) 18.3 
Transfer coefficient from vascular 
space to tissue spacee 
a. The value inside the parenthesis was calculated from literature and used as a 
starting value for the optimization, and the value outside is the optimized parameter. 
Vmax value of 0.95 nmol/min/mg protein was obtained from Yamazaki(Yamazaki et 
al. 2001) and converted to per g tissue basis by multiplying by microsomal protein 
content of 54.9 mg/g tissue, calculated from Quick (Quick and Shuler 1999). The 
microsomal protein needed to be converted to per g tissue basis before multiplying 
using the organ volume and weight data from Davies (Davies and Morris 1993).  
b. Km value was taken from Yamazaki (Yamazaki et al. 2001) and was used 
without modification. 
c. Calculated from Vmax value from Ikenaka (Ikenaka et al. 1979), which is 0.51 
nmol/mg protein/min. The Vmax was converted to per g tissue basis by multiplying by 
total protein content in liver, which is 376.3 mg/g tissue, obtained from Quick (Quick 
and Shuler 1999). The total protein content needed to be converted to per g tissue 
basis before multiplying, using the organ volume and weight data from Davies (Davies 
and Morris 1993).  
d. Km value taken from Ikenaka (Ikenaka et al. 1979).  
e. Transfer coefficients between the tissue space and the vascular space of liver 
for uracil were obtained by fitting 
f. For other parameters refer to the methods section. 
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2.2.5 Pharmacodynamic (PD) Model 
 
To model the growth of tumor cells under the influence of 5-FU, three 
different pharmacodynamic models were used. The three PD models that were tested 
are, 1) a cell cycle phase-specific model, 2) transit compartment model, and 3) dual 
transit compartment model with two sets of transit compartments. The schematic 
representations of the three PD models are shown in Figure 2.3.  
 
1) Cell cycle phase-specific model 
 
SRSSSSS
S CCC)C/C1(C
dt
dC  Kkkk rssrg   (2.1) 
 
RRS
R CCC
dt
dC  drssr kkk      (2.2) 
 
FUEC
FUKK
50
max

        (2.3) 
 
5-FU is generally known to be cell cycle specific and cause S-phase arrest 
(Yoshikawa et al. 2001). This property can be characterized by using a two-
compartment model, which separates the total cell population into sensitive (Cs) and 
resistant groups (Cr) (Mager et al. 2003). The first-order rate constant ksr and krs refer 
to the rates of cell cycling between the two populations. kg and kd refer to the rates of 
cell growth and death, respectively. Css is the maximum cell number that can be 
reached due to space and nutrient limitation. K is the nonlinear function for the cell 
kill effect of the drug, described to follow Michaelis-Menten Kinetics. FU is the 
concentration of 5-FU, Kmax is a maximal cell kill rate, and EC50 is a Michaelis 
constant.     
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2) Transit compartment model 
 
C)C/C1(C
dt
dC
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C, Kmax, EC50, CSS, 5-FU and K are as defined above. The rate function of 5-
FU-induced cell killing (Kn) is related to K via a series of transit compartments (Lobo 
and Balthasar 2002). τ refers to the mean transit time in each compartment (Simeoni et 
al. 2004). This transit compartment model is useful for modeling the pharmacological 
effect of compounds that may be mediated by time-dependent transduction, and when 
there is a time lag in the final drug response (Sun and Jusko 1998). It can be 
particularly useful for modeling the cell kill effect of chemotherapeutic agents, since 
chemotherapeutic agents exert their effects through a complex mechanism of action, 
and in many cases there is a time delay in the observed effect after the administration 
of the agents (Lobo and Balthasar 2002). One advantage of the transit compartment 
model is that a mechanistic knowledge about each step is not required to construct the 
model. The model contains a minimal number of drug (Emax and EC50) and system 
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parameters (τ) that may be applied to data and may provide a simple structure on 
which future knowledge of specific processes may be integrated (Mager et al. 2003). 
 
3) Dual transit compartment model 
 
CC)C/C1(C
dt
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SS  nng LKk    (2.10) 
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This is a modification of the transit compartment model. This model assumes 
that there are two independent mechanisms of action of the drug, and each mechanism 
of action is modeled by two separate sets of transit compartment models (K and L).  
The parameters used in the three PD models were determined by fitting the simulated 
growth curve to the growth curve of colon cancer cell line (HCT-116) under the 
influence of various concentrations of 5-FU. The experimental data was taken from 
the study by Yoshikawa (Yoshikawa et al. 2001). The lsqnonlin routine in the 
optimization toolbox of Matlab software was used to find the optimal parameter sets,  
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Figure 2.3 Pharmacodynamic models to simulate the growth of tumor cells 
(a) Cell cycle phase specific model. Cell population is divided into resistant and 
sensitive groups. Cell death occurs through K, which is a function of drug 
concentration (b) Transit compartment model where cell death is mediated by a series 
of transit compartments defined by a function of drug concentration (c) Dual transit 
compartment where two cell death pathways exist. 
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Table 2.4 Parameters for the pharmacodynamic models 
 
Cell cycle specific model 
Css (unitless) 90 
Kg (1/hr) 0.1 
Ksr (1/hr) 0.1 
krs (1/hr) 0.1 
Kmax (1/hr) 0.119 
EC50 (μM) 0.153 
Transit compartment model 
Kg (1/hr) 0.0597 
Css (unitless) 125 
Kmax (1/hr) 0.0985 
EC50 (μM) 0.329 
τ (hr) 2.97 
Dual transit compartment model 
Kg (1/hr) 0.07 
Css (unitless) 120 
Kmax1 (1/hr) 0.0602 
EC501 (μM) 0.0074 
τ1 (hr) 20.1 
Kmax2 (1/hr) 0.142 
EC502 (μM) 2.81 
τ2 (hr) 2.59 
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which solves a nonlinear least-square problem by minimizing user-defined function. 
We found the optimal parameter set by minimizing the difference between the model 
solution and the experimental data. The optimized parameters for the three models are 
listed in table 2.4. 
The PBPK model and PD model were then combined, by using the 
concentration profiles of 5-FU in the tumor compartment from the PBPK model as the 
input values for 5-FU concentration in the PD model. The combined model can model 
dynamically the tumor response to the drug, since the drug concentration changes as a 
time dependent variable, and the growth of tumor will change depending on the drug 
concentration it is exposed to. It was assumed that the transport of the drugs is not 
limiting, based on the study that 5-fluorouracil uses a facilitated transport mechanism 
and achieves a rapid equilibration across the cell membrane (Wohlhueter et al. 1980). 
The resulting growth kinetics of tumor was compared with the experimental result by 
Rustum, in which the tumor cells were inoculated into rats and the rats were treated 
with either Tegafur or UFT for a period of time (Rustum 1997). For optimization of 
parameters, the lsqnonlin routine in the Matlab software was used (Table 2.5). 
 
2.3 Results 
2.3.1 Construction of PK-PD model 
 
The result of parameter fitting for the PBPK model is shown in Figure 2.4 and 
2.5. The experimental results shown in the figures for comparison were taken from 
Kawaguchi et al. (Kawaguchi et al. 1980). In general, the PBPK model made a 
reasonably good fit to the experimental data in all organs. The model was able to make 
accurate predictions for Tegafur concentration profiles in all organs. It should be noted 
that the result shown in Figure 2.5(b) was not used for curve fitting. We used this 
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Table 2.5 Parameters for PD model for tumor growth in a rat 
 
Kg (1/hr) 0.012 
Css (mg) 14000 
Kmax1 (1/hr) 0.0075 
EC501 (nmol/ml) 3.8 
t1 (hr) 20 
Kmax2 (1/hr) 0.65 
EC502 (nmol/ml) 70 
t2 (hr) 2.59 
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Figure 2.4 PK profiles after Tegafur or uracil administration 
(a) Simulated and experimental concentration profiles of uracil after administration of 
uracil (33.6 mg/kg) (b) Tegafur after administration of Tegafur (15 mg/kg) (c) 5-FU 
after administration of Tegafur (15 mg/kg). Lines are the simulated profiles and dots 
are experimental data taken from literature (Kawaguchi, Nagayama et al. 1980). 
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Figure 2.5 PK profiles after UFT administration 
 (a) Uracil (b) Tegafur and (c) 5-FU after UFT administration (uracil 33.6 mg/kg  and 
Tegafur 15 mg/kg). Lines are simulated profiles and dots are experimental data taken 
from literature (Kawaguchi, Nagayama et al. 1980) 
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independent set of data to test the ability of the model to predict the Tegafur 
concentration profiles, and the result in Figure 2.5(b) shows that the constructed model 
is able to make predictions for Tegafur consistent with data. The predictions for uracil 
and 5-FU were fairly accurate, except the uracil concentration in the liver and 5-FU 
concentration in the tumor were predicted to have faster elimination than the observed 
pharmacokinetics, indicating possible binding events of the drug which were not 
included in our model. The observed uracil concentration in the liver was distinctively 
lower than the uracil concentration in the other organs, and if perfusion-limitation 
assumption was used, the partition coefficient of uracil in the liver would have to be 
reduced significantly to match the experimental data. Thus instead of using the 
partition coefficient approach, we assumed that there was limitation in the transport of 
the drug and separated the liver compartment into vascular space and tissue space. 
After fitting the transport coefficients across the vascular space and the tissue space, 
the uracil concentration profile in the liver matched the experimental data better. 
Three different pharmacodynamic (PD) models of tumor cells were tested. 
Figure 2.6 shows the simulation of the three models, with the measured response of 
tumor cells (HCT-116) treated with five different doses of 5-FU (Yoshikawa et al. 
2001). The phase-specific model in Figure 2.6(a) shows that it predicts the growth of 
untreated cancer cells fairly accurately. It also predicts the growth inhibition effect at 
early periods, but it is not able to predict the cell death at later times (after 80 hour). 
The transit compartment model in Figure 2.6(b) predicts the longer term cell death 
better. However, the prediction by the transit compartment model tends to become less 
accurate for lower drug concentrations and longer incubation times. Figure 2.6(c) 
shows the simulation result of dual transit compartment model, and the result shows 
that this model is able to predict the growth kinetics of tumor cells more accurately for 
all concentration and time ranges than the other models. 
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The PBPK model and the dual transit PD model were combined to predict the 
dynamics of tumor growth, which was compared with experimental results from 
literature (Rustum 1997).  Since the previously developed PD model simulates the 
growth of tumor cells in vitro, the growth pattern in the in vivo situation can be 
expected to be different. Therefore we tested the model while maintaining the 
structure, but allowing the parameters to be re-adjusted. The pharmacokinetic profiles 
of the drugs were obtained using the PBPK model using the same doses used in the 
paper, and the simulated concentration profiles were used in the pharmacodynamic 
model to predict the tumor growth. The result in Figure 2.7 shows that the combined 
PK-PD model was able to make good predictions for three different dosing conditions, 
which are control (no treatment), Tegafur 150mg/kg/day and UFT 60mg/kg/day for 26 
days. In case of Tegafur treatment, the model does not predict the re-growth of tumor 
after 12 days which may be the result of tumor developing resistance to the treatment. 
  
2.3.2 Optimization of Dosing Regimens 
 
We used the PK-PD model to examine various UFT dosing strategies. First the 
effect of the ratio of uracil and Tegafur was tested. To compare the efficacy and the 
toxicity of the drugs, the cell growth in the tumor was related to the efficacy of the 
drug and the cell growth in the blood was related to the toxic effect of systemic drug 
exposure to the body. The same model was used to simulate the growth of cells in the 
tumor and the blood compartment. Figure 2.8 show that the increase in the ratio of 
uracil and Tegafur results in higher 5-FU concentration and a slower cell growth in 
both the tumor and the blood compartment. A ratio that is too low will result in almost 
no toxic effect, but also no appreciable tumor reduction, whereas a high ratio will 
result in almost complete removal of tumor but a great amount of systemic toxicity. 
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Figure 2.6 Comparison of PD model simulation with experimental result 
(a) Phase-specific model (b) transit compartment model (c) dual-transit compartment 
model. Dots are experimental data from literature (Yoshikawa, Kusunoki et al. 2001) 
and lines are simulation results. 
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Figure 2.7 PK-PD model simulation for tumor growth in a rat 
The rat was treated with UFT 60 mg/kg or FT 150 mg/kg. Dots are experimental 
results from literature (Rustum 1997) and lines are simulation results. Shown in inset 
is the pharmacokinetic profiles of 5-FU in tumor for the two dosing conditions. 
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Figure 2.8 Simulation of cell growth with various combination ratios 
Simulated cell growth in (a) tumor and (b) blood compartment for various U:FT ratios. 
5-FU concentration profiles in each compartment are shown in smaller boxes. (c) 
Toxicity and efficacy index of UFT for various U:FT combination ratios.  
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In the tumor compartment, 5-FU concentration increases the most between 
ratios of two to four, whereas in the blood compartment a steeper increase occurs after 
the ratio of four. It is shown more clearly in Figure 2.8(c), with the predicted efficacy 
and the predicted toxicity of the drug. The efficacy index of the drug was calculated as 
the relative tumor reduction (zero being no reduction and one being complete 
elimination of tumor, compared to the tumor growth in the case of no treatment), and 
the toxicity index was calculated as ratio of cell death in the blood compartment (zero 
being no toxicity and one being complete cell death in the blood compartment 
compared to the cell growth in the case of no treatment). The overall index was 
calculated by dividing the efficacy index by toxicity index, thus a higher overall index 
means a higher tumor reduction with lower blood toxicity. The plot of overall index 
shows that the optimal combination ratio is achieved between combination rations of 
two and four, where the efficacy is the highest relative to the toxic effect. This optimal 
ratio of uracil to Tegafur that was predicted from our mathematical model agrees with 
the reported optimal combination ratio in experiment reported by Fujii (Fujii et al. 
1979). 
The effect of dihydropyrimidine dehydrogenase (DPD) activity was tested by 
varying the value of Vm for dihydropyrimidine dehydrogenase (DPD) enzyme, shown 
in Figure 2.9. Since DPD enzyme catalyzes degradation of 5-FU, it is predicted that a 
higher DPD activity will result in a low 5-FU concentration. With a high DPD activity, 
there was almost no tumor remission, but relatively rapid cell proliferation in the 
blood compartment. On the other hand, with a low DPD enzyme activity, there was a 
complete tumor remission, but also a complete cell death in the blood. Based on the 
simulation a high DPD activity will result in a weak tumor response while toxic side 
effects will also be negligible. A low DPD activity will result in complete remission of 
tumor, although a severe side effect is likely to make the dosing unacceptable. 
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Figure 2.9 Simulation of cell growth for various DPD activities 
Cell growth in (a) tumor and (b) blood compartment for various DPD activities, with 
5-FU concentration profiles shown in inset. Low DPD activity results in increased 5-
FU concentration, resulting in rapid cell death in both tumor and blood. High DPD 
activity results in reduced 5-FU concentration with rapid cell proliferation. 
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Due to the dramatic effect of changes in the DPD activity on the 
pharmacokinetic profiles of 5-FU, the dosage of UFT which would be effective at 
normal DPD activity becomes impractical with abnormal DPD levels. The main 
criterion for adjusting the dosage was the 5-FU level in the blood, since 5-FU in the 
blood will determine the systemic drug exposure. In the study by Rustum, the 
maximum tolerated dose (MTD) for a rat was 60mg/kg/day of UFT, three times daily. 
From our PBPK model with normal DPD activity, this dosing schedule resulted in the 
AUC of 470 nmol·min/ml in the blood. In case of abnormal DPD activity, the dosage 
was adjusted so that it would result in the same 5-FU AUC value. In case of low DPD 
activity, the original dose had to be reduced by 56%, whereas in case of high DPD 
activity, it was increased by 86%. In case of low DPD activity, changing the drug 
combination ratio did not have noticeable effect on the pharmacodynamic profile, 
whereas in case of high DPD activity, about 50% increase in the overall index of the 
drug resulted from changing the ratio of uracil to Tegafur (Figure 2.10). Therefore in 
case of a rat with a low DPD activity, even after reducing the dose, not much benefit is 
expected from combining uracil with Tegafur. 
In Figure 2.11, we tested the pharmacokinetic/pharmacodynamic profile of two 
different dosing strategies, pharmacokinetic modulating chemotherapy (PMC) and 5-
FU continuous infusion. PMC is a combination of 5-FU continuous infusion with 
periodic oral administration of UFT, which has been shown to enhance the response 
significantly compared to 5-FU infusion (Kusunoki et al. 2000). The total drug dose 
was kept same at 40mg/kg/day. The model simulation showed that continuous 
infusion of 5-FU results in a low concentration of 5-FU in the tumor, whereas UFT 
administration causes a spike in the 5-FU concentration. Consequently, the tumor 
growth is significantly reduced with PMC, whereas 5-FU infusion alone has a much 
weaker anti-tumor activity than PMC. 
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Figure 2.10 Effect of U:FT ratio on efficacy and toxicity of UFT 
(a) low DPD activity, (b) high DPD activity. In case of low DPD activity changing 
U:FT combination ratio does not result in enhancement of efficacy or toxicity profiles 
of the drug, whereas in case of high DPD activity, U:FT combination ratio of 2 to 4 
gives the highest efficacy relative to the toxic effect. 
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Figure 2.11 Simulation of pharmacokinetic-modulating chemotherapy (PMC) 
(a) Predicted tumor growth in response to two different dosing regimens, 
pharmacokinetic modulating chemotherapy (PMC), and continuous intravenous 
infusion of 5-FU (5-FU CVI). 5-FU concentration profile in tumor after (b) PMC (c) 
5-FU CVI. Total dosage of 5-FU was same at 40 mg/kg/day. Combination of oral UFT 
and continuous venous infusion (CVI) of 5-FU resulted in enhanced pharmacokinetic 
profile and tumor growth inhibition than the same dose of 5-FU CVI alone. 
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2.4 Discussion 
2.4.1 The construction of PBPK model and PD model 
 
The PBPK model was fitted to the concentration profiles of three compounds 
in four different organs for two different dosing conditions. In total, 24 concentration 
profiles were used for fitting the PBPK model. Simulation results of the developed 
PBPK model showed a good fit to the experimental data from literature (Kawaguchi et 
al. 1980), with exception of 5-FU concentration in the tumor and uracil concentration 
in the liver. In both cases the observed pharmacokinetics showed a slower clearance 
than predicted, which suggests possible binding mechanisms not included in the model. 
The most serious deviation occurred in case of 5-FU in the tumor after UFT 
administration, which implies that the simple competitive inhibition mechanism 
assumed in the model may not be sufficient to fully describe the interaction between 
5-FU, uracil and DPD enzyme. For example, it is possible that there may be different 
active sites on DPD enzyme for 5-FU and uracil, and the inhibition kinetics for 5-FU 
and uracil may be more complex. Another possibility is that in addition to the 
degradation by DPD, they may also be competing for the transport into cells, since 
they are known to share the same facilitated transport mechanism (Wohlhueter et al. 
1980).  
Three different models for tumor cell growth were tested and compared with 
experimental data for the colon cancer cell line (HCT-116) treated with various 
concentrations of 5-FU (Figure 2.6) (Yoshikawa et al. 2001). A cell cycle specific 
model is often used to model the growth of tumor cells treated with chemotherapeutic 
agents, since many chemotherapeutic drugs are known to be cell cycle specific (Mager 
et al. 2003). 5-FU is also known to be G1/S phase-specific (Yoshikawa et al. 2001), 
thus it is reasonable to divide the cell population into a sensitive and a resistant group. 
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A transit compartment model is also often used to model the growth of tumor cells 
under the influence of chemotherapeutic agent, where transit compartments are 
assumed to mimic the time delay in the process of cell killing (Sun and Jusko 1998; 
Lobo and Balthasar 2002).  
We also tested the modified form of the transit compartment model, with two 
different groups of transit compartments. The idea of having two different groups of 
compartments arose from the fact that there is more than one mechanism of action of 
5-FU on tumors. Currently there are three known mechanisms of action (DNA 
misincorporation by FdUTP, RNA misincorporation by FUTP and TS inhibition by 
FdUMP) (Longley et al. 2003). Since TS is an enzyme responsible for de novo 
synthesis of thymidylate, the cause of cytotoxicity by 5-FU can be roughly divided 
into either DNA based mechanism or RNA based mechanism. There is evidence that 
the primary mechanism of action depends on the concentration range of 5-FU; high 5-
FU concentration is known to cause RNA disruption, whereas low 5-FU concentration 
causes DNA disruption (Spiegelman et al. 1980; Parker and Cheng 1990; Yoshikawa 
et al. 2001). By incorporating two separate sets of transit compartments in the model, 
two separate mechanisms of action can be captured.  
The simulation result of the three different PD models showed that the dual 
transit compartment model showed the best fit to the experimental data. It is 
interesting to note that the optimized KC50 and τ values for the two sets of transit 
compartments differ from each other. KC50 and τ for the first set of transit 
compartments are 0.0074μM and 20.1 hours and KC50 and τ for the second is 2.81μM 
and 2.59 hours, respectively. Since DNA inhibition is known to be dominant at low 
concentration of 5-FU (Parker and Cheng 1990), the first set of transit compartments 
may represent the DNA inhibition mechanism. RNA inhibition is known to be 
dominant at high concentration of 5-FU (Spiegelman et al. 1980), therefore the second 
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set may represent the RNA inhibition mechanism. It is also interesting to note the 
difference in the τ values. τ represents a theoretical residence time which the cells stay 
in each transit compartment during the progression to the cell death, therefore low τ 
value represents an rapid response, whereas high τ value means slower response of 
tumor cells to the drug. In a study by Petak, colon carcinoma cell lines treated with 5-
FU went through either acute apoptosis or delayed apoptosis depending on their 
genotypes (Petak et al. 2000), also suggesting dual mechanism of action. We believe 
that the dual transit compartment model can be an adequate model to describe this 
dual action of 5-FU on tumor cells. However, the parameters for the two pathways 
were obtained by fitting and they do not have molecular basis. Relating the transit 
compartments in our model with specific states in the molecular pathways was not 
straightforward since the exact molecular mechanisms that mediate further 
downstream events have not been fully elucidated (Longley et al. 2003). However, 
there have been continued research efforts to elucidate molecular mechanisms of 5-
fluorouraicl toxicity (Takeda et al. 1999; Li et al. 2004; Chinery et al. 1997). As more 
information becomes available, specific molecular mechanisms could be integrated 
into the transit compartment model. 
 
2.4.2 Finding Optimal UFT Combination Ratios for Various DPD Activities 
 
In Figure 2.8, varying the combination ratio of uracil and Tegafur resulted in a 
significant change in the pharmacokinetic and pharmacodynamic profiles. Increasing 
uracil results in more inhibition of 5-FU degradation, improving the pharmacokinetic 
profile. In a study by Fujii, the optimal combination ratio was determined by 
comparing the tumor-to-blood ratio of 5-FU (Fujii et al. 1979). The rationale behind 
this approach was that the efficacy of the drug would be proportional to the 5-FU in 
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the tumor, and the systemic toxicity would be proportional to the 5-FU in the blood. 
Therefore, the ratio of uracil to Tegafur that gives the maximum value of the tumor-to-
blood ratio of 5-FU would be the most ideal ratio. The molar ratio of 4 to 1 was 
determined to be the optimal ratio of uracil to Tegafur, giving the highest tumor to 
blood ratio of 5-FU. Our PK-PD simulation results were close to the experimental 
result since the ratio of the efficacy and the toxicity index reaches maximum at the 
ratio of uracil to Tegafur between two and four. Increasing the combination ratio 
beyond that point would result in a better efficacy, but too much toxicity. We believe 
that this agreement further validates our PBPK model, since the model parameters 
were optimized based on the study by Kawaguchi (Kawaguchi et al. 1980), which is a 
separate study from Fujii (Fujii et al. 1979). In figure 2.9, we assessed the effect of 
having different DPD activities. The importance of DPD enzyme in 5-FU related 
chemotherapy has been widely recognized (Wei et al. 1996; Ichikawa et al. 2003; 
Kornmann et al. 2003; van Kuilenburg 2004). DPD activity in vitro in tumor cells is 
strongly related to 5-FU sensitivity such that the lower the enzymatic activity, the 
greater the cytotoxicity (Ichikawa et al. 2003). In vivo DPD activity can also be related 
to the efficacy of 5-FU; It was demonstrated that a high DPD level was associated 
with 5-FU resistance (Kornmann et al. 2003), and Salonga et al. reported that a 
colorectal cancer patients with a low DPD activity responded better to 5-FU treatment 
than the patients with a high DPD activity (Salonga et al. 2000). The DPD level has 
also been associated with toxicity of 5-FU. There is ample evidence that a deficiency 
of DPD is associated with severe toxicity after 5-FU administration (van Kuilenburg 
2004). Based on these findings, a pharmacokinetic-based test to prevent severe 5-FU 
toxicity has been proposed (Bocci et al. 2006). The individual variations in the DPD 
enzyme level is known to be quite common. According to a study on population 
characteristics of human DPD enzyme levels, 14% of the population would be at risk 
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of developing severe 5-FU related toxicity (Van Kuilenburg et al. 2002). In another 
study using 138 donor liver samples, DPD activity followed a normal Gaussian 
distribution, and the lowest DPD activity and the highest DPD activity showed about 
20 fold difference (Lu et al. 1995). It has also been found that there is a circadian 
variation in the DPD activity (Lévi et al. 1992). Therefore, quantitative analysis of the 
pharmacokinetic profiles of 5-FU in patients with different DPD activities is crucial to 
optimizing and individualizing the dosing strategy of 5-FU related chemotherapy. 
The PK-PD model predictions in Figure 2.9 agree with previous clinical 
findings. Low DPD activity caused unacceptable toxicity, whereas high DPD activity 
compromised the efficacy of the drugs. In addition, using the combined PK-PD model 
dosage was optimized in the cases of abnormal DPD level. In a clinical situation, the 
DPD enzyme level in a patient can be analyzed by measuring the DPD activity in 
tumor or liver tissue obtained from surgery. Measurement of DPD activity in 
peripheral blood mononuclear cells was suggested to circumvent the practical issue of 
obtaining biopsy samples (Lu et al. 1993). Advances in pharmacogenetics have also 
identified genetic mutations responsible for DPD deficiencies, allowing high-
throughput screening of DPD activity in a patient (Park et al. 2003; van Kuilenburg 
2004; Deeken et al. 2007). Combined with these methods, the PK-PD model may be a 
useful tool for the individual optimization of the dosing strategies of 5-FU based 
chemotherapy. 
Pharmacokinetic modulating chemotherapy (PMC) has been developed as a 
strategy to maximize the anti-tumor effect of 5-FU based chemotherapy. Continuous 
infusion provides a baseline of low 5-FU concentration while periodic administration 
of UFT provides an increase in the 5-FU concentration. In a study by Fujii, PMC 
greatly enhanced the pharmacokinetic profile of 5-FU and anti-tumor effects without 
severe toxicities (Fujii et al. 1989). In a clinical trial involving 58 patients having 
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hepatic colorectal cancer, combination of 5-FU infusion with periodic UFT 
administration gave a dramatic improvement in 5-year survival rate (59% vs. 27%) 
and a decrease in hepatic recurrence (34.2 vs. 18.4 months) compared to 
administration of UFT alone (Kusunoki et al. 2000). Such an enhancement in the anti-
tumor activity observed with combination of two different dosing regimens, although 
using the same drug, is attributed to a dual anti-tumor effect of 5-FU on cell cycle 
(Yoshikawa et al. 2001). In this study, where tumor cell lines were treated with 
various 5-FU concentrations, tumor cells showed different responses depending on the 
concentration. For example, G2 arrest was seen after 24-72 hour exposure to 10ng/ml 
of 5-FU, while G1 arrest was seen after 12-24 hour of exposure to 100ng/ml. These 
results suggest that 5-FU acts on the tumor cells via different pathways depending on 
the dose, and PMC exploits the dual pathways of 5-FU by exposing the tumor to 
different concentration ranges in a time dependent manner. A PK-PD model is an ideal 
tool to test such a hypothesis. Figure 2.11 shows that a significant enhancement in the 
pharmacokinetics of 5-FU can be achieved with PMC, resulting in enhanced anti-
tumor activity compared to 5-FU continuous infusion. It clearly demonstrates that 
even with the same total drug dose, the pharmacological effect of the drug can vary 
considerably simply by varying the administration strategy. 
Extrapolation of animal model analysis to human model is not always 
straightforward and the verification of animal model does not warrant the successful 
implementation of human model (Aarons 2005). However, during a drug development 
or risk assessment process, a rat model is often considered to be a surrogate species for 
a human model, because it is the most commonly used animal species for ADME 
(absorption, distribution, metabolism and excretion) characterization (Theil et al. 
2003). For extrapolation of animal to human, an allometric scaling have often been 
(Luttringer et al. 2003), and a corollary approach was used in rat to human 
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extrapolation by comparing the pharmacokinetics of structurally similar molecules 
(Williams et al. 1996). While incorporation of human physiological and anatomical 
data would be relatively simple, metabolism and disposition of the drugs may differ 
between different species. However, now it is well established that in vitro metabolism 
data obtained from microsomes or hepatocytes can be useful for the prediction of in 
vivo clearance of drugs with appropriate use of mathematical models and scaling 
factors to account for in vitro - in vivo differences and the physiology of the liver 
(Theil et al. 2003). We believe that the PK-PD modeling approach we used in this 
study for a rat provides a valid mathematical framework for developing a human 
model as well. 
 
2.5 Conclusion 
 
We developed a combined PK-PD model that describes the response of tumor in a 
rat to the administration of UFT. A PBPK model and a PD model were developed 
separately and fitted to experimental data in literature, and a combined PK-PD model 
was used to describe tumor progression in a rat. It was shown that this mathematical 
model can be used to test various dosing strategies and simulate the effects of 
variations in the enzyme levels. Furthermore, the model was used to optimize a dosing 
strategy to exploit the dual toxicity mechanism of 5-FU. This model should be useful 
in an effort to individualize cancer chemotherapy on a patient by patient basis. In 
addition, with the combination of a pharmacokinetic and a pharmacodynamic model, it 
can be useful in gaining more insight into the mechanism of the cytotoxicity of 5-FU. 
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CHAPTER 3 
SILICON MICRO CELL CULTURE ANALOG (µCCA) WITH 3-D 
HYDROGEL CULTURES FOR ASSESSING METABOLISM-DEPENDENT 
CYTOTOXICITY OF ANTI-CANCER DRGS2 
 
3.1 Introduction 
 
During the preclinical phase of drug development process, evaluation of a New 
Chemical Entity (NCE) is typically performed using cell-based assays, which are 
readily adaptable to a high-throughput format. However, current in vitro cell-based 
assays have limitations due to the fact that only a single cell type is used in the assay, 
and multi-organ interactions cannot be observed. Also, current multi-well plate 
systems are static systems in which cells are incubated with medium containing test 
compounds as a bolus dose. The in vivo situation is much more complicated; after 
administration, drugs undergo a complex process of absorption, distribution, 
metabolism and elimination (ADME). Consequently, changes in pharmacokinetic, 
pharmacodynamic (PK/PD) profiles due to organ interactions in vivo may result in 
revelation of unpredicted toxicity or lack of efficacy that would otherwise not become 
apparent until later stages of drug development. 
Another important limitation of current in vitro cell-based assay systems is that 
a 2-D monolayer culture of an established cell line is used, which may not replicate 
the physiological response in human tissue. For example, HepG2/C3A is a hepatoma 
cell line originated from human hepatocellular carcinoma, but lacks many liver 
specific functions. The issue of achieving authentic responses from cells can be 
                                                 
2 This chapter has been modified from, Sung, J. H. and M. L. Shuler (2009). "A micro cell culture 
analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent 
cytotoxicity of anti-cancer drugs." Lab Chip 9(10): 1385-94, with permission of Royal Society of 
Chemistry (http://www.rsc.org/publishing/journals/LC/article.asp?doi=b901377f ). 
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partially addressed with a 3-D hydrogel cell culture. In their natural environment, 
extracellular matrix (ECM) and cell-to-cell interactions play a significant role in 
maintaining the physiological function of cells in vivo through complex chemical and 
mechanical signaling mechanisms (Daley et al. 2008). Culturing cells in vitro in a 3-D 
hydrogel has been shown to help cells retain their native tissue-specific functions and 
differentiated state (Cushing and Anseth 2007). In particular, it has been noted that the 
combination of a microfluidic system with a 3-D hydrogel cell culture can improve the 
tissue specific functions of cultured cells, since it can easily mimic the native 3-D 
tissue environment with blood flow supplying oxygen and nutrients. The potential 
significance of 3-D hydrogel cell cultures in microfluidic systems has gained 
increasing attention recently (Choi et al. 2007; Kim et al. 2007; Wong et al. 2008). 
In this chapter we report incorporation of 3-D hydrogel cell cultures of 
multiple cell types into a μCCA for testing drugs for colon cancer. A μCCA was 
designed based on a human PBPK model, and 3-D hydrogel cultures of colon cancer, 
liver, and myeloblasts were incorporated into the μCCA using Matrigel and alginate as 
hydrogel matrix for cell encapsulation. Matrigel is a basement membrane matrix 
which is a complex mixture of various proteins including laminin and collagen 
(Brown et al. 2007; Wong et al. 2008). Alginate is a copolymer of mannuronate and 
guluronate, which forms a gel in the presence of multivalent cations (Peirone et al. 
1998). Both hydrogels are widely used for cell encapsulation. The effect of an anti-
cancer drug on each cell line was tested using the μCCA to assess tumor kill, 
hepatotoxicity, and hematological toxicity. There have been several reports of 
microfluidic systems for assessing toxicity of anti-cancer drugs (Fujii et al. 2006; Lee 
et al. 2007; Sugiura et al. 2008; Wu et al. 2008), but these systems cannot reproduce 
the pharmacokinetics of drugs. There are commercial 3-D cell culture system for drug 
screening such as the ones by Synthecon Inc. or Global Cell Solutions Inc. (Becker 
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and Blanchard 2007; Lederman 2007), but these systems cannot reproduce the PK-PD 
profiles and can only test the direct effect of a drug, rather than prodrugs. To our 
knowledge, this is the first report of a 3-D hydrogel microfluidic cell culture system 
with medium recirculation that examined the metabolism and the toxicity of an anti-
cancer drug on multiple cell types simultaneously. 
 
3.2 Materials and Methods 
3.2.1 Chemicals and Cell Line 
 
McCoy’s 5a medium was purchased from Sigma Aldrich (St Louis, MO). 
MEM medium, RPMI 1640 medium, and fetal bovine serum (FBS) were purchased 
from Invitrogen (Carlsbad, CA). A live/dead viability kit was obtained from 
Invitrogen. HEPES, sodium chloride, uracil, 5-fluorouracil, and Tegafur were 
purchased from Sigma Aldrich. The colon cancer cell line, HCT-116, was obtained 
from American Type Culture Collection (ATCC, Manassas, VA) and cultured in 
McCoy’s 5a medium (Sigma Aldrich) with 10% FBS. A hepatoma cell line, 
HepG2/C3A (ATCC), was maintained in MEM medium with 10% FBS. Myeloblast 
cell line Kasumi-1 was maintained in RPMI-1640 medium with 20% FBS. Cell lines 
were cultured in an incubator at 37Ԩ with 5% CO2. 
 
3.2.2 Design and Fabrication of a µCCA 
 
The methods for design and fabrication of a μCCA have been elaborated 
elsewhere (Sin et al. 2004; Viravaidya et al. 2004). In this study we designed a three-
chamber μCCA for liver, colon cancer and bone marrow cells (Figure 3.1). Each 
chamber was designed so that they would have residence times that closely match the  
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Figure 3.1 A mathematical PBPK model and a corresponding μCCA 
A μCCA consists of liver, tumor and marrow chamber, interconnected with channels 
mimicking the blood flow pattern in human body. The compartments inside the box in 
the left figure are fabricated on a μCCA chip shown on right, and the blood 
compartment and all the other organs are represented by medium reservoir, which is 
not shown in the figure, to match the dynamic hold up of fluid that would be retained 
in other tissues. Colon cancer cell line (HCT-116) is cultured in the tumor chamber, 
and hepatoma cell line (HepG2/C3A) is cultured in the liver chamber. Myeloblast cell 
line (Kasumi-1) was cultured in the marrow chamber. 
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physiological residence times of blood in the corresponding organs in the human body 
(Davies and Morris 1993). A medium reservoir that acts as a debubbler represents all 
other tissues. The flow rates and the pressure drops across a microfluidic network can 
be analyzed by an analogy to an electric circuit (Ajdari 2003). The resistance across 
channels and chambers were adjusted by controlling the geometries (widths and 
lengths) so that chambers would have the desired residence times at given chamber 
volumes and a flow rate. 
The μCCA chips were fabricated using conventional photolithographic 
techniques. The μCCA was drawn using a software AutoCAD (Autodesk, San Rafael, 
CA), and a mask was made by GCA/MANN 3600F Optical Pattern Generator 
(Ultratech, San Jose, CA). Photoresist Shipley 1813 (Shipley, Marlborough, MA) was 
spin coated on a 50 mm diameter silicon wafer at 3000 rpm, and the pattern from the 
mask was exposed using a contact aligner (AB-M HTG 3HR Contact Proximity 
Aligner, San Jose, CA). The pattern was etched by inductively coupled plasma ion 
etcher (Plasmatherm 770, Zurich, Switzerland) to 100 μm depth. After removing the 
photoresist, the silicon wafer was cut into 1 inch by 1 inch pieces with a wafer saw. 
To measure the fluid velocity more accurately, the movement of polystyrene 
microspheres (FluoSpheres, 10 μm, blue-green, Invitrogen, Carlsbad, CA) was 
recorded with a fluorescent microscope (Fisher Scientific; Pittsburgh, PA) and a CCD 
camera (Fisher Scientific), and the fluid velocity was calculated. The thickness of 
Matrigel inside a μCCA chamber was measured by comparing the fluid velocity in the 
presence of the gel with the velocity in the absence of the gel at the same volumetric 
flow rate. With a given flow rate, the presence of a gel would result in a shallower 
chamber, resulting in an increased fluid velocity. By comparing the fluid velocity in 
the two conditions, the thickness of the gel could be back-calculated. 
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3.2.3 Incorporation of Hydrogel into a μCCA and Assembly of a μCCA Device 
 
Incorporation of cell-embedded Matrigel (BD Matrigel™ Basement Membrane 
Matrix, 5 ml LDEV-Free, BD Biosciences, San Jose, CA) into a μCCA was achieved 
by gel formation on μCCA chips with the shrinkage of Matrigel during gelling process 
(Figure 3.2(a)). The MatrigelTM was thawed in a refrigerator overnight and diluted 
three-fold in McCoy’s 5a medium. A desired number of cells re-suspended in diluted 
Matrigel in a 1 ml centrifuge tube to the final concentration 1x107 cells/ml. The tubes 
were kept in an ice bath to prevent premature gel formation. A base frame with a 1 
mm thick silicone gasket (Grace Bio Labs, Bend, OR) on top was placed in an ice bath, 
and a μCCA chip was placed on top of the silicone gasket. 10 μL of cell-Matrigel 
mixture was pipetted onto a chamber. After 10 minutes at room temperature, 1 ml of 
DPBS was pipetted onto each μCCA chip, and the polycarbonate top housing was 
secured with screws. After the assembly, the μCCA devices were incubated at 37Ԩ for 
1 hour for complete gel formation. Since the shrinking process results in withdrawal of 
outside air through the inlet and outlet holes, 200 μL of cell culture medium was 
pipetted on the inlet and outlet holes to prevent air withdrawn into the device. 
To encapsulate cells in alginate, 1% (w/v) sodium alginate (10/60 LF sodium 
alginate, FMC biopolymer) was made in HEPES solution (15 mM HEPES, 117 mM 
sodium chloride), and filtered through a sterile 0.2 μm pore size syringe filter (VWR 
scientific, West Chester, PA). Cell suspension in the 1% alginate solution at 3x106 
cells/ml was prepared and 2 μL of the cell suspension was pipetted into a chamber in a 
μCCA followed by 30 mM calcium chloride solution (Figure 3.2(b)). After the gel was 
formed, the μCCA chip was flooded with DPBS and a polycarbonate top cover was 
closed. Figure 3.3(a) shows the schematic diagram of a μCCA with top and bottom 
housing pieces, and a picture of an assembled μCCA in Figure 3.3(b). 
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Figure 3.2 Incorporation of hydrogel into a µCCA 
(a) Schematic diagrams describing the incorporation of Matrigel hydrogel into a 
μCCA. Cell-embedded Matrigel is inserted into a chamber in a liquid state and the 
device is sealed with a plastic top cover and a bottom housing piece. After the sealing, 
the gel is formed by raising the temperature. (b) Incorporation of alginate hydrogel 
into a μCCA. A drop of cell suspension in alginate solution is placed inside a chamber 
and the gel is formed by addition of calcium chloride solution. By sealing with the top 
cover, a disk-shaped hydrogel is formed inside the chamber. 
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Figure 3.3 Assembly and operation of a μCCA 
(a) Schematic diagram showing how the μCCA is assembled. The silicon μCCA chip 
with features on top is sandwiched between the plastic top cover and an aluminum 
bottom housing with a recess. The sealing is secured by screws around the edges of 
the housing. (b) A picture of an assembled μCCA with red dye for visualization of 
channels and chambers. (c) Schematic diagram of operation setup of a single μCCA 
with medium recirculation. Medium is withdrawn from a reservoir, which also 
functions as a debubbler, and goes through a bubble trap for further prevention of 
bubble trapping inside a μCCA. After circulating through the channels and chambers 
in a μCCA, medium goes back to the reservoir for recirculation. (d) Picture of the 
μCCA system with multiple chips. 
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3.2.4 Operation of a μCCA and Cell Viability Analysis 
 
Before the assembly of a μCCA, sterilized PharMed tubings (0.25 mm inside 
diameter, Cole Parmer, Vernon Hills, IL) were installed on a peristaltic pump 
(Watson-Marlow, Wilminton, MA), and 99.5% ethanol (Sigma Aldrich) was passed 
through the tubing for 1 hour to remove air bubbles. Then the tubing was thoroughly 
washed with sterile water for 2 hours, and bubble traps were connected to the tubing 
and flushed with sterile water. A microscale bubble trap was designed to prevent small 
air bubbles from entering the μCCA and interfering with the flow (chapter 4). The 
whole system was placed inside an incubator. The flow diagram and a picture of the 
assembled system are shown in Figure 3.3(c) and 3.3(d), respectively.  
Cell viability inside the device was measured by staining the cells with 
live/dead staining solution (5 μM calcein AM and 5 μM ethidium homodimer-1 in 
DPBS, Invitrogen). The medium reservoir was switched to the live/dead staining 
solution and μCCA chips were perfused for 1 hour. The sample was analyzed by 
fluorescent microscope and a CCA camera. Fluorescent images of cells in a μCCA 
were taken, and the areas occupied by the live and dead cells were calculated using 
image-processing software CellProfiler (Broad Institute, Cambridge, MA). The 
viability of cells was calculated as the ratio of the live cells to the total cells (live + 
dead cells).    
 
3.2.5 96-well Microtiter Plate Cytotoxicity Assay 
 
In a 96-well microtiter plate assay, cells were resuspended in medium at the 
concentration of 1x106 cells/ml, and 100 μL of cell suspension was seeded into each 
well. After overnight incubation, the medium was replaced with medium containing 
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either 100 μM Tegafur, 5-fluorouracil (5-FU) or nothing (control). 100 μM uracil was 
also added to all wells to inhibit the rapid degradation of 5-FU (Kajita et al. 2003).  
 
3.2.6 Image Processing 
 
CellProfiler, a software designed for high-throughput image processing, was 
used for processing the live/dead images of cells inside a μCCA. Briefly, the image 
processing goes through following cycles. 1) Cropping of the original image. This was 
done to exclude the edge areas with non-uniform illumination. 2) The cropped image 
is converted to grayscale. 3) Background illumination function is calculated. 4) 
Calculated illumination function is applied to the grayscale image to create an image 
with more uniform background brightness. 5) The area occupied by the cells is 
calculated. 6) Number of cells inside the image is calculated. The steps 1 through 6 are 
shown in Figure 3.4. 
 
3.2.8 Simulation of Transport inside a μCCA 
 
Comsol multiphysics modeling software (Burlington, MA) was used to 
simulate the transport of calcein AM inside a μCCA with alginate. To save simulation 
time, geometries were reduced to 2D x-y plane. The boundary conditions and 
parameters used in the simulation are summarized in Table 3.1 and Table 3.2. The 
simulation was compared with experiment by injecting 5 μM Calcein AM solution in 
DPBS into a μCCA containing HCT-116 cell-embedded alginate gel and taking 
fluorescent images of the gel every ten minutes.   
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Figure 3.4 Steps of image processing of live cells stained with CalceinAM. 
1) Cropping 2) Conversion to grayscale 3) Calculation of illumination function 4) 
Applying illumination function 5) Calculation of occupied area 6) Calculation of cell 
number. 
 
 
 
 
 
 
 
 70 
 
Table 3.1 Parameters used in the simulation of diffusion of calcein AM in alginate 
Name description Value 
v Average fluid velocity 1.7*10-3m/min (from experiment) 
Dcalcein Diffusivity of calcein AM 2.4*10-8m2/min (Choi et al. 2007) 
Rho Density 1*103 kg m-3 
Mu viscosity 6*10-2 kg m-1min-1 
Vm 
Rate constant for calcein AM 
consumption  
5*10-4 1/sec (Choi et al. 2007) 
S Initial substrate concentration 5 μM 
 
 
Table 3.2 Boundary and sub-domain conditions used in the simulation of diffusion of 
calcein AM in alginate. N-S: Navier-Stokes, C-D: Convection-diffusion model 
Boundary N-S C-D  
Inlet 
Velocity, u0=0, 
v0=-v 
Concentration, c0=S 
Outlet Pressure, P0=0 Convective flux 
Others No slip Insulation/Symmetry 
Sub-domain N-S C-D  
Perfusion area ρ=rho, μ=mu D(isotropic) = Dcalcein 
Hydrogel area No convection D(isotropic) = Dethres 
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3.3 Results 
3.3.1 Verification of Design and Operation of a μCCA 
 
The residence times and the fluid velocities were measured by tracking the 
interface between water/fluorescein, and the movement of fluorescent beads, 
respectively (Table 3.3). Measurement of flow residence time in the liver chamber was 
not possible since multiple flow channels are merged into the liver chamber, and the 
interface between two liquids was not maintained. We were able to operate eight 
μCCA devices simultaneously for 3 days, maintaining good cell viability (>80%). The 
only limiting factor was the recirculation of cell culture medium. Recirculation 
eventually led to nutrient depletion and accumulation of metabolic wastes.  
 
3.3.2 Cell Culture in Hydrogel in a μCCA 
 
It was tested whether the assembly process was gentle on cells. The operation 
of a μCCA with the cell-embedded hydrogel was also tested after 48 hours of 
operation. Figure 3.5 (a) and (b) shows that cells maintained a high viability 
immediately after the assembly, and also after 48 hours of a μCCA operation. 
However, when myeloblasts (Kasumi-1) were also encapsulated in Matrigel and 
cultured with medium recirculation in a μCCA, unlike other cell types, they failed to 
remain inside Matrigel after 24 hours. These myeloblasts are a suspension cell type 
and displayed greater motility than the other cell types used. Therefore, they were 
encapsulated in alginate, which retained the myeloblasts better than Matrigel in the 
presence of flow in a μCCA. Figure 3.5(c) shows that myeloblasts encapsulated in 
alginate in the device remained healthy after 48 hours of culture in the device. 
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Table 3.3 Comparison of calculated residence times and velocities in each chamber 
with measured values. 
 Tumor Liver Marrow 
Calculation       
Residence time (s) 70 52 128 
Velocity (um/s) 71.5 160.7 53.6 
Measurement    
Residence time (s) 69.7±3.8 NA 136.5±2.9 
Velocity (um/s) 68.9±1.6 167.9±6.2 58.6±0.5 
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Figure 3.5 Pictures of live/dead staining of cells cultured in a μCCA. 
(a) Tumor cells in Matrigel (b) liver cells in Matrigel (c) myeloblast cells in alginate in 
the device immediately after the device was assembled and after 48 hours of a μCCA 
operation with medium recirculation. 
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The thickness of Matrigel was characterized by comparing the flow rate with 
and without the gel. The presence of Matrigel matrix inside the chambers of a μCCA 
would result in shallower chamber, and therefore higher flow velocity at a given 
volumetric flow rate. When multiple μCCA chips were assembled using the described 
protocol and the flow velocity in each chip was measured, the fluidic velocity 
increased by approximately 40% over the case when the gel was not inserted, 
implying the gel thickness of approximately 40 μm in a 100 μm deep chamber.  
The morphologies of tumor and liver cells embedded in Matrigel inside a 
μCCA were compared with the same cells cultured in 2-D monolayer in a μCCA. To 
culture cells in 2-D monolayer in a μCCA, cells were plated in corresponding 
chambers in a μCCA the day before, and after overnight incubation for cell attachment, 
a μCCA was assembled by closing the top and bottom base frames. The pictures 
shown in Figure 3.6 were taken after 2-days of a μCCA operation in both cases of 
Matrigel and monolayer culture in a μCCA. Initially cells are round immediately after 
being encapsulated in Matrigel (Figure 3.5(a) and 3.5(c)), and after two days they 
were observed to have more elongated morphology (Figure 3.6(a) and (b), left). 
However, the cells were less elongated when compared to the cells cultured in 2-D 
monolayer (Figure 3.6, right). The less elongated cell morphologies were similarly 
observed in cells encapsulated in Matrigel in a 96-well microtiter plate. 
 
3.3.3 Toxicity of Tegafur and 5-FU 
 
5-fluorouracil (5-FU) is an anti-cancer drug that has been widely used for 
colon cancer (Longley et al. 2003). However, 5-FU has an unpredictable 
bioavailability when taken orally, and is subject to a rapid degradation by the enzyme 
dihydropyrimidine dehydrogenase (DPD), resulting in a low response rate when  
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Figure 3.6 Morphology of tumor and liver cells cultured in Matrigel and in monolayer 
in a μCCA. 
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administered alone (Malet-Martino and Martino 2002). Tegafur is an oral prodrug of 
5-FU, and has a better oral bioavailability. It is not cytotoxic to tumor cells, but 
becomes cytotoxic after conversion to 5-FU by P450 enzymes in the liver. In addition, 
uracil is often added to Tegafur to inhibit the degradation of 5-FU by DPD enzyme. 
Uracil is a natural substrate of DPD, and competes with 5-FU for the enzyme. Since 
DPD is a major route for elimination of 5-FU, combination of uracil with Tegafur 
(often called UFT) significantly enhances the pharmacokinetic profile of 5-FU, 
consequently resulting in a better therapeutic index (see Figure 2.1) (Bissett et al. 
2000). 
The cytotoxicity of Tegafur on tumor cells was tested in a 96-well microtiter 
plate first. HCT-116 cells were incubated with medium containing 100 μM Tegafur 
for three days and cell viability was measured each day by live/dead staining (Figure 
3.7(a)). Uracil was added to the medium to inhibit rapid degradation of 5-FU by DPD. 
Cells incubated with 100 μM Tegafur maintained a high viability for three days almost 
comparable to the control (no drug), although on day 3 cell viability dropped slightly, 
possibly due to a spontaneous degradation of Tegafur into 5-FU in the culture medium 
(Ikeda et al. 2000). On the other hand, 100 μM 5-FU caused a significant decrease in 
the viability of tumor cells in a time-dependent manner, as expected.  
The cytotoxicity of Tegafur was tested in a μCCA containing HepG2/C3A 
(hepatoma cell line) in the liver compartment, HCT-116 (colon cancer cell line) in the 
tumor compartment, and Kasumi-1 (myeloblasts) in the marrow compartment. 100 
μM Tegafur with 100 μM uracil was added to the recirculating medium (Figure 3.7(b)). 
The response of tumor cells to Tegafur in a μCCA was different from that of tumor 
cells in a 96-well plate. Tumor cells treated with Tegafur showed significantly lower 
cell viability than the control cultures without Tegafur (p<0.01). This observation was 
consistent with the hypothesis that Tegafur was converted to 5-FU by HepG2/C3A 
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cells in the liver compartment and the metabolite, 5-FU, recirculated into the tumor 
chamber and exerted the toxic effect on the HCT-116 cells. We tested this by running 
the same experiment without HepG2/C3A cells. As expected, Tegafur showed a 
considerably weaker cytotoxic effect than when the liver cells (HepG2/C3A) were 
present in the system, as seen in Figure 3.7(b). A small drop in the cell viability 
observed with Tegafur without the liver cells is thought to be due to a low level of 
Tegafur conversion by HCT-116 cells and by spontaneous conversion, similar to the 
situation with HCT-116 cells treated with Tegafur in a 96-well microtiter plate. 
However, as observed in the result, the contribution of the liver cells to the conversion 
was significantly greater than the contribution of HCT-116 cells and the non-specific 
conversion, and the removal of liver cells from the system eliminated most of the 
cytotoxicity due to Tegafur. 5-FU showed toxicity to tumor cells in a time-dependent 
manner, as expected. It is notable that the cytotoxic effect of 5-FU was observed more 
quickly than the effect of Tegafur, which can be explained by the time needed for 
Tegafur to be converted to 5-FU. The effect of uracil as a modulator of Tegafur 
toxicity was tested in a μCCA by administering Tegafur without uracil (Figure 3.7(c)). 
As expected, tumor cells treated with Tegafur alone in a μCCA showed a higher 
viability than the cells treated with Tegafur and uracil in a μCCA. 
 The toxicity of 5-FU and Tegafur on liver cells and myeloblasts were 
measured, representing hepatotoxicity and hematological toxicity, respectively. Figure 
3.8(a) shows the viability of liver cells (HepG2/C3A) treated with Tegafur or 5-FU in 
a μCCA. In both cases Tegafur and 5-FU had cytotoxic effect on the liver cells, 
although the liver cells were considerably less sensitive to the drugs than colon cancer 
cell line (HCT-116). It is also notable that 5-FU had a greater effect than Tegafur at 
each time point, similar to Figure 3.7(b). The effect of Tegafur and 5-FU on 
myeloblast cell line Kasumi-1 was tested in two-day experiment in a μCCA (Figure  
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Figure 3.7 Cytotoxicity of Tegafur on tumor cells 
(a) Cytotoxicity experiment results of Tegafur in a 96-well microtiter plate. Tegafur 
does not exert cytotoxic effect on HCT-116 cells (colon cancer cell line), whereas 5-
fluorouracil induces cell death after two days. (b) In a μCCA with liver and tumor 
cells, Tegafur has cytotoxic effect on HCT-116 cells. When liver cells (HepG2/C3A) 
were removed, the cytotoxic effect of Tegafur was considerably reduced. (c) Effect of 
a modulator, uracil, on the toxicity of Tegafur in a μCCA with liver and tumor cells.  
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Figure 3.8 Cytotoxicity of Tegafur on liver and marrow cells 
(a) Toxicity of Tegafur and 5-FU on liver cells (HepG2/C3A) in a μCCA with liver 
and tumor cells. Both drugs showed toxicity on the cells, but liver cells are less 
sensitive to the drugs than tumor cells. (b) Toxicity of Tegafur and 5-FU on 
myeloblast cells (Kasumi-1) in a μCCA with liver, tumor, and myeloblasts in two-day 
experiment. Both 5-FU and Tegafur showed toxicity to the cells. The difference 
between the control and UFT treated myeloblasts was statistically significant (p<0.01). 
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3.8(b)). Myeloblasts showed decreasing viability in response to both 5-FU and 
Tegafur in a μCCA. The extent of cell death was similar to the tumor cells at 48 hour. 
 
3.3.4 Gradient Formation inside Alginate 
 
It has been known that the transport inside a hydrogel is dominantly diffusive 
(Brown et al. 2007). Due to the geometry of an alginate gel inside a μCCA, molecules 
would have to diffuse into the gel to reach the center area. Therefore, it was possible 
to form a gradient of chemicals across the area of hydrogel inside a μCCA. The 
formation of a gradient was analyzed by flowing Calcein AM solution through a 
μCCA. The Calcein AM is cell membrane permeable and can diffuse through alginate 
and into the cells. Once inside the cell, Calcein AM is hydrolyzed by intracellular 
esterase enzymes and becomes fluorescent, which is sequestered inside the cell since 
the hydrolyzed product is not cell membrane permeable. Due to the diffusion 
limitation inside alginate, cells located near the periphery will be stained faster than 
the cells located near the center. Figure 3.9(a) shows that the formation of a gradient 
results in differential fluorescent staining of cells. The mathematical simulation in 
Figure 3.9(b) also agrees with the experimental result that a gradient of Calcein AM is 
formed across the diameter of the circular gel. As verified by the experiment and the 
simulation using Calcein AM, it is expected that a gradient of nutrient would be 
formed inside the gel. Consequently, it was observed that after three days of operation 
there was a significant geometric variation in the viability of cells. Although this was 
undesirable for our purpose, this feature may have an application in case where the 
formation of gradient is desirable, such as in vitro liver zonation (Camp and Capitano 
2007). 
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Figure 3.9 Formation of gradient in alginate hydrogel inside a μCCA 
(a) Pictures of HCT-116 cells stained with calcein AM. As calcein AM diffuses into 
the gel, the cells in the peripheral area stain quicker than the cells in the center area. 
The time shown in the upper-right corner of the pictures is the time after the beginning 
of perfusion of the staining solution. (b) Mathematical simulation of diffusion of 
calcein AM into the gel inside a μCCA. Even after 40 minutes the concentration of 
calcein AM in the center area is maintained relatively low. In both cases the direction 
of the flow was from right to left. There was a time lag of approximately 30 minutes 
for the hydrolysis reaction to take place inside the cell and show fluorescent signal. 
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3.4 Discussion 
3.4.1 Long-term Operation of a μCCA 
 
The measurement of residence times of the flow in each chamber in a μCCA 
verifies that the fabrication of the device was done accurately according to the flow 
rate calculation. However, during three days of operation, occasional trapping of air 
bubbles inside the channels or chambers resulted in a drastic change in the flow 
distribution and cell death in the chambers which did not get enough supply of 
medium. Thus a way of preventing air bubbles from entering a μCCA during the 
operation was devised. Bubble prevention was more important in case of long term 
operation of the device (several days) than short term operation (several hours). Even 
after extensive flushing with sterile water before the start of experiment, air bubbles 
were eventually trapped within the system after operating for several days due to air 
leakage through the interface between the tubing and a μCCA. Installment of a bubble 
trap on the front end of a μCCA improved the bubble issue significantly, enabling 3-
day operation. 
 
3.4.2 3-D Hydrogel Cell Culture in a μCCA 
 
In this study, a hydrogel cell culture in a μCCA was explored using Matrigel 
and alginate, which have different properties and mechanisms of gel formation. 
Matrigel is a natural basement membrane matrix obtained from Engelbreth-Holm-
Swarm (EHS) mouse sarcoma, and is a mixture of various proteins including growth 
factors and extracellular matrix proteins such as laminin and collagen, which stays 
liquid at 4Ԩ but self-assembles into a gel when incubated at 37Ԩ (Brown et al. 2007). 
This feature allows formation of a gel after the sealing of a μCCA, since a gel can be 
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formed simply by raising the temperature, and there is no need to add extra reagent. 
Shrinking of a gel during gelling process provides space on top of the gel for medium, 
resulting in a thin layer of cell-embedded matrix. This characteristic has been 
exploited to create a thin layer of Matrigel in a microfluidic channel by filling a sealed 
channel with Matrigel and incubating the device at 37Ԩ (Frisk et al. 2005). We 
utilized this technique with modifications to create a thin layer of cell-embedded 
Matrigel inside a μCCA.  
On the other hand, alginate is a linear copolymer of mannuronate (M) and 
guluronate (G) which forms a gel in the presence of multivalent cations (Peirone et al. 
1998). Formation of alginate gel is achieved by adding calcium chloride solution to 
the alginate solution. The requirement of adding extra reagent for gel formation made 
it difficult to create a thin layer of cell-embedded hydrogel. Instead, a cylindrical 
shape of hydrogel (~3 mm in diameter) was created inside the cell culture chamber of 
a μCCA. The difference in the mode of gel formation and the resulting geometries of 
hydrogel inside the device would result in a different microenvironment within the 
hydrogel. For instance, the thin geometry of Matrigel formed essentially eliminated 
the transport limitation and gradient formation often observed in 3-D hydrogel 
structure. This was evident from a cell staining experiment, where cells were quickly 
and uniformly stained within 30 minutes after starting perfusion of the staining 
solution. In case of alginate, which has a greater diffusion length, a chemical gradient 
would be observed with cells exhibiting the stain in non-uniform manner.  
Three cell lines were used in this study; HCT-116, HepG2/C3A and Kasumi-1. 
HCT-116 is an epithelial cell originated from colorectal carcinoma, and represents 
tumor compartment. HepG2/C3A, representing the liver, is a derivative cell line of 
HepG2, and is originated from hepatocellular carcinoma. It has nitrogen metabolizing 
activity comparable to perfused rat livers, and relatively higher cytochrome P450 
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activity than HepG2 cells (Kelly 1994). Kasumi-1 is a myeloblast cell line originated 
from leukemia, and was chosen from the fact that neutropenia is one of the main 
hematological toxicities observed in patients treated with 5-FU related chemotherapy 
(van Kuilenburg 2004; Testart-Paillet et al. 2007). HCT-116 and HepG2/C3A are 
anchorage-dependent cell types and were well maintained inside Matrigel. Presumably 
these cells would attach to various proteins in the Matrigel. When Kasumi-1, which is 
suspension cell type, was cultured inside Matrigel, they escaped from the hydrogel 
matrix upon medium perfusion. From a separate study where the same cells were 
encapsulated in Matrigel and placed in a 96-well microtiter plate, they remained viable 
inside Matrigel for several days. Therefore, it seemed that the presence of fluid flow 
was causing the loss of cells from Matrigel in a μCCA. Since alginate retained 
myeloblasts better in the presence of flow than Matrigel, we encapsulated the cells in 
alginate and other anchorage-dependent cell types in Matrigel. 
One important factor in achieving a realistic pharmacokinetic profile of a drug 
in vitro is the authentic behavior of cells, especially liver cells. A microfluidic system 
with 3-D hydrogel cell culture can be a potential partial solution to the issue of 
achieving authentic cell response. When cells are cultured in a μCCA, ECM proteins 
constituting Matrigel can provide chemical signals while medium perfusion provides 
mechanical signals. Although cells are embedded in Matrigel and are not directly 
exposed to the flow, the Matrigel layer inside a μCCA is relatively thin (~40μm thick), 
and since Matrigel is easily deformed, the mechanical cues can be propagated through 
the 3-D matrix of Matrigel to the embedded cells. It has been found that chondrocytes 
embedded in collagen gels respond to mechanical stimulation by altered gene 
expression profiles and extracellular matrix synthesis (Hunter et al. 2002). 
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3.4.3 Toxicity of Chemotherapeutic Agents in a 96-well Plate and a μCCA 
 
When the cytotoxic effect of Tegafur and 5-FU on HCT-116 cells was tested in 
a 96-well microtiter plate, Tegafur showed only a slight cytotoxic effect, whereas 5-
FU caused significant cell death during the 3-day culture. A small drop in the viability 
of cells treated with Tegafur on day 3 is thought to be due to a small amount of 5-FU 
produced from spontaneous conversion of Tegafur in vivo (Tanaka et al. 2000). In a 
separate experiment, we observed a small but detectable P450 1A2 activity in the 
tumor cell line (HCT-116), although much lower than that of HepG2/C3A (data not 
shown). With P450 1A2 being one of the major enzymes involved in the conversion of 
Tegafur into 5-FU (Komatsu et al. 2000), incubation of Tegafur with HCT-116 cells 
could have generated a low level of 5-FU, which caused a small, but detectable 
toxicity to the cells. In contrast, Tegafur exerted toxic effect on cells when it was 
tested in a μCCA. In addition, combining uracil with Tegafur was shown to enhance 
the cytotoxic effect of Tegafur on tumor cells. The cytotoxic effect of Tegafur and the 
enhancement of anti-tumor effect of Tegafur by uracil observed are consistent with 
previous findings in animal and human clinical studies (Rustum 1997; Bissett et al. 
2000; Tanaka et al. 2000; Malet-Martino and Martino 2002).  
It is interesting to note that the response of tumor cells to 5-FU was greater in a 
μCCA than in a 96-well microtiter plate. This observation may be partially explained 
by the fact that when cells are cultured in monolayer in a 96-well microtiter plate, 
dead cells may detach from the surface and will not be included in the counting of 
dead cells, whereas when cells are encapsulated in a matrix in a μCCA, most of dead 
cells will be retained within the matrix even after cell death. Another explanation for 
the difference in the observed sensitivity of tumor cells to the drugs may be the 
combined effect of Matrigel environment and a microfluidic environment, such as 
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shear. It has been reported that the response of tumor cells to anti-tumor agents was 
drastically different when cultured in 3-D compared from when they were cultured in 
monolayer (Horning et al. 2008). Tumor cell cycle arrest induced by exposure to shear 
stress was observed by Chang et al (Chang et al. 2008). Consistent with the 
explanation, when cells were plated in monolayer in a μCCA and treated with 5-FU, 
the observed cytotoxic effect appeared to be weaker than when cells were in Matrigel 
in a μCCA (tumor cells seeded in monolayer in a μCCA showed 71±8.8% viability 48 
hours after 5-FU treatment, compared to 50±5.9% for the same cells in Matrigel in a 
μCCA). It is uncertain which factor contributes the most to the different response of 
tumor cells, and the effect may be synergistic.  
The responses of liver cells (HepG2/C3A) and marrow-related cells 
(Myeloblasts, Kasumi-1) to Tegafur and 5-FU were also examined. In general, the 
responses were consistent with tumor cells, in that both Tegafur and 5-FU showed 
toxicity to both the HepG2/C3A and Kasumi-1 cell lines, with slightly greater 
response to 5-FU than Tegafur. However, there were some quantitative differences in 
the responses, depending on the cell types examined. Liver cells were considerably 
less sensitive to Tegafur and 5-FU than tumor cells, whereas the sensitivity of 
myeloblasts to the drugs was similar to the tumor cells. Typically, hematological 
toxicity is a more serious, often dose-limiting toxicity of 5-FU related chemotherapy, 
whereas hepatotoxicity is a relatively less serious problem (van Kuilenburg 2004; 
Testart-Paillet et al. 2007), which is consistent with the observed response in a μCCA. 
The mode of action of Tegafur combined with uracil is an example of complex 
interaction of multiple organs; the conversion of Tegafur to 5-FU and inhibition of 5-
FU degradation by uracil mainly occur in the liver, whereas the cytotoxic effect of 5-
FU is observed in the tumor. Previously, in vivo experiments have been the only way 
to test the effect of a combination of Tegafur and uracil. For example, the optimal 
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combination ratio of uracil to Tegafur was determined based on a test using a rat 
where the concentrations of 5-FU in the tumor and the blood were measured after 
administration of various combination ratios (Fujii et al. 1979). However, doing a 
similar study in human clinical trials would be difficult, since the number of patients 
required would be high. We believe that the μCCA system can be useful in 
complementing animal and human studies. 
 
3.5 Conclusion 
 
A micro cell culture analog (μCCA) with 3-D hydrogel cell cultures was 
developed and used to test Tegafur, the oral prodrug of an anticancer drug, 5-
Fluorouracil. Matrigel and alginate were used to encapsulate cells that were inserted 
into chambers of a μCCA. Using a μCCA, the cytotoxic effect of Tegafur was 
observed, which was not seen in a 96-well plate. The toxicity of the drug on tumor 
cells, liver cells, and myeloblasts were assessed to quantify tumor killing effect, 
hepatotoxicity, and hematological toxicity, respectively. The response of those cell 
lines to Tegafur and 5-FU combined with uracil were consistent with previously 
published clinical results. These results demonstrate that a μCCA is able to test the 
metabolism-dependent toxicity of anti-cancer drugs. 
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CHAPTER 4 
MICROSCALE BUBBLE TRAP3 
 
4.1 Introduction 
 
Microfluidics is the technology of systems that process or manipulate small 
(10-9 to 10-18 liters) amount of fluids, using channels with dimensions of tens to 
hundreds of micrometers (Whitesides 2006). Advance in the microfluidics technology 
and has contributed to the development of a new research area known as ‘lab-on-a-
chip’ (Dittrich and Manz 2006; Haeberle and Zengerle 2007). In particular, integration 
of the microfluidics technology and a cell culture technique has yielded a ‘cells-on-a-
chip’, which can be exploited to answer biological questions that cannot be answered 
with conventional macroscale systems (Park and Shuler 2003; El-Ali et al. 2006). The 
advantages of microfluidic cell culture systems are many-fold. In addition to reduced 
sample consumption and an efficient heat and mass transfer, the small length scale 
creates laminar flow and a controlled gradient of chemicals (Keenan and Folch 2008). 
Moreover, the microscale length scale mimics that of biological systems, allowing 
researchers to create cellular environment mimicking physiological environment better 
than their macroscale counterparts (Bhadriraju and Chen 2002; Leclerc et al. 2004; 
Baudoin et al. 2007; Fisher and Peattie 2007). 
The technique for culturing cells in vitro has been well established. However, 
culturing cells in a microfluidic system requires biocompatibility of materials, good 
sealing of a device, maintenance of sterility during cell culture, and prevention of 
bubble accumulation within the system. Several of these issues with microfluidic 
                                                 
3 This chapter has been modified from an article, Sung, J. H. and M. L. Shuler (2009). "Prevention of 
air bubble formation in a microfluidic perfusion cell culture system using a microscale bubble trap." 
Biomed Microdevices 11(4): 731-8, with permission of Springer. 
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perfusion culture of mammalian cells have been discussed in detail (Kim et al. 2007). 
While some of these problems are manageable by careful selection of materials or 
protocols, bubble accumulation is an obstacle that is extremely difficult to avoid in a 
microfluidic system, particularly if fluid is recirculated through the device. Unlike 
macroscale systems, surface tension is often dominant at the microscale, causing air 
bubbles to stick easily to the inner surface. These air bubbles inside microscale 
systems are extremely difficult to remove. Occurrence of air bubbles not only 
obstructs the fluidic path and distorts the flow, but also can damage the cells at the 
liquid-gas interface. Any attempt to remove the bubbles by increasing the flow rate 
inside the system can also result in further damage to the cells due to shear. This issue 
is especially important in long-term microfluidic cell cultures, since small air bubbles 
tend to coalesce and accumulate.  
The accumulation of air bubbles has been a constant problem in microfluidic 
systems, and several strategies have been developed to solve the problem. To avoid 
capturing bubbles in a microscale free-flow electrophoresis chip, a semi-impermeable 
membrane or arrays of bubble-blocking microchannels has been used to block entry of 
bubbles (Kohlheyer et al. 2008). Meng and his colleagues reported a degassing plate 
with hydrophobic bubble capture area which can be distributed across a microfluidic 
device at critical locations (Meng 2006). Yang et al. developed an ultrasonic micro-
degassing device intended for used with portable dialysis system and evaluated the 
degassing process (Yang 2002). Although these novel strategies can remove bubbles 
in a microfluidic system, they are not always compatible with microfluidic cell culture 
systems which pose the additional requirement of maintaining cell viability. In 
addition, intricate modules may add complexity to the system which hinders consistent 
operation. One method is to integrate a bubble trap before the main system so that any 
fluid that goes into the main system is free of bubbles (Eddington 2006). Typically, 
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such bubble traps utilize the buoyancy of an air bubble, and capture bubbles by 
providing an area where bubbles can float and be separated from the flow. However, 
such a scheme depends on other parameters, such as the flow rate inside the device 
and the size of bubbles. In case of low Reynolds number fluid, the rising velocity of a 
spherically-shaped bubble is mainly determined by the drag and the buoyancy forces, 
and can be expressed by Stokes equation (Zheng and Yapa 2000), 
 
18μ
dgΔv
2      (4.1) 
where g is gravity acceleration, Δρ is the density difference between a bubble and 
ambient fluid, d is the diameter of a bubble, and μ is dynamic viscosity of ambient 
fluid. Since the rising velocity is proportional to the square of a diameter, it can be 
predicted from the equation that a smaller bubble will rise considerably slower than a 
bigger bubble. Depending on the flow rate and the dimension of a bubble trap, it is 
possible that a small bubble may still escape from the bubble trap and enter the cell 
culture area.  
Recently, Kang et al reported a practical analysis model of air bubble 
elimination through a gas-permeable PDMS microfluidic channels (Kang et al. 2008). 
In this study the authors used a positive pressure to force out the bubbles, and cultured 
human breast cancer cells (MCF-7) in a microfluidic device for 5 days by periodically 
removing bubbles. However, the disadvantage of this system is that the medium 
supply has to be stopped and cells are exposed to a high pressure during the bubble 
removal process. Another example is an active bubble trap and debubbler which can 
trap and remove air bubbles maintaining continuous flow in the microfluidic device 
(Skelley and Voldman 2008). It utilizes a pneumatic valve-like geometry to trap 
bubbles and removes the trapped bubbles by applying vacuum. Using this device, they 
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were able to trap bubbles up to 25 µl and remove them in under 3 hours. However, this 
device requires an additional vacuum connection to work. Moreover, the bubbles were 
removed through a restricted area, resulting in a slow bubble removal rate (0.0023 
µl/s), which means that if bubbles accumulate fast, it may eventually fill up the trap 
and invade cell culture area.  
In this chapter, we report a microscale bubble trap which mechanically traps 
air bubbles while allowing fluidic paths to be unhindered. It consists of two-layer 
PDMS channel structure; larger top-layer channels provide the space for bubbles, and 
narrower bottom-layer channels provide alternative fluidic paths. Rather than relying 
solely on the buoyancy of air bubbles in liquid, it physically traps the bubbles within 
the structure of two-layer channels and the barrier. Barriers located in the middle of 
the bubble trap acts as a sieve that blocks bubbles larger than the channel size in the 
main system, offering controllability over the size of bubbles captured. We 
demonstrate the ability of the bubble trap to confine air bubbles within the device, and 
examine the pattern of the flow to verify that the presence of the bubble trap does not 
cause distortion of the flow. The bubble trap was able to trap bubbles up to 10 µl, and 
the trapped bubbles could be easily removed by degassing the device for 15 minutes, 
resulting in the bubble removal rate of 0.01 µl/s. We also demonstrate that the 
presence of a bubble trap enhances the operation of microfluidic cell culture by using 
a micro cell culture analog (μCCA).  
 
4.2 Materials and Methods 
4.2.1 Materials 
 
PDMS monomer and curing agents Sylgard 184 was obtained from Dow 
Corning (Midland, MI), and Fluorescein was purchased from Sigma Aldrich (St. Louis, 
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MO). PharMed tubing with inside diameter of 0.25 mm (Cole Parmer, Vernon Hills, 
IL) was used to connect a bubble trap, a microfluidic device, and liquid reservoir. A 
peristaltic pump (Watson-Marlow, Wilminton, MA) was used to pump liquid into a 
bubble trap and a microfluidic device. Live/dead staining solution (calcein AM green 
and ethidium homodimer-1) was purchased from Invitrogen (Carlsbad, CA). 
 
4.2.2 Design of a Bubble Trap 
 
A bubble trap consists of a two-layer PDMS structure, as in Figure 4.1. The 
main function of the two-layer channels is to capture air bubbles while still allowing 
liquid flow. Because of the large surface area inside a microscale bubble trap, captured 
air bubbles fill the top channel but not the narrower bottom channels. Additional 
sieve-like barriers blocks further migration of trapped bubbles towards an outlet. The 
sizes of the sieve-like structures become smaller as they get closer to the outlet. The 
last sieve-like structure has the size of 100 μm, which is smaller than the narrowest 
channel in a main microfluidic device. Therefore, any air bubbles that are large 
enough to occlude the channels in the main microfluidic device will be trapped inside 
the bubble trap, whereas bubbles that were small enough to pass through the bubble 
trap will be able to pass through the main microfluidic device without being trapped. 
The device could be designed for trapping smaller bubbles (for example 10 μm), if 
smaller channels are in use. 
Two different types of bubble traps were designed. In the first type, a bubble 
trap was built as an independent module and was connected to a main microfluidic 
device using tubes (Figure 4.2(a)). In the second type, a bubble trap was integrated 
into the main microfluidic device so that no external connection was necessary 
(integrated module, Figure 4.2(b)). 
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Figure 4.1 The schematic diagrams of design of a bubble trap 
(a) Top-layer (b) Bottom-layer. (c) Cross-section view of a bubble trap. A top-layer 
contains barriers which block air bubbles from migrating further downstream. A 
bottom-layer contains alternative fluidic paths for liquid when air bubbles are captured 
in the-top layer. 
 
 
 
Figure 4.2 Pictures of a bubble trap 
(a) An independent module bubble trap, which is connected to a μCCA (not shown in 
the picture) by additional tubing. (b) An integrated bubble trap. A bubble trap is 
integrated with a μCCA to eliminate the need of additional tubing. In each picture, a 
captured air bubble is seen inside the trap. The sizes of the bubble trap are the same in 
both modules. 
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4.2.3 Fabrication of a Bubble Trap 
 
The design of a bubble trap was drawn using AutoCAD (Autoworks, San 
Rafael, CA), and the design was converted and exposed onto a Chrome-coated glass 
mask using GCA/MANN 3600F Optical Pattern Generator (Ultratech, San Jose, CA). 
Two separate masks were made for top and bottom layer with alignment marks. A SU-
8 master for a bubble trap was fabricated on a 4 inch diameter silicon wafer. The first 
layer (wider channels) of 50 μm thickness was made by spin coating SU-8 50 
(MicroChem, Newton, MA) at 2000 RPM for 30 seconds. After soft-baking at 65 Ԩ 
for 6 minutes the temperature was raised to 95 Ԩ and left for 20 minutes. The pattern 
on a first layer mask was exposed to SU-8 coated silicon wafer at 350 mJ/cm2 using 
EVG620 contact aligner (EV Group, Tempe, AZ). After exposure of the first layer, the 
second layer of SU-8 was spin coated at 2000 RPM to create a 50 μm thickness layer. 
The second layer was exposed at 350 mJ/cm2 after aligning the second layer mask 
with the exposed first layer using EVG620 contact aligner. Then post-exposure bake 
was done at 65 Ԩ for 1 minute and 95 Ԩ for 10 minutes, and the master was 
developed in a SU-8 developer solution for 6 minutes with agitation.  
PDMS monomer and a curing agent were mixed in 10:1 ratio. After degassing 
to remove foams, the mixture was gently poured onto a SU-8 master. The PDMS was 
cured at 65 Ԩ for 90 minutes and the PDMS structure was cut and peeled off from the 
master. A bubble trap and a 3x1 inch plain microscope glass slide (Fisher Scientific, 
Pittsburg, PA) were treated with air plasma cleaner (Harrick Plasma, Ithaca, NY) for 4 
minutes and immediately bonded together for irreversible sealing. Inlet and outlet 
holes were punched with 23 gauge stainless steel needle and sealed with Torr Seal 
(Varian, Palo Alto, CA). 
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4.2.4 Bubble Trap Efficiency 
 
The efficiency of bubble removal was tested (Figure 4.3(a)). The inlet of a 
bubble trap was connected to a reservoir containing water, and water was pumped 
through tubing and the bubble trap using a peristaltic pump. Bubbles were artificially 
generated in the reservoir by vigorous pipetting. The outlet of a bubble trap was 
connected to a waste reservoir where the liquid was collected. For easy visualization 
of the liquid and the bubbles, calligraphy color ink (blue and green, Winsor & Newton, 
Harrow, Middlesex, England) was used when photographs were taken. 
It was tested whether the presence of captured air bubbles in the bubble trap 
causes alterations in the flow pattern. The liquid residence time in each chamber was 
measured by alternating the liquid source between water and fluorescein and tracking 
the interface. Measurements were initially taken without the presence of bubbles, and 
the same measurements were taken again after the bubble trap was partially filled with 
air bubbles. The comparison was made for both a separated bubble trap and an 
integrated bubble trap. 
 
4.2.5 Finite-Element Simulation of Flow 
 
The velocity profile inside a bubble trap was simulated by finite-element 
simulation using Comsol software (Comsol, Burlington, MA). The model was 
simplified to 2-dimensional structure. The Navier-Stokes equation was solved using 
the following set of parameters; density = 1x103 kg/m3, viscosity = 1x10-3 Pa·s, inlet 
velocity = 1x10-3 m/s.  
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4.2.6 Cell Culture Test Using Micro Cell Culture Analog (μCCA) 
 
The human hepatoma cell line, HepG2/C3A, was cultured in a microfluidic 
device using an independent module bubble trap. The HepG2/C3A cell line was 
obtained from American Type Culture Collection (ATCC, Manassas, VA) and 
maintained in MEM medium (Invitrogen, Carlsbad, CA) with 10% FBS (Invitrogen) 
at 37Ԩ with 5% CO2. In this study, a micro cell culture analog (μCCA) was used as 
the main microfluidic cell culture device connected to a bubble trap. HepG2/C3A cells 
were cultured in a chamber of a μCCA connected to a bubble trap, and cell culture 
medium was recirculated through a bubble trap and a μCCA for 72 hours.  
Cells were seeded and attached to the surface of chambers in a μCCA 
overnight. The next day, μCCA devices were assembled and connected with bubble 
traps. Before the assembly of a μCCA, tubes were thoroughly rinsed with ethanol to 
remove air bubbles within the tubes, followed by rinsing with sterile water to wash out 
ethanol. Devices were assembled, and the whole system was placed inside an 
incubator maintained at 37 Ԩ with 5% CO2. After 72 hours of cell culture in a μCCA, 
the reservoir was switched to a live/dead staining solution in DPBS (5μM calcein AM 
and 5μM ethidium homodimer-1, Invitrogen). The pictures were taken using a 
fluorescent microscope (Olympus, Tokyo, Japan). 
 
4.3 Results and Discussion 
4.3.1 Design and Fabrication of a Bubble Trap 
 
Figure 4.1(a) shows the top-layer channel, which provides the space for 
trapping bubbles and also barriers to block further migration of the trapped bubbles. 
The gaps in the first line of barriers are 200 μm apart, and the size of the gaps becomes 
 100 
smaller as they get closer to the outlet, down to 100 μm. It was designed so that any 
air bubbles with a diameter greater than 100 μm will be blocked by the barriers, since 
the narrowest channel in the main microfluidic system (μCCA) was 100 μm wide. 
Figure 4.1(b) shows the bottom-layer channels, which are narrower channels designed 
to be a by-pass in case the top-layer becomes occupied by bubbles. The bottom-layer 
channels are 30 μm to 50 μm wide, and both top and bottom-layers are 50 μm deep. 
The aspect ratio of the bottom channels ensures that the bubble that is trapped in the 
top space will not fill the bottom space completely, as illustrated in the schematic 
diagram of the cross sectional view of the bubble trap in Figure 4.1(c). 
Figure 4.2 shows pictures of two different types of a bubble trap. Figure 4.2(a) 
shows an independent bubble trap module. In an experiment, the bubble trap would be 
connected before the main microfluidic device so that the flow will go through the 
bubble trap. An independent module requires additional connection between the 
bubble trap and the μCCA, which leaves the possibility of air bubbles entering at the 
interface between the device and tubing. To eliminate such a possibility, an integrated 
version of bubble trap was fabricated. In this design, an SU-8 master was made with a 
bubble trap integrated with a μCCA, and a PDMS structure from the master was 
bonded to a glass slide (Figure 4.2(b)). Such a design eliminates the requirement of 
additional connection and the possibility of bubbles originating from interfaces. 
 
4.3.2 Trapping and Removal of Bubbles 
 
The efficiency of bubble removal was tested using the bubble trap. Liquid was 
withdrawn from a source reservoir using a peristaltic pump, and passed through a 
bubble trap and collected in a collection reservoir. Air bubbles were artificially created 
in the source reservoir. In case a bubble trap was not used, air bubbles were withdrawn 
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into tubes and traveled to a collection reservoir. On the other hand, the presence of a 
bubble trap successfully prevented the migration of bubbles to the collection reservoir 
as seen in Figure 4.3, verifying that the bubble trap was efficiently trapping the 
bubbles. The bubbles in a trap still remained in place even after the flow rate was 
increased to ten-fold of normal operating rate to a value of 50 μl/min to increase the 
pressure. The location within the bubble trap where the bubble was captured was 
examined under a microscope, and it was verified that the bubble was trapped, with 
liquid flowing through the bottom-layer channels.  
By measuring the time it takes to fill the bubble trap with air at a known 
volumetric pumping rate, it was observed that the bubble trap was able to capture 
bubbles of up to 10 μl volume, which is close to the calculated volume of the trap. The 
trapped air bubbles could be easily removed by degassing the trap with in-house 
vacuum line (relative pressure of negative 78 kPa) for 15 minutes. According to the 
analysis model of bubble elimination through a PDMS membrane, the bubble removal 
rate can be expressed as follows (Kang et al. 2008); 
 
atm
12
P
76
273
T
b
)PPA(P
dt
dV       (4.2) 
where P is the permeability of PDMS (1.92x10-15 m2s-1Pa-1), p2-p1 is net pressure 
difference (-78 kPa), b is the membrane thickness (1 mm), A is the membrane area 
through which the bubble is removed (100 mm2), T is temperature in Kelvin, and Patm 
is the atmospheric pressure in cmHg. Using given parameters, the bubble removal rate 
in our device is predicted to be about 0.01 μl/s. Consistent with the calculation, when 
the trap was filled with bubbles and placed under vacuum, bubbles disappeared within 
15 minutes of degassing. In the study by Skelley, they reported that the bubble  
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Figure 4.3 Testing bubble trap efficiency 
(a) Testing the efficiency of bubble removal by an independent bubble trap module. 
Bubbles are artificially created in the source reservoir by pipetting, and water and 
bubbles were pumped into the collection reservoir. (b) Picture of the collection 
reservoir in the case where a bubble trap was not used. (c) Picture of the collection 
chamber where a bubble trap was used. The presence of a bubble trap prevented 
bubbles from travelling through the tubes and reaching the collection reservoir. (d) A 
picture of bubbles trapped in a bubble trap. Narrow bottom channels can be seen 
where liquid is flowing underneath the bubbles. Color ink was used to visualize the 
channels. 
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removal times were proportional to the bubble volumes, because the bubble was 
exposed to vacuum in a restricted area only, giving a constant bubble removal rate. In 
our device, the exposed area is proportional to the bubble volume. Therefore, the 
bubble removal rate is proportional to the bubble volume, resulting in a constant 
bubble removal time regardless of the bubble volume. The short bubble removal time 
(~15 minutes) allows temporarily detaching the bubble trap from the main μCCA 
device and removing the bubbles, without compromising the viability of cultured cells. 
 
4.3.3 Microfluidic Cell Culture Test 
 
The function of a bubble trap is to prevent the formation of bubbles in a 
microfluidic system, therefore it must not distort the flow going into the main 
microfluidic system. The potential distortion of the flow inside the bubble trap was 
tested by mathematical simulation and experiment. The simulation results of the flow 
inside a bubble trap and the exit channel with or without a bubble are shown in Figure 
4.4. The results show that even though the presence of a bubble results in temporary 
distortion of the velocity profile inside the bubble trap, the profile returns to the 
original parabolic profile after going through the exit channel. The velocity profiles 
across the exit channel did not show differences in both cases (Figure 4.4(c) and (d)).  
 To verify this simulation result experimentally, the flow rate in each chamber 
in a μCCA was measured. The μCCA consists of microfluidic network, and the 
geometry of the circuit was calculated and designed so that each chamber would have 
specific liquid residence times. The liquid residence time is a critical parameter in a 
μCCA in that it controls the extent of reaction in a chamber. The liquid residence time 
in each chamber is designed to be similar to the residence time of blood flow in the 
corresponding organ in human body. By comparing the residence times in each  
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Figure 4.4 Finite-element simulation of the flow inside a bubble trap. 
(a) Without bubbles inside, a parabolic velocity profile is maintained. (b) With a 
bubble trapped inside, the velocity profile is disrupted but restored to the original 
parabolic profile after going through the exit. (c) Velocity profile of the flow in the 
exit conduit without a bubble in the trap. (d) Velocity profile of the flow in the exit 
conduit with a bubble trapped. The location where the cross-sectional velocity profile 
was taken from is marked by a dashed line. 
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Table 4.1 Residence times of flow in each chamber in a microfluidic device attached 
after a separate bubble trap module. 
Chamber With bubble  Without bubble  
1 67.3±2.5 67.7±2.5 
2 69.0±3.6 66.0±4.3 
3 48.0±2.0 47.3±3.1 
4 132.7±1.1 132.3±9.7 
 
 
 
Table 4.2 Residence times of flow in each chamber in a microfluidic device with 
integrated bubble trap. 
Chamber With bubble Without bubble 
1 85.3±2.5 79.7±4.51 
2 68.7±2.3 66.3±1.5 
3 83.0±6.1 82.0±7.6 
4 166.0±5.3 175.3±6.8 
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chamber of a μCCA with and without bubbles in a bubble trap, we could test if the 
presence of bubbles causes any distortion in the flow pattern. Table 4.1 summarizes 
the measured residence times in each chamber. The result verifies that an independent 
bubble trap module does not change the residence times even when the bubble trap 
was occupied with bubbles. In case of an integrated bubble trap, the presence of 
bubbles caused small amount of deviations in the flow residence times, but the 
deviation was less than 10% in all cases (Table 4.2). We speculate that the 
independent bubble trap was more robust from alterations in the flow pattern since the 
tubing connection from a bubble trap and a μCCA was several centimeters in length 
providing enough distance for complete re-mixing, whereas in case of an integrated 
bubble trap the distance between the bubble trap and a μCCA is millimeter range. 
However, in both cases, a consistent flow pattern was established after passing 
through the bubble trap to ensure robust flow pattern in a μCCA. 
In general, formation of air bubbles in a microfluidic system during long-term 
perfusion cell culture can originate from two main sources; residual air bubbles that 
were present in the system due to incomplete priming (Kim et al. 2007), or formation 
air bubbles at the sites with incomplete sealing, such as the connections between a 
device and tubes (Christensen 2005). From our experience, priming the system with 
liquid with lower surface tension and better wettability than water such as ethanol 
before the experiment considerably decreased the chance of air bubble formation. In 
addition, care was taken to make sure the connections at the end of tubes were tight to 
minimize the chance of air entering through a loose connection. Even after such 
precautionary steps, without the presence of a bubble trap, it was difficult to 
completely avoid formation of air bubbles during long-term (> 24 hours) operation of 
microfluidic cell culture system with medium recirculation, which eventually led to 
 107 
the failure of system. Medium recirculation is a particularly stringent test since small 
bubbles are retained in the system and can eventually coalesce. 
The use of a bubble trap in a microfluidic cell culture system was tested to 
examine the long-term efficiency of bubble removal and cell-compatibility. An 
independent bubble trap module was connected to the front end of a μCCA, as shown 
in Figure 4.5(a). The μCCA system was operated with medium recirculation in a cell 
culture incubator for 72 hours. After 72 hours of medium recirculation, the viability of 
cells inside a μCCA was assessed by live/dead staining. The bubble traps at the front 
end of μCCA devices considerably decreased the air bubble formation during the 72-
hour period. In an experiment where half of the μCCA devices were connected 
directly to the medium reservoir without bubble traps and the other half was connected 
with bubble traps, μCCA devices with bubble traps had significantly fewer air bubbles 
in the culture chambers than the μCCA devices without bubble traps. Although it was 
difficult to quantitatively compare the amount of captured air bubbles in the system, 
this result verifies that the bubble trap efficiently removes air bubbles in a long-term 
experiment. Figure 4.5(b) shows typical fluorescent images of cells in a μCCA after 
the operation. The majority of cells are viable, with less than 10% of cells stained dead. 
This picture also verifies that the bubble trap is cell culture compatible. Although the 
pictures in Figure 4.5(b) are three-day results, in general it was possible to operate the 
device with a bubble trap for up to four days. After four days the waste accumulation 
and nutrient depletion in the recirculating medium prevented further experiment. 
However, the bubble trap was still functioning after four days and it was possible to 
continue using it. The limit was on cell viability due to recirculation of medium 
without addition of fresh medium, and not on the bubble removal process. 
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Figure 4.5 Cell culture compatibility of a bubble trap 
(a) Schematic diagram of setup for microfluidic perfusion cell culture system. Medium 
is pumped from a reservoir into a bubble trap, and into a μCCA, which is a main 
microfluidic cell culture device. After circulating through the chambers, medium 
flows back into the reservoir for recirculation. (b) Live/dead staining results of 
HepG2/C3A cells in a μCCA device connected to a bubble trap after 72 hours of 
operation with medium recirculation. Live cells were stained with calceinAM and 
dead cells were stained by ethidium homodimer-1. 
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4.4. Conclusion 
 
A bubble trap with two-layer PDMS structure was designed and fabricated 
using soft lithography technique. The two-layer structure with barriers physically traps 
air bubbles rather than relying solely on the buoyancy of air bubbles, while allowing 
fluidic paths to remain connected. The fabricated bubble trap was able to remove air 
bubbles efficiently to enable successful culture of HepG2/C3A cells in a microfluidic 
device with medium recirculation for three days. The proposed device may work as an 
independent or integrated module for microfluidic cell culture systems. 
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CHAPTER 5 
IN SITU FLUORESCENCE OPTICAL DETECTION SYSTEM FOR 
INTEGRATION WITH µCCA FOR REAL-TIME ANALYSIS4 
  
5.1 Introduction 
 
Microfluidic perfusion cell culture systems can serve as biological models to 
study complex biological processes with a precise control over cellular 
microenvironment (Pihl et al. 2005; Sivaraman et al. 2005; Cheng et al. 2007; Kim et 
al. 2007). One disadvantage of microfluidic systems is that the analysis and detection 
of physiological functions is difficult due to their closed and miniaturized nature. 
Therefore, the development of a non-invasive analytical technique for use in 
microfluidic cell culture devices is crucial. Fluorescence detection is a popular method 
for non-invasive detection of cellular response. Fluorescent probes have been used for 
detecting cell viability, oxygen concentration, protein expression, and metabolic 
activity (Bambot et al. 1994; Giepmans et al. 2006). For example, drug metabolism is 
often assessed by cytochrome P450 enzyme activity, by incubating cells with a 
fluorogenic substrate, which yields fluorescent product upon enzyme reaction (Donato 
et al. 2004). Typically, these products are analyzed with a fluorescent microscope, or a 
fluorescent plate reader for high-throughput measurement, but they are not optimized 
for microfluidic perfusion cell culture systems. One issue is that mammalian cell 
culture requires temperature and CO2 control, which interferes with real-time detection. 
The tubes and fluidic connections associated with microfluidic devices would have to 
                                                 
4  This chapter has been modified from following articles. Oh, T. I., et al. (2007). "Real-time 
fluorescence detection of multiple microscale cell culture analog devices in situ." Cytometry A 71(10): 
857-65, and Sung, J. H., et al. (2009). "Fluorescence optical detection in situ for real-time monitoring of 
cytochrome P450 enzymatic activity of liver cells in multiple microfluidic devices." Biotechnol Bioeng 
(accepted), with permission of Wiley Interscience.  
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be disconnected for measurements in a fluorescent plate reader, which not only 
interferes with continuous operation of microfluidic devices, but also raises the 
possibility of bacterial contamination and introduction of air bubbles. 
Obtaining real-time data from an operating microfluidic device, i.e., 
simultaneous fluidic perfusion and detection, is important because it allows easier 
extraction of information. For instance, enzyme kinetic parameters can be more easily 
and reliably extracted from real-time data than end-point measurements. Since the 
miniaturized and closed nature of microfluidic systems makes real-time analysis 
difficult, the systems are generally analyzed by end-point measurements, i.e., by 
collecting data of perfused medium or the cells after an experiment (Sivaraman et al. 
2005). If a microfluidic system does not require a cell culture, it is relatively easier to 
operate the device under a microscope for real-time investigation. However, if cells 
are cultured inside the device, real-time investigation becomes even more challenging. 
For example, Garcia et al. utilized laminar flow in a microfluidic channel to generate a 
concentration gradient of inhibitor molecules and studied the enzyme inhibition 
kinetics in a high-throughput manner (Garcia et al. 2007). Since immobilized enzymes 
were used in this study, they were able to use an epifluorescence microscope for 
monitoring the fluorescence in the system. If a similar study were to be done using a 
microfluidic cell culture system, it would have been difficult to obtain real-time data 
using a microscope without the use of expensive and specialized incubator stages. One 
approach to this problem was suggested by Yu et al., who developed a plate-reader 
compatible microchannel array that can be readily integrated and operated with a 
conventional fluorescence plate reader (Yu et al. 2007). Although this system allows 
easy integration with a plate reader, its utilization is limited since it did not involve 
simultaneous fluidic perfusion and detection.  
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There have been research efforts towards the development of an integrated 
optical detection system for microfluidic systems. Novak et al. reported an integrated 
fluorescence detection system for lab-on-a-chip applications, inspired by mass-
produced optical systems such as DVD, consisting of a blue LED for excitation and a 
photodiode for detection (Novak et al. 2007). However, the reported optical system 
was a single channel system, and consequently does not support an automated 
multichannel measurement for high-throughput analysis. Also the authors did not 
show that the system was compatible with cell culture, which typically requires more 
stringent operating conditions.  
In this chapter, we use an in situ fluorescence optical detection system 
(ISFODS), which is designed for detection of fluorescent signal in a micro cell culture 
analog (µCCA). The system employs a minimal number of optical components to 
reduce artifacts associated with imaging aberration. The compact design allows the 
whole system to be placed inside a cell culture incubator with the microfluidic device 
including a pump. We use this system for two main purposes; real-time detection of 
cell viability during toxin application, and real-time measurement of enzymatic 
activity of hepatoma cell line in a microfluidic. In the first study, to measure cell 
viability, an imaging detector array is used to capture the image of live cells inside the 
device. Using this setup, we were able to monitor the acute cell-killing effect of 
ethanol, and also monitor the long-term growth of cells in the device for 85 hours. For 
the second study a single photodetector is used for easier quantification of fluorescent 
signal directly from the cell culture medium in the device. The system was used to 
monitor, in real-time, the P450 1A1/1A2 enzyme activity of liver cells. The P450 
enzymes are a major enzyme family in liver metabolism, and fluorescence-producing 
substrates are known for various isoforms of P450 enzyme family (Stresser et al. 2002; 
Donato et al. 2004). The ethoxyresorufin-O-dealkylase (EROD) fluorescence assay, 
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which measures the conversion of ethoxyresorufin to a fluorescent product resorufin, 
has been widely used for quantification of both P450 1A1 and 1A2 enzyme activity of 
liver cell line (Donato et al. 1993; Kelly and Sussman 2000; Coward et al. 2005; Camp 
and Capitano 2007). A mathematical model was developed to characterize the 
enzymatic reaction and the transport of substrate and fluorescent product, which was 
then compared to experimental data for improved quantification and extraction of 
reaction associated parameters. 
 
5.2 Materials and Methods 
5.2.1 Cell Culture and Chemicals 
 
The cell lines used in this study (HepG2/C3A and MES-SA) were obtained 
from ATCC (American Type Culture Collection, Manassas, VA). All cell lines were 
cultured in the media recommended by ATCC, with 10% FBS (Invitrogen, Carlsbad, 
CA). Media used for culture the cell lines were MEM and McCoy’s 5a medium from 
Sigma Aldrich (St Louis, MO). CalceinAM and cell tracker green were purchased 
from Invitrogen, and ethanol was purchased from Sigma Aldrich. MES-SA cell line 
has been transfected to express the fusion protein H2B-GFP, which is a human histone 
protein fused at the amino terminus to EGFP. The viability of a cell can be determined 
by measuring the fluorescence intensity of the cell. 
 
5.2.2 ISFODS for Cell Viability Measurement 
 
The optical system, is shown in Figure 5.1 and employs a high-power light 
emitting diode (LED) and a charge coupled device (CCD) camera, respectively, as a 
light source and a detector. The overall imaging system is designed to offer low 
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magnification (M ~ 5.8) in order to provide cell status information on the basis of 
statistical average by imaging a large number of cells simultaneously. Light from a 
high power royal blue LED (Luxeon LXHL-BR02, Philips, San Jose, CA, U.S.A.) of 
peak wavelength at λ = 455 nm (manufacturer provided) and optical power at 220 mW 
lumens is focused by an imaging lens L1 (f = 35 mm, d = 24.5 mm) to excite EGFP on 
μCCA samples. Excited fluorescence is imaged by L1, occasionally relayed by L2 (f = 
150 mm, d = 50 mm), to a CCD (QICAM FAST 1394, Qimaging, Burnaby, BC, 
Canada). A pinhole aperture is placed for baffling out the noise from background. The 
center wavelength / band width of the excitation filter (F1) and emission filter (F2) in 
a fluorescence filter cube (31054GFP, Chroma Technology, Rockingham, VT, U.S.A.) 
is respectively given by 455 nm / 70 nm and 525 nm / 30 nm (provided by the 
manufacturer). The effect of non-collimation through F2 is minimal because the 
sample-to-L1 distance is close to the focal length of L1 and thus the image distance 
from L1 is large relative to the overall size of the system. Two μCCA chips were 
mounted on a motorized stage (UTM100CC1DD, Newport, Irvine, CA, U.S.A.) with a 
linear resolution of 1 μm. The total dimension of the optical system is 30(L) x 23(W) x 
20(H) cm3. Potentially, the system can be made more compact to accommodate more 
μCCA chips. 
 The light source spectra have been measured by an optical spectrometer. 
Maximum power has been measured at λ = 459.5 nm with the full width-half 
maximum as 25 nm. Thus, slight discrepancy exists between measured and 
manufacturer provided peak wavelengths. The cutoff wavelength, defined as the 
wavelength at which the optical power is reduced to 1% of the maximum is 524 nm 
without using F1. This overlaps the emission spectrum of EGFP signal. When the 
excitation filter F1 is mounted on the LED, the cutoff wavelength is decreased to 498 
nm, which removes the source interference due to excitation of EGFP. Using 
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programmed control, μCCA samples have been exposed minimally at 0.7~5 seconds 
for each measurement to protect cells from getting photobleached. Since a CCD is 
inherently afflicted with dark current noise, thermal noise characterization is required 
at an incubating temperature 37.5°C. From an initial test of a CCD, the dark current 
noise has been determined to be saturated at a constant level 25 minutes after the 
system was installed in an incubator. The maximum change in the dark current noise is 
a 10% increase, compared to that of room temperature. Experimental measurements 
were initiated at least 30 minutes after a CCD was turned on. The transition between 
chambers has been made mechanically. The transition time has been controlled to be 
short for minimal disparity between measurement conditions and yet sufficiently long 
to take observable time not to affect the drug diffusion process in μCCA. Registration 
error of the motorized stage was less than 1 µm, which is far smaller than the cell size. 
Thus, misregistration in the images taken at different time points was minimal. 
The μCCA used in this study is shown in Figure 5.2(a). The liver hepatoma 
cell-line HepG2-C3A was seeded on the liver chamber (A) and a uterine cancer cell 
line, MESSA H2B-GFP was seeded on the uterus cancer chamber (B). The normal 
colon cell chamber (C) and colon tumor cell chamber (D) were not used in this study. 
For cell seeding, the chips were immersed in piranha solution for 20 minutes to 
remove organic residues, and autoclaved for sterilization. Then the chips were coated 
with 0.1 mg/ml poly-D-lysine (Sigma-Aldrich, St. Louis, MO, U. S. A.), followed by 
washing with PBS and coating with 50 μg/ml fibronectin (Chemicon International, 
Temecula, CA, U. S. A.). Cells were trypsinized and resuspended in medium to the 
final concentration of 7.5 x 105 cells/ml. An appropriate volume of cell suspension (20 
μl ~ 50 μl) was placed on each chamber to completely cover the chamber without 
spilling over. Chips loaded with cells were incubated at 37.5°C with 5% CO2 
overnight. 
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Figure 5.1 Overview of ISFODS for cell viability measurement 
The black and gray solid lines represent an illuminating and emitted beam, 
respectively. The rectangle with dotted line represents the incubator, and inside the 
dotted circle is shown a µCCA. (F1: excitation filter, F2: emission filter, L1, imaging 
lens, L2: relay lens, P: pin-hole, and BS: beam splitter). 
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Figure 5.2 A μCCA used with ISFODS for cell viability measurement. 
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In case it was necessary, the whole chip was stained with calceinAM in order 
to distinguish live cells. Before assembling the CCA device, whole chip was immersed 
in 2μM calceinAM solution for 30 minutes. Then the chips were assembled and sealed 
with a PMMA holder. Silicone tubes (PharMed Pump Tubing, inside diameter = 0.25 
mm, Cole-Parmer, IL, U.S.A.) were used to connect the assembled CCA with a 
medium reservoir. A peristaltic pump was used to supply the medium at a constant 
speed (0.5 RPM equivalent to 2 μl/min approximately). 
 
5.2.3 Ethanol Toxicity Experiment 
  
In order to verify that the optical system is able to detect the process of cell 
death in real-time, the cells in the CCA device were treated with various 
concentrations of ethanol. For this experiment, the cells on the chips were stained with 
calceinAM prior to the assembly of the CCA device. After setting up the CCA device 
and the optical system, initial measurements were made for 20 minutes while 
supplying media with a peristaltic pump, in order to ensure that the cells were being 
monitored consistently. After 20 minutes have passed, various concentrations of 
ethanol (0%~20% v/v) in MEM media were flown into the system to induce a rapid 
cell death. The measurements were continued until there were no live cells detected, 
which took up to 120 minutes depending on the concentration of ethanol. 
 
5.2.4 Cell Growth Monitoring 
 
The long-term growth of cells in the CCA device was monitored with the 
optical system in order to verify that the system can be operated for several days while 
making real-time measurements. For the long-term growth study, MES-SA and 
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HepG2/C3A cell line transfected with H2B-GFP gene were used. Cells transfected 
with H2B-GFP express GFP protein constitutively, thus giving off green fluorescent 
signal as long as they are healthy. The CCA chips loaded with both cells lines were 
assembled and the whole optical system with the CCA device and a peristaltic pump 
were put in an incubator which was kept at 37Ԩ, 5% CO2. For the long-term growth 
experiment, the CCA device was connected to a medium reservoir via silicone tubes, 
and the media coming out of the CCA device were fed back into the medium reservoir, 
therefore the media were being recirculated into the system for the whole time. The 
volume of the medium reservoir was 200 μL, which supports the growth of cells for 
about three days, and the measurements were made for 90 hours until the nutrients in 
the media became depleted and the accumulation of toxic wastes by cells eventually 
caused the cells to die.  
 
5.2.5 Image Processing 
 
Intensity graphs have been produced from acquired fluorescent images using 
Cell Profiler® after several steps of removing the effect of background noise. The 
steps involve cropping, illumination correction, and cell-number counting. In general, 
image processing based on cell numbers, occupied areas of cells, and the image 
intensity provided consistent results.  
 
5.2.6 ISFODS for Metabolic Activity Measurement 
 
The ISFODS was constructed with discrete optical components for optimum 
optical performance and ease of assembly (Figure 5.3(a)). The light from a green LED 
(Luxeon LXHL-MM1D, Philips, San Jose, CA) with peak wavelength at λ = 530 nm 
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and luminous flux at 53 lumens (typical, manufacturer provided) passes through a 
50/50 dichroic beam splitter and is collimated by a lens (f = 35 mm,  = 25.4 mm) to 　
excite resorufin in the detection chamber. Fluorescence emission from resorufin is 
focused by a lens and detected by a low-power photodiode (818-UV, Newport, Irvine, 
CA). The system employs a filter set that consists of fluorescence excitation and 
emission filters. The center wavelength/bandwidth of the excitation and emission filter 
is 535/40 nm and 630/60 nm, respectively (Model #: D535/40m and D630/60m, 
Chroma Technology, Rockingham, VT). This filter set has a cutoff wavelength at 570 
nm; therefore, it can discriminate fluorescence emission of resorufin from the source 
light. For detection at multiple locations, a transition between detection chambers was 
made by a motorized stage (UTM100CC1DD, Newport, Irvine, CA) with a linear 
resolution of 1 μm (manufacturer provided). The data acquisition and linear translation 
between chambers were all controlled by LABVIEW  (　 National Instrument, Austin, 
TX). The ISFODS was operated in a working condition inside a cell culture incubator 
(water-jacketed incubator, model 3187, Forma Scientific, Marietta, OH) with 5% CO2, 
37ºC temperature, and humidity control. The overall dimension of the entire set-up is 
approximately 30 cm (L) x 20 cm (W) x 20 cm (H), excluding an external personal 
computer. 
For cell culture in a µCCA, we followed the previous methods, with some 
modifications to culture cells in 3-D matrix of hydrogel (Sung and Shuler 2009). In 
short, the surface of a µCCA was filled with medium (MEM, Invitrogen, Carlsbad, 
CA). After sealing, the µCCA was kept in a refrigerator at 4ºC. HepG2/C3A cells 
were trypsinized and an appropriate number of cells was resuspended in 100 μL of 
MatrigelTM (BD Biosciences, San Jose, CA) to the final concentration of 1.5 x 107 
cells/mL, unless specified otherwise. The cell mixture was kept in an ice bath to 
prevent polymerization. Approximately 6 μL of the cell suspension in MatrigelTM was 
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withdrawn using a gel loading tip (VWR, West Chester, PA), and was slowly 
introduced into the liver chamber of the µCCA device. The number of cells introduced 
into a chamber was approximately 100,000 cells. After the cell loading, the µCCA 
device was placed in a cell culture incubator at 37ºC to initiate gel formation.  
A detection chamber was made from an 8-well strip plate (VWR). After 
separating a single well, holes punched using a sharp needle heated with a flame at 
two opposite locations on both sides of the well. As seen in Figure 5.3(b), the location 
of the inlet/outlet holes allows the medium to flow into the detection chamber at 
bottom, fill up the chamber and flow out through the top. The total volume of the 
medium in the detection chamber is always kept constant at 300 µL. Therefore, any 
change in the fluorescence signal from the detection chamber reflects a change in the 
concentration of fluorescent molecules. A 23-gauge stainless steel needle was inserted 
into the holes and fixed with epoxy glue (Epotek 301, Epoxy Technology, Billerica, 
MA). It should be noted that the custom-made detection chamber has the same 
geometry and dimensions as the individual well of a 96-well microtiter plate, 
preventing any potential differences caused by differences in the detection 
environment when compared to a commercial fluorescence plate reader using a 96-
well microtiter plate. 3 mL BD syringes (Fisher Scientific, Pittsburg, PA) and the 
custom-made detection chambers were filled with medium containing 1 μM or 10 μM 
ethoxyresorufin (Sigma, St. Louis, MO). The syringes, µCCA chips, and detection 
chambers were connected using Teflon tubing (1/16 inch inside diameter, Small Parts 
Inc., Miramar, FL). For detection at multiple locations during an experiment using the 
ISFODS, several sets of a syringe, a µCCA, and a detection chamber were prepared in 
the same way, as can be seen in Figure 5.3(a). The syringes were installed on a syringe 
pump (World Precision Instruments, Sarasota, FL), which were used to provide a flow  
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Figure 5.3 In situ fluorescence optical detection system (ISFODS) for enzyme activity 
measurement. 
(a) Overall schematics of ISFODS (b) A cross-sectional view of a µCCA, with cell-
embedded MatrigelTM. (c) A schematic diagram of a µCCA device assembled with top 
and bottom frames. A µCCA consists of a liver, tumor and marrow chamber (Sung 
and Shuler 2009). In this study only liver chamber was used and the other two 
chambers were left empty.  
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at 2 μL/min. The fluorescent intensity in the detection chamber was measured every 
five minutes for three hours.  
Additionally, two different conditions for the cells, uninduced and chemically 
induced by 3-Methyl Cholanthrene (3-MC), were tested. 3-MC is known to induce 
P450 genes by binding to ligand-binding nuclear receptor AHR (Sivaraman et al. 
2005). Uninduced cells were taken directly from cultured cells and used for 
experiment. In the case of chemical induction, cells were incubated in a 96-well plate 
in culture medium containing 5 μM 3-MC. After 48 hours of incubation, cells were 
trypsinized and inserted into a µCCA for experiment. 
 
5.2.7 Linearity Calibration of Fluorescence Intensity 
 
The performance of the ISFODS on µCCA chips was calibrated with that of a 
commercial fluorescence plate reader (Molecular Devices, Sunnyvale, CA) in 96-well 
plates in response to various concentrations of resorufin solution in medium. 
Resorufin solutions in MEM medium were prepared in concentrations ranging from 50 
nM to 10 μM. 
 
5.2.8 96-well Plate Experiment for Cell Metabolic Activity Measurement 
 
96-well experiments were performed as a control modality in contrast to 
µCCA. HepG2/C3A cells were initially trypsinized and suspended in MEM medium, 
and seeded in the wells of Corning 96-well plate (Fisher Scientific, Pittsburg, PA) at 
the final concentration of 100,000 cells per well. The medium in the wells were 
replaced with pre-warmed medium containing 10 μM ethoxyresorufin and the 96-well 
plate was incubated at 37ºC with 5% CO2 for 3 hours. The enzymatic conversion of 
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ethoxyresorufin to resorufin was monitored using a fluorescent plate reader for 3 hours 
at the excitation wavelength of 544 nm and emission wavelength of 590 nm. For 
chemical induction of the cells, cells were cultured and pre-treated with 3-MC for 48 
hours prior to experiment. After 48 hour incubation, cells were trypsinized, suspended 
in MatrigelTM solution, and cell-MatrigelTM mixture was pipetted into the wells. After 
incubation for 15 minutes at 37ºC, 300 μL medium with ethoxyresorufin was added to 
each well. After P450 1A1/1A2 activity was assessed, the protein content in each well 
was assessed by using Bradford method (Sigma Aldrich, St. Louis, MO) to normalize 
the enzyme activity on the per-mg-protein basis. In case of cells cultured in a µCCA, it 
was difficult to recover the intact cells and measure the protein content inside the 
microfluidic device. Therefore the total enzyme activity was compared, while the total 
cell number was kept the same in both µCCA and 96-wells.  
 
5.2.9 Mathematical Simulation  
 
A two-compartment mathematical model was set up to interpret the results 
obtained by µCCA integrated with the ISFODS (Figure 5.4(a)). The first compartment 
represents the liver cell chamber in a µCCA, and the second compartment represents 
the detection chamber. If both compartments are well-mixed, the concentration of the 
product resorufin is described by the following set of equations, 
 
 ୢ஼಴಴ಲୢ௧ ൌ
௏೘·஼
௄೘ା஼ െ
ொ·஼಴಴ಲ
௏಴಴ಲ        (5.1) 
 ௗ஼೏ௗ௧ ൌ
ொ·஼಴಴ಲ
௏಴಴ಲ െ
ொ·஼೏
௏೏        (5.2) 
where CCCA and Cd represent the concentration of resorufin in a µCCA and in a 
detection chamber, respectively. Q denotes the flow rate in and out of the chamber. 
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VCCA and Vd are the volume of a µCCA and a detection chamber, respectively. Vm is a 
maximum reaction rate and Km a Michaelis-Menten constant. Equations 5.1 and 5.2 
were solved by using the ode45 routine in MATLAB (Mathworks, Natick, MA). 
Since the well-mixed model does not account for the transport phenomenon, a 
more detailed convection-diffusion model was constructed (Figure 5.4(b)). The flow 
inside a microfluidic system is governed by the Navier-Stokes equation, and the 
diffusion of molecules is described by a mass balance equation as follows: 
 
ߩݑሬԦ · ׏ݑሬԦ ൌ െ׏ܲ ൅ ߤ׏ଶݑሬԦ     (5.3) 
ப஼
ப௧ ൅ ݑሬԦ · ׏ܥ ൌ ܦ׏ଶܥ ൅ ܴ     (5.4) 
where C is the concentration of the molecule, u velocity, and D the diffusion 
coefficient. R is the reaction rate which is given by the following Michaelis-Menten 
equation. 
 
 ܴ ൌ ௏೘·஼௄೘ା஼      (5.5) 
 
Equations 5.1~5.5 were solved simultaneously on COMSOL (COMSOL, 
Burlington, MA). To reduce the size and the simulation time of the model, two-
dimensional x-z geometry was assumed. The concentration profiles of resorufin at a 
fixed point inside the detection chamber were exported and plotted. The parameters 
for both models and the boundary conditions for the convection-diffusion model are 
summarized in Table 5.1 and 5.2. The diffusivity of a substrate (ethoxyresorufin) and 
a product (resorufin) in water was found from literature (Benes et al. 2001). The 
diffusivity of the substrate and the product in hydrogel was assumed to be 75% of the 
diffusivity in water, based on the study by Brown et al (Brown et al. 2007). 
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Figure 5.4 Mathematical models describing the micro cell culture analog system and a 
detection chamber. 
(a) Simple two-compartment model. It is assumed that the two compartments are well-
mixed and homogeneous. In the first compartment enzymatic reaction occurs, which is 
described by the Michaelis-Menten kinetics. The two compartments are connected by 
flow rate Q. (b) Convection-diffusion model. The exact geometries were drawn and 
the Navier-Stokes equation and mass balance equation were solved simultaneously to 
obtain concentration profiles of product resorufin. The schematic diagram shown here 
is not drawn to the actual scale of the system. 
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Table 5.1 Parameters used in the simulation of a well-mixed model and a convection-
diffusion (C-D) model. 
Name description value 
Well-mixed 
model   
Q Flow rate 2 μL/min 
VCCA Volume of CCA 5 μL 
VD 
Volume of detection 
chamber 400 μL  
Vm 
Maximum enzyme 
activity  
44 nM/min  
(fitted to experimental data) 
Km Michaelis constant 
2400 nM  
(fitted to experimental data) 
C-D model   
V Average fluid velocity 2.2  10-3 m/min  (from experiment) 
Dethres 
Diffusivity of 
ethoxyresorufin 
2.4  10-8 m2/min  
(Benes et al. 2001) 
Dres Diffusivity of resorufin 1.8  10
-8 m2/min  
(Benes et al. 2001) 
Rho Density 1  103 kg m-3 
Mu Viscosity 6  10-2 kg m-1min-1 
Vm 
Maximum enzyme 
activity  
44  10-13/min/cell  
(fitted to experimental data) 
Km Michaelis constant 
2400 nM  
(fitted to experimental data) 
S Initial substrate concentration 1  104 nM 
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Table 5.2 Boundary and sub-domain conditions used in the simulation of a 
convection-diffusion model. N-S: Navier-Stokes, C-D: Convection and Diffusion. 
 
Boundary N-S C-D substrate C-D product 
Inlet Velocity, u0=0, v0=-v 
Concentration, c0=S Concentration, c0=0 
Outlet Pressure, P0=0 
Convective flux Convective flux 
Others 
 
No slip 
 
Insulation/Symmetry 
 
Insulation/Symmetry 
 
Sub-domain N-S C-D substrate C-D product 
Perfusion area ρ=Rho, μ=Mu D = Dethres D = Dres 
Hydrogel area N/A D = 0.75Dethres D = 0.75Dres 
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5.3 Results 
5.3.1 Ethanol Toxicity Experiment 
 
We tested cell response to ethanol addition and in two identical µCCA chips. 
HepG2/C3A cells were treated with calceinAM for fluorescence detection prior to the 
packaging of µCCA. Figure 5.5 shows the result in terms of cell viability index (CVI). 
CVI was defined as the ratio of the cell number at a specific time to the initial cell 
number. In other words, CVI measures relative increase or decrease in reference to the 
initial cell number. The graph shows that when the cells were exposed to ethanol, it 
immediately caused cell death, and all cells died within the time range of few minutes 
to one hour, depending on the applied concentration of ethanol. 
Figure 5.6 shows real-time fluorescence images of HepG2-C3A cells at various 
EtOH concentrations. Figures 5.5 and 5.6 emphasize the strengths of our system to 
track the migration and motility of an individual cell and also to observe cell dynamics 
quantitatively. Here, τ was obtained as a function of EtOH concentration from an 
exponential fit, i.e. CVI(t) = CVI(t = 0)exp(-t/τ), with the reference CVI for cell death 
set to be 1%. Figure 5.7 presents the necrosis time constant τ over different EtOH 
concentration values. More specifically, at 20% EtOH, HepG2-C3A cells die quickly 
in 10 minutes, while it takes 30 and 100 minutes at 10% and 5% EtOH, respectively. 
In other words, the time constant τ itself is a function of EtOH concentration, as 
shown in Figure 5.7. Figure 5.7 suggests that the dependence of τ on EtOH is not 
linear. Good correlation was achieved with an inverse relationship, i.e. τ(CEtOH) = 
A/CEtOHn, where CEtOH denotes ethanol concentration. A and n are fitting constants 
and were found to be A = 1300 and n = 1.6. 
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Figure 5.5 Time course of cell viability index in response to ethanol 
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Figure 5.6 Exposure of cells to ethanol 
Fluorescence images of HepG2-C3A cells exposed to EtOH concentration of 0% 
(control, top row, a-d), 5% (second row, e-h), 10% (third row, i-l), and 20% (bottom 
row, m-p). EtOH was injected 20 minutes after the test was begun. 
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Figure 5.7 Necrosis time constant at various ethanol concentrations 
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5.3.2 CalceinAM Injection and Cell Staining Experiment 
 
CalceinAM was supplied by injecting it through microfluidic channels. The 
main purpose of this is to understand the dynamics of calceinAM staining. Results in 
Figure 5.8 shows that the calceinAM fluorescence intensity increases until 10% EtOH 
was injected at 90th minute and delivered through a tube to reach cells. Figure 5.8 (b) 
shows fluorescent images that reflect the dynamics of staining and the fluorescence 
intensity loss caused by EtOH.  
 
5.3.3 Cell Growth Monitoring 
 
The growth curve of MESSA H2B-GFP cells in the chamber B of the first 
μCCA chip has been obtained after an experiment for over 85 hours, as shown in 
Figure 5.9. The growth curve for MESSA H2B-GFP cells shows that cells start 
proliferating after an initial lag phase (about 30 hours). Cells then grow until about 65 
hour (from 0.95 to 1.33 a.u.). After the stationary phase, the cell number starts to 
decrease. The death of cells can be attributed to nutrient depletion and a change in the 
pH due to the accumulation of wastes from cell metabolism.   
Figure 5.9 also presents the cell growth and maintenance curve of HepG2-C3A 
H2B-GFP cells in the chamber A of the second μCCA chip. Cell growth index was 
defined for quantitative comparison as normalized cell number with respective to an 
initial cell number. The results show that HepG2-C3A H2B-GFP are subject to contact 
inhibition and cell number does not change significantly, which was expected as the 
cells were seeded on the chip at about 90% confluency. HepG2-C3A is a derivative 
cell-line of HepG2 cell-line, selected for strong contact inhibition of growth and high 
albumin production.  
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Figure 5.8 Staining/cell death experiment 
(a) Fluorescence intensity graph of HepG2-C3A cells in liver and uterus cancer 
chamber that shows initial calceinAM uptake and following cytotoxicity of 10 % 
EtOH injected at 90th minute. (b) Corresponding fluorescence images of HepG2-C3A 
cells in the liver chamber. 
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Figure 5.9 Cell growth of MESSA H2B-GFP and HepG2-C3A cells in a μCCA 
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5.3.4 Linearity Calibration of Resorufin Fluorescent Intensity 
 
Figure 5.10 presents the calibration results measured by a commercial 
fluorescence plate reader and the ISFODS. Various concentrations of resorufin 
samples were made and measured with a plate reader and ISFODS. The measured 
output from the 96-well microtiter plate was recorded for each sample. With the 
ISFODS, measurements were made in a static environment without flow. These results 
demonstrate similar sensitivity and response linearity of the ISFODS to those of a 
commercial fluorescence plate reader.    
The lowest detection limit of resorufin in the current experimental setting was 
approximately 1 nM. In the concentration range of 1 nM to 10 μM resorufin, both 
systems showed similar bi-phase responses. In the low concentration range (1 nM~1 
μM), the data showed linear responses in the fluorescence plate reader and ISFODS 
with correlation coefficients R2 = 0.9946 and 0.9869, respectively (Figure 3, inset). 
Highly linear responses were also observed at higher concentrations (1 μM~10 μM) 
with a decreased slope. Correlation coefficients for the fluorescence plate reader and 
the ISFODS in this range were 0.9957 and 0.9967, respectively. In both measurement 
systems, the changes of slopes occur at near 1 μM, which further validates the 
consistency of the ISFODS with conventional detection systems. In the case of the 
ISFODS, the y-intercept was not zero, which we believe to be associated with the fact 
that the incubator door was not completely closed due to the cables connecting the 
ISFODS and a computer. A small, but noticeable amount of stray light through the 
opening could have interfered with the system. For the following experiments, the 
measured output readings from the ISFODS were converted to the corresponding 
resorufin concentrations. 
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Figure 5.10 Linearity calibration of ISFODS 
Comparison of (a) fluorescent plate reader and (b) ISFODS for linearity calibration of 
fluorescent signal measurement. Both show similar responses to resorufin 
concentrations with two linear regions between 0 and 10 μM. Shown in the inset is a 
close-up of the low concentration range. Different slopes of linear responses were 
observed in the low concentration range (1 nM~1 μM), and the high concentration 
range (1 μM~10 μM) for both detection systems. 
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5.3.5 Measurement of P450 1A1/1A2 Enzyme Activity of HepG2/C3A Cells in a 
96-well Plate and a μCCA 
 
In this study, we used a hepatoma cell line HepG2/C3A, which is a derivative 
cell line of HepG2 (Kelly 1994). The P450 1A1/1A2 activity of the cells was tested in 
two different environments (96-wells and µCCA). In a 96-well plate, cells were 
cultured in a 2-D monolayer in culture medium containing ethoxyresorufin. As the 
P450 1A1/1A2 enzymes in the cells convert the weakly fluorescent substrate 
ethoxyresorufin to a fluorescent product resorufin, the fluorescence intensity of the 
product was measured using a fluorescence plate reader. In a µCCA, cells were 
embedded in a matrix of MatrigelTM and medium containing ethoxyresorufin was 
perfused through a microfluidic channel. As the medium flows over the Matrigel-cell 
matrix, ethoxyresorufin diffuses into the matrix and is converted to resorufin by 
enzyme reaction (Figure 5.3(b)). Along with the medium flow, the fluorescent product 
is moved to the detection chamber and detected by the ISFODS (Figure 5.3(a)). For 
both the fluorescent plate reader and the ISFODS, multiple measurements were taken 
in a single experiment (n > 3). Field of view changes at each measurement with a 
fluorescent plate reader, while it is maintained as constant with the ISFODS. 
Figure 5.11 shows the fluorescence activity measured in a 96-well plate by a 
plate reader (a) and in a µCCA by the ISFODS (b). In the case of measuring resorufin 
in a µCCA with the ISFODS, time zero corresponds to the time for the initial detection 
of fluorescence activity, rather than the time the medium perfusion was started, due to 
time delays associated with flow. Note that it would take a certain amount of time 
(usually 15 to 20 minutes) for medium to flow through channels and reach the 
detection chamber. In the case of a 96-well plate with a fluorescence plate reader, the 
time zero corresponds to the time ethoxyresorufin was added, when the enzymatic 
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reaction starts. In Figure 5.11, both the fluorescence plate reader with a 96-well plate 
and the ISFODS with a µCCA showed a gradual decrease of background signal, if 
there were no cells present. The similarity implies that the decrease in background is 
caused by the object of detection, either the culture medium or the wells, rather than 
the detection systems. The decrease may be associated with photobleaching or binding 
of weakly fluorescent molecules in the medium to the surfaces of the wells or the 
µCCA. 
 In a 96-well plate, uninduced HepG2/C3A cells showed a detectable, yet a low 
P450 1A1/1A2 activity. If the cells were chemically induced, they showed 
significantly higher activity (Figure 5.11(a)). This observation was consistent with a 
previous report (Kelly and Sussman 2000). On the other hand, the behavior of the cells 
cultured in 3-D matrix in a µCCA was different from that of the cells in a 96-well 
plate. Uninduced cells in the µCCA showed a higher P450 1A1/1A2 activity than 
those cultured in a 96-well plate, whereas the activity of induced cells was not 
statistically different from the activity of uninduced cells for the first 100 minutes 
(Figure 5.11(b)). The reason for the lack of response to chemical induction in the 3-D 
gel cultures in the µCCA is uncertain. One possibility would be that the gel and the 
microfluidic environment have already acted as an inducer, saturating the induction 
response of the liver cells. Another possibility is a stress response in the cells due to 
the extra handling required to move and place the cells in a gel and a microfluidic 
device. It should also be noted that the inducer 3-MC was observed to reduce cell 
viability during 48 hours of induction (data not shown). Regardless of the reason, it is 
important that the dynamics of the system were captured by the ISFODS.  
To further explore the sensitivity and the resolution of the ISFODS, we 
investigated a µCCA with the ISFODS in different conditions and compared the data 
with simulation results. First, we tested different substrate concentrations (1 μM and  
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Figure 5.11 P450 1A1/1A2 activity of HepG2/C3A cells as measured by the formation 
of resorufin 
(a) 96-wells + fluorescence plate reader (b) µCCA + ISFODS. In 96-wells, uninduced 
HepG2/C3A cells showed slightly higher signal than no-cell control, whereas in a 
µCCA, uninduced cells showed significantly higher activity than no-cell control. In 
96-wells, cells induced with 3-MC showed significantly higher activity than 
uninduced cells, whereas in a µCCA, induction did not increase the enzyme activity. 
The total number of cells in a 96-well and a µCCA were controlled to be 
approximately at 100,000 cells. 
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10 μM, Figure 5.12). As expected, higher substrate concentration resulted in faster 
conversion kinetics, consistent with simulation results. This data was used to fit the 
kinetic parameters of P450 1A1/1A2 enzyme in the mathematical models, which were 
found to be Vm = 44 nM/min and Km = 2400 nM. In the case of measuring cells in 
well-plates with a plate reader, the kinetic parameters of P450 1A1/1A2 enzyme are 
not available to the best of our knowledge. A potential reason for this absence of prior 
data is that the cells did not show significant activity in a well plate unless they were 
artificially induced, which makes the acquisition of kinetic parameters difficult. Also 
note that the measurement performed with a plate reader is not in situ, thus obtained 
kinetic parameters would be subject to larger errors even if they can be extracted. This 
presents the strength of in situ measurement of a µCCA using the ISFODS in 
extracting reaction coefficients such as conversion rate of ethoxyresorufin into 
resorufin products on a quantitative basis. Secondly, the cell density inside µCCA was 
varied, while the substrate concentration was fixed at 1 μM (Figure 5.13). Three 
different cell densities were tested (1X, 2X, and 4X correspond to 5 x 104, 1 x 105, and 
2 x 105 cells/ml, respectively). In general, the higher cell density resulted in the higher 
P450 1A1/1A2 activity, which was verified with mathematical analysis based on 
convection-diffusion model. In the experimental data shown as dots in Figure 5.13, 
when the cell number in a µCCA was increased from 5 x 104 cells/ml to 1 x 105 
cells/ml, the product of enzymatic reaction increased approximately two-fold. For 
example, after 75 minutes, the resorufin concentration was measured to be 5.52 nM 
and 10.6 nM in cases of 1X and 2X cell number, respectively. However, in the case 
where the cell number was increased from 1 x 105 cells/ml to 2 x 105 cells/ml, the 
product concentration increased only about 50% (10.6 nM and 16.9 nM). To examine 
the effect of hydrogel cell culture on the P450 1A1/1A2 activity of HepG2/C3A cells, 
the cel ls  were encapsulated in Matr igelT M and cul tured,  both in 96- 
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Figure 5.12 Simulated and measured resorufin formation at different substrate 
concentrations 
 (a) 1 μM and (b) 10 μM substrate concentration. In both cases, the well-mixed, two-
compartment model predicts faster saturation than experimental results or the 
convection-diffusion model. 
 
 
Figure 5.13 Simulated and measured resorufin formation at varying cell concentration. 
1X corresponds to 50,000 cells, 2X corresponds to 100,000 cells, and 4X corresponds 
to 200,000 cells in the liver chamber. The increase in the cell number resulted in the 
increased enzyme activity, although the amount of increase was not proportional at the 
highest cell number. 
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well plates. The P450 1A1/1A2 activities of the hydrogel-embedded cells and cells in 
monolayer were compared. Cells cultured in MatrigelTM showed slightly higher 
enzyme activity over the control, although the difference was not statistically 
significant (Figure 5.14). This result suggests that the microfluidic versus the static 
environment was responsible for the different responses of the uninduced cells. 
 
5.4 Discussion 
5.4.1 Ethanol Toxicity and CalceinAM Staining 
  
The acute toxicity ethanol upon cells was observed in real-time using the 
ISFODS. As seen in Figure 5.5 and 5.6, cells showed dose-dependent response to 
ethanol. Ethanol causes an immediate cell lysis and death, and subsequent loss of 
fluorescence signal of CalceinAM. The major cause of fluorescence loss was due to 
the damage of cell membrane and leakage of fluorescent calcein molecules from the 
cytoplasm. The calcein molecules are subsequently washed away by the flow inside a 
µCCA. At a sufficiently low flow rate, the calcein molecules are not washed away as 
quickly, and we could observe the whole background getting brighter, due to the 
calcein molecules leaking. One difficulty associated with observing the cell staining 
process inside a µCCA was that initially the area of detection is completely dark, so it 
is difficult to focus onto the cells. To avoid such an issue, we needed to work out in 
advance the appropriate position of the optical components so that when cells start to 
become fluorescent, the cells are appropriately focused. Still, we needed to further 
adjust the focus in a relatively short time to ensure that the early phase images are 
taken.  
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Figure 5.14 P450 1A1/1A2 activities of chemically induced HepG2/C3A cells 
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5.4.2 Cell Growth Monitoring with ISFODS 
 
It was demonstrated that using the ISFODS, the growth of cells could be 
monitored for several days while operating a microfluidic device. The reason for 
seeding the cells at a high density was to ensure that the cells made a good contact to 
the silicon surface, so that the cells could maintain their viability in the presence of 
hydrodynamic shear stress. When cells were seeded in a lower density and the flow 
was introduced, often cells seemed to be less healthy and less spread out, judging from 
the cell morphology under the microscope. It has been shown that the spreading and 
making a strong adhesion to the surface is important for the viability of cells 
(Ruoslahti 1997; Chen et al. 1998).  
In the case of HepG2-C3A H2B GFP cells, the cell number does not decrease 
significantly even after 80th hour, although the decrease appears to start after about 
55th hour. This trend is associated with the nature of the HepG2-C3A cell-line that 
typically adheres to the surface more strongly than the tumor cell-line MESSA H2B-
GFP. When HepG2-C3A cells are cultured in culture flasks and trypsinized for a 
subculture, they are rinsed with 0.25% (w/v) trypsin and 0.53 mM EDTA solution. 
They generally require a longer incubation time with trypsin-EDTA than other tumor 
cell-lines until the cells detach from the surface. For an identical incubation time, 
HepG2-C3A cells likely adhered to the surface even at a critical stage where the tumor 
cells have already been detached. HepG2-C3A cells may also be more resistant to the 
stress conditions that inhibit MESSA H2B-GFP cells.  
Unlike experiments where cell-based assays are measured for a relatively short 
period of time, cells in long-term assays undergo a number of cell mitoses that are 
often accompanied by cell detachment. Unlike static cell culture conditions, in a 
microfluidic environment mitotic cells can detach from the surface due to shear, 
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therefore a quiescence state of cells can be obtained depending on the flow rate 
(Prokop et al. 2004). This means that cell growth index tends to be underestimated, 
which may explain why cell growth index in the case of HepG2-C3A cells does not 
grow significantly and relative mild increase for MESSA H2B-GFP cancer cells.  
 
5.4.3 Enzyme Activity Monitoring in µCCA 
 
Experiments with HepG2/C3A cells revealed that the hepatoma cells showed 
considerably different behavior when they were cultured in 3-D matrix in a 
microfluidic environment. The level of P450 enzymes in hepatoma HepG2 is reported 
to be significantly lower than the level in hepatocytes (Wilkening et al. 2003), which 
was consistent with our 96-well plate experiment result. However, it was observed in 
this study that the P450 enzyme activity of hepatoma cells cultured in the matrix of 
MatrigelTM inside a µCCA was significantly higher than the same cells cultured in 2-D 
monolayer in a well. Possibly the higher activity observed in a µCCA may be because 
the microfluidic environment inside a µCCA is closer to the physiological 
microenvironment than a 2-D monolayer cell culture in a 96-well plate. According to 
recent studies, a culture of hepatocytes with an ECM layer is known to help 
hepatocytes retain liver-specific functions better (De Smet et al. 2000), and culturing 
hepatocytes in 3-D scaffold has shown to be advantageous for restoring liver-specific 
functions (Sivaraman et al. 2005). A sub-lethal shear stress that is present in a 
microfluidic device can also be advantageous in enhancing P450 activity (Mufti and 
Shuler 1995). The microenvironment in a µCCA may provide all these factors, since 
the cells are cultured embedded in MatrigelTM, which is a mixture of various ECM 
proteins and growth factors. In addition, the medium perfusion may provide an 
appropriate level of hydrodynamic shear for the cells. To assess the effect of culturing 
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the cells in Matrigel, P450 1A1/1A2 activity of HepG2/C3A cells in Matrigel was 
measured in a 96-well plate and a slight increase in the P450 activity was observed 
(Figure 5.14). Therefore the contribution of a constant flow seems to be greater than 
MatrigelTM, although the effect may be synergistic. The effect of microenvironment in 
a hydrogel matrix on the metabolic activity of liver cells inside a microfluidic device 
is under further study.  
 
5.5 Conclusion 
 
The ISFODS described in this chapter is a compact optical system built to 
enable integration with an operating microfluidic cell culture system for real-time 
fluorescence measurements. Combined with mathematical modeling, the system was 
shown to provide detailed quantitative analysis of reactions within a microfluidic 
device and extraction of enzyme kinetic parameters without disrupting the operation. 
In previous studies, we demonstrated that a combined effort of an experimental 
approach such as μCCA and a mathematical modeling, e.g., a PBPK model, can be a 
powerful tool in gaining insights into the mechanism of drug toxicity (Sweeney 1995; 
Ghanem and Shuler 2000). The development of more accurate and detailed 
mathematical models of a microfluidic system depends critically upon the availability 
of real-time data measured, for example, by the ISFODS described in this paper. The 
in situ measurement system can be a versatile tool as an analytical module combined 
with various microfluidic perfusion cell culture devices in diverse formats and can 
provide real-time, on-chip analysis that may not be available using a plate reader or a 
conventional microscope. Furthermore, multiplexing the µCCA devices with this type 
of an optical detection system would facilitate operation in high-throughput modes.  
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CHAPTER 6 
A MICROFLUIDIC DEVICE FOR A PHARMACOKINETIC-
PHARMACODYNAMIC (PK-PD) MODEL ON A CHIP 
 
6.1 Introduction 
 
The potential importance of microfluidic systems in improving the drug 
development process has been widely recognized (Kang et al. 2008). Microfluidics 
can be especially useful for reproducing the pharmacokinetics of drugs, since 
structures with multiple components, for example, a metabolizing component and a 
target component, can be created and connected with fluidic channels for interactions. 
Recently, Ma et al. developed a three-layer microfluidic system to test metabolism-
dependent toxicity of drugs (Ma et al. 2009). The device consists of a top-layer for 
feeding drugs, a middle layer with sol-gel human liver microsomes bioreactor for 
metabolism, and a bottom-layer for cell culture chambers. Molecules are transported 
through the layers via diffusion, and the effect of acetaminophen metabolism on target 
cells was observed using the system. In another study, a hepatocyte-bioreactor was 
developed to assess hepato-activated transformation of substrates (Koebe et al. 2000). 
These systems successfully demonstrated that the metabolism-dependent toxicity of 
drugs can be observed in vitro, but does not reproduce the true dynamics of drug 
exposure to the human body.  
Previously, we developed a micro cell culture analog (µCCA), also known as 
‘body-on-a-chip’, which is a microfluidic device for pharmacokinetic-based drug 
toxicity test (Sin et al. 2004; Khamsi 2005). Multiple cell types representing different 
organs are cultured on a single chip, interconnected by channels mimicking the blood 
flow pattern. The fluid pattern in the µCCA is calculated to mimic the blood 
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circulation, thus mimicking the pharmacokinetics of drugs. In a proof-of-concept 
study, a µCCA was used to test the metabolism-dependent toxicity of naphthalene, 
doxorubicin, and Tegafur (Viravaidya et al. 2004; Sung and Shuler 2009; Tatosian and 
Shuler 2009). The µCCA was originally conceived as a physical realization of 
physiologically-based pharmacokinetic (PBPK) modeling approach. It has been 
demonstrated that the combination of a PBPK modeling and a µCCA can provide an 
insight into the mechanism of naphthalene toxicity (Ghanem and Shuler 2000).  
Although microfluidic systems have a great potential in enhancing the drug 
development process, actual applications of microfluidic systems in medical or life 
science area have been limited. One important reason for this is because current 
microfluidic devices require specialized skills for fabrication and operation, which 
makes it difficult to be used by non-experts in the field (Meyvantsson et al. 2008). In 
addition, unlike conventional cell culture systems that have been well-established over 
the past century, microfluidics have several issues that need more in-depth study, such 
as biocompatibility of materials, maintenance of sterility, formation of air bubbles, and 
the effect of shear stress on cells (Kim et al. 2007). We have seen a substantial amount 
of progress in terms of developing highly-complex microfluidic devices for high-
throughput implementation (Yang et al. 2008), but not much progress has been 
achieved in terms of simplifying the design and improving the usability of 
microfluidic systems, which will facilitate a wider use of microfluidic devices in the 
area outside engineering. 
The work described in this chapter has two main focuses. First, a microfluidic 
device was designed to enhance the usability of the device and make a high-
throughput operation easier, while allowing 3-D hydrogel cell cultures of multiple cell 
types to be inserted into separate chambers of a device to reproduce a multi-organ 
interaction. The simplicity in the device design offers several advantages. The use of 
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gravity-induced flow eliminates the need for a pump, and prevents formation of air 
bubbles. 3-D hydrogel cell cultures of defined shape and thickness can be inserted into 
the device. Secondly, the microfluidic device was combined with a mathematical 
model to quantitatively analyze the effect of a chemotherapeutic agent, 5-fluorouracil 
(5-FU). A PK-PD model that describes the response of cells to 5-FU was developed 
and fitted to experimental results, and the effect of combining the drug with a 
modulator, uracil, was predicted and compared with experimental results. To the best 
of our knowledge, this is the first attempt to combine a microfluidic system with an 
integrated PK-PD modeling approach to achieve ‘PK-PD model-on-a-chip’. We 
believe that this combined approach of an in vitro/in silico system enables prediction 
of drug toxicity in a more realistic manner than conventional in vitro systems. 
 
6.2 Materials and Methods 
6.2.1 Cell Culture and Chemicals 
 
McCoy’s 5a medium was purchased from Sigma Aldrich (St Louis, MO). 
MEM medium, RPMI 1640 medium, and Fetal bovine Serum (FBS) were purchased 
from Invitrogen (Carlsbad, CA). A Live/Dead viability/cytotoxicity kit for mammalian 
cells was obtained from Invitrogen. HEPES, sodium chloride, uracil, and 5-
fluorouracil (5-FU) were purchased from Sigma Aldrich. The colon cancer cell line, 
HCT-116, was obtained from American Type Culture Collection (ATCC, Manassas, 
VA) and cultured in a T-flask in McCoy’s 5a medium (Sigma Aldrich) with 10% FBS 
(Invitrogen). A hepatoma cell line, HepG2/C3A (ATCC), was maintained in MEM 
medium (Invitrogen) with 10% FBS. Myeloblast cell line Kasumi-1 (ATCC) was 
maintained in RPMI-1640 medium (ATCC) with 20% FBS. All cell lines were 
cultured in a mammalian cell incubator maintained at 37Ԩ with 5% CO2. 
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6.2.2 Design and Fabrication of a Micro Cell Culture Analog (µCCA) 
 
The µCCA device consists of multi-layers of PDMS (polydimethyldisiloxane), 
sealed between aluminum bottom and plexiglass top frames with screws (Figure 6.1). 
Underneath the top plexiglass top frame, a PDMS fluidic channel layer is placed. This 
provides the fluidic conduits for three cell culture chambers and inlet and outlet holes 
for medium recirculation. The geometry of the channels for each chamber is designed 
to mimic the blood flow distribution of the human body (58%, 18%, and 24% into the 
liver, tumor, and the marrow compartment, respectively) (Davies and Morris 1993; 
Sung and Shuler 2009). Beneath the channel layer, cell culture chamber layer is placed. 
This layer is a 0.2 mm thick silicone layer with three through-holes for cell culture 
chamber and two through-holes for inlet and outlet. Hydrogel-encapsulated cells 
representing the liver, tumor and the marrow will be placed in each chamber. The cell 
culture chamber layer is placed on top of a polycarbonate base, which provides a 
surface to support the hydrogel matrix. Between the polycarbonate base and the 
bottom aluminum frame, a 0.5 mm silicone gasket (Grace Bio Labs) is placed, mainly 
to provide a sealing between the aluminum and polycarbonate pieces. The 
polycarbonate base and a silicone gasket also have two inlet and outlet through-holes, 
which are to be aligned with inlet/outlet holes in other layers. All of these layers are 
clamped between top and bottom frames, as explained in the assembly section.  
 The channel layer was fabricated using conventional soft-lithography 
techniques. The design of the channels was drawn using AutoCAD (Autoworks, San 
Rafael, CA), and the design was converted and exposed onto a Chrome-coated glass 
mask using GCA/MANN 3600F Optical Pattern Generator (Ultratech, San Jose, CA). 
SU-8 2075 (MicroChem, Newton, MA) of 225 µm thickness was spin-coated on a 
silicon wafer by spinning at 300 rpm for 30 seconds. After soft-baking at 65 Ԩ for 5 
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minutes the temperature was raised to 95 Ԩ and left for 45 minutes. The pattern on the 
glass mask was exposed to SU-8 coated silicon wafer at 650 mJ/cm2 using EVG620 
contact aligner (EV Group, Tempe, AZ). Then post-exposure bake was done at 65 Ԩ 
for 1 minute and 95 Ԩ for 15 minutes, and the master was developed in a SU-8 
developer solution for 12 minutes with agitation. PDMS monomer and a curing agent 
were mixed in 10:1 ratio. After degassing to remove foams, the mixture was gently 
poured onto the SU-8 master. The PDMS was cured at 65 Ԩ for 90 minutes and the 
PDMS structure was cut and peeled off from the master. Each channel layer was cut to 
the size of approximately 30 mm by 30 mm. The cell culture chamber layer was made 
by punching three holes with 4 mm biopsy punch (Fisher Scientific, Hampton, NH) in 
a 0.25 mm thickness silicone gasket (Grace Bio Labs, Bend, OR). The polycarbonate 
base frame was made by cutting a 0.5 mm thickness polycarbonate piece into 30 mm 
by 30 mm size, and drilling 2 mm diameter holes at two corners for medium 
recirculation. For the silicon gasket layer, a 0.5 mm thick silicon sheet was cut to the 
same size, and inlet and outlet holes were punched with a biopsy punch (2 mm, Fisher 
Scientific). The aluminum bottom and plexiglass top frames were made with a milling 
machine, by drilling a screw hole on each side. The bottom frame also has two 
inlet/outlet holes (~ 2 mm diameter) at each corner. A well, or medium reservoir is 
made by curing a 5 mm thick PMDS sheet, cutting it to 1 cm by 1 cm size, and 
punching a 4 mm through-hole with a biopsy punch. The PDMS well was fixed on the 
drilled inlet/outlet hole with biocompatible, non-toxic glue (Epotek 301-2, Epoxy 
Technology, Billerica, MA). Aluminum was chosen for easy sterilization by 
autoclaving, and plexiglass was chosen for an easy visual inspection with a 
microscope. The plexiglass top frame does not need to be sterilized since it is not in a 
direct touch with cell culture medium, but was wiped with 70% ethanol before use. 
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6.2.3 Device Assembly and Operation 
 
The device assembly process begins by placing the silicone gasket layer and 
the polycarbonate base frame on top of the aluminum frame. Then the cell culture 
chamber layer is placed on top. To prevent wrinkling of the 0.25 mm thin cell layer, a 
drop of 95% ethanol is placed on top of the polycarbonate base before placing the cell 
layer. After placing the cell layer on top, the whole device is placed in a hot oven for 
evaporation of ethanol, leaving the cell culture chamber layer in a uniform contact 
with the polycarbonate base frame. The assembled aluminum bottom frame, silicone 
gasket, polycarbonate base, and the cell culture chamber layer are placed in a Pyrex 
dish (150 x 20 mm, Fischer Scientific), and then sterilized by autoclaving. Cells are 
prepared by trypsinizing and centrifuging, and resuspending in 2% (w/v) alginate 
solution at 4x106 cells/ml. The alginate solution was made by dissolving alginate 
powder (10/60 LF sodium alginate, FMC biopolymer) in a HEPES buffer (15 mM 
HEPES, 92 mM sodium chloride). The alginate solution was filter-sterilized with 0.2 
μm pore size syringe filter (VWR scientific, West Chester, PA). Cell-alginate 
suspensions of three cell types were prepared (HepG2/C3A, HCT-116, Kasumi-1, 
representing the liver, tumor and the marrow, respectively), and 10 μl of each cell 
suspension was placed in corresponding cell culture chamber. A porous polycarbonate 
membrane filter (8 μm pore size, VWR Scientific, West Chester, PA) was placed on 
top to flatten the alginate solution, and sterile-filtered 30 mM calcium chloride 
solution was applied onto each chamber to polymerize the hydrogel. After 30 minutes 
incubation at room temperature, calcium chloride solution and the membrane filter are 
removed. Then the top surface is flooded with 1 ml of DPBS, and the PDMS channel 
layer is closed on top, with channels facing down. The PDMS channel layer needs to 
be closed in a tilted manner to avoid capturing air bubbles. In addition, the PDMS 
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channel layer was sterilized by autoclaving the day before the assembly, and immersed 
in a sterile-filtered 3% pluronic F68 solution (Sigma-Aldrich, St. Louis, MO) 
overnight. This helps wet the surface of a hydrophobic PDMS surface, and prevents 
capturing air bubbles upon closing the channel layer. After closing the channel layer, 
the plexiglass top frame is placed on top, and the whole device is secured with screws. 
The device assembly and cell seeding process are summarized in Figure 6.1(b). 
Typically, twelve chips (with three cell types in each device) could be assembled in 
about two hours, excluding the time for autoclaving.  
 In case of using MatrigelTM instead of alginate to encapsulate cells, the same 
protocol was used except three differences. First, instead of a polycarbonate base piece, 
a glass piece was used for an improved sealing. A more secure sealing was required to 
use Matrigel in the device, which is softer than alginate. Secondly, gel was 
polymerized by incubating at 37 Ԩ, instead of using calcium chloride solution. Lastly, 
gel was dissolved in DPBS/5 mM EDTA solution to retrieve cells.     
 After assembly, the device is flipped upside-down, and two PDMS medium 
reservoirs on the bottom frame were filled with medium. The device in a sterile Pyrex 
dish was placed on a rocking platform, which was set to change direction at 
approximately every three minutes. Unless stated otherwise, uracil was added to 5-FU 
in 5:1 molar ratio, to prevent premature degradation of 5-FU. The whole system was 
placed inside a temperature-controlled mammalian cell culture incubator with 5% CO2. 
After specified amount of time, the device was removed from the incubator and 
dissembled. Cells were retrieved by dissolving the alginate in a dissolving buffer (55 
mM sodium citrate, 30 mM EDTA, 0.15 M NaCl) for 30 minutes at 37 Ԩ. Cell 
viability was determined by Trypan-blue exclusion assay using a hemocytometer. At 
least triplicates were done for each data point.    
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Figure 6.1 Schematics of device assembly 
(a) A schematic of device components. A channel layer and a cell culture chamber 
layer are superimposed and sealed by top and bottom frames. A silicone gasket and a 
polycarbonate base are inserted for better sealing. (b) Cell seeding and device 
assembly process. Hydrogel-encapsulated cells are seeded into corresponding holes on 
a cell culture chamber layer, and flattened with a porous membrane. Alginate gel is 
formed by wetting with calcium chloride solution for 30 minutes. After gel formation 
membrane is removed and the channel layer is closed on top, and the top layer is 
closed for sealing. (c) A picture of the assembled device. A red dye was used for 
visualization of channels, and a blue dye was mixed with alginate. 
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6.2.4 Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling 
 
A PK-PD model was developed by constructing a PK and a PD model 
separately, and then combining the two. A PK model has the same layout as a µCCA 
device. Inside each compartment, there is a PD model, which predicts how fast cells 
die in response to 5-fluorouracil. Combination of a PK and a PD model enables 
prediction of how fast cells would be killed in response to a given dosage of 5-FU and 
uracil.  
To construct a PK model for a µCCA, mass balance equations describing the 
flow in, flow out, and metabolism were set up for each compartment. Solving the 
equations requires several parameters, such as physiological parameters (flow rate and 
size of chambers) and enzyme kinetic parameters for the metabolism of 5-FU and 
uracil, which are summarized in Table 6.1. The predicted concentration profiles of 5-
FU and uracil were used as inputs of a PD model in each compartment. To construct a 
PD model that predicts the response of cells to the drugs, a transit compartment model 
was used. A transit compartment is useful for modeling the growth kinetics of tumor 
in response to chemotherapeutic agents (Lobo and Balthasar 2002). Figure 6.2 shows 
the design of the three-chamber µCCA device, and a corresponding PK model of the 
device, and a PD model for each compartment. All of equations for the PK-PD model 
were solved using the ode45 routine of Matlab software (Mathworks, Natick, MA). 
The parameters for the PD model were fitted to experimental data by using the 
lsqnonlin (non-linear least square) routine of the optimization toolbox in the Matlab 
software. The fitted parameters were Kmax, KC50, and kd. Other parameters were fixed 
at C0 = 3000, Css = 14000, kg = 0.001, tau = 5 (Sung et al. 2009). The viability at each 
time point was calculated as the ratio of the number of live cells to the number of total 
cells. 
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Figure 6.2 A µCCA and corresponding PBPK and PD models 
(a) A design of a three-chamber µCCA. (b) A corresponding PBPK model, with the 
liver, tumor and marrow compartment. (c) A PD model for cell death in each 
compartment. The ‘organ’ can be the liver, tumor or marrow. 
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Table 6.1 Parameters for the PK model of a µCCA 
 
Name Description Value 
Physiological parameters1 
V_L Volume of liver chamber 11.3 μl 
V_T Volume of tumor chamber 11.3 μl 
V_M Volume of marrow chamber 11.3 μl 
V_B Volume of medium reservoir 300 μl 
Q_L Flow rate into liver chamber 87.6 μl/min 
Q_T Flow rate into tumor chamber 26.7 μl/min 
Q_M Flow rate into marrow chamber 35.6 μl/min 
Enzyme kinetic parameters2  
Vm_FU Maximum rate of 5-FU metabolism  2385 nmol/min/ml
Km_FU Michaelis-Menten constant for 5-FU metabolism 40 nM 
Vm_U Maximum rate of uracil metabolism 1695 nmol/min/ml
Km_U Michaelis-Menten constant for U metabolism 40 nM 
Ki_U3 Inhibition constant of uracil on 5-FU metabolism 20 nM 
Ki_FU3 Inhibition constant of 5-FU on uracil metabolism 10 nM 
 
1. Physiological parameters such as volumes and flow rates of organ chambers 
were determined based on reported values of organ sizes and blood flow rates in the 
human body (Davies and Morris 1993; Sung and Shuler 2009) 
2. The enzyme kinetic parameters were calculated from the rate of 5-FU and 
uracil metabolism in a rat (Ikenaka et al. 1979), and reported protein content and cell 
number in the liver(Quick and Shuler 1999). The reported rates of 5-FU and uracil in a 
rat and human are comparable (Naguib et al. 1985).   
3. Inhibition constants were taken from a previous study (Sung et al. 2009). 
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6.3 Results 
6.3.1 Device Assembly and Gravity-induced Flow 
 
Bonding of PDMS by oxygen plasma treatment is the most common method of 
sealing a microfluidic device made of PDMS. However, micro cell culture analog 
requires seeding multiple types of cells in a single device to achieve a multi-organ 
interaction; therefore the device has to be assembled after seeding each cell in the 
chambers of the device. The device was sealed by securing a plastic top and aluminum 
bottom frame with screws, with the PDMS channel layer and a hydrogel layer 
sandwiched between the frames. Although this method is reversible and may not be as 
robust as the irreversible sealing by plasma bonding, the sealing was sufficiently 
robust to prevent the leakage of recirculating medium from the device. The sealing at 
the interface between the channel and the gel layer was verified by using a fluorescein 
solution and fluorescent beads. Figure 6.3 shows the microscope pictures of the device 
after assembling the device, showing the sealing between the channels and the 
hydrogel. A bright-field image in Figure 6.3(a) shows both of channels and a chamber, 
and in Figure 6.3(b) the channels are visualized with fluorescein solution. Figure 3(c) 
shows the fluorescent beads embedded in the hydrogel. When cell-hydrogel mixture is 
introduced into the chamber, the height of the hydrogel must higher than the surface of 
the PDMS hydrogel layer to avoid leaking. In addition, gels shrink in volume during 
gelling process, so excess amount of cell-hydrogel mixture had to be inserted. On the 
other hand, inserting too much volume of hydrogel would result in blocking the 
channels above. In case of 0.5 mm thickness hyFdrogel layer, it was calculated that 
volume of a chamber in a hydrogel layer is about 10 μl. The sealing of the device gave 
the best result when the amount of cell-hydrogel mixture inserted was 18 μl. In case of 
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0.2 mm thickness gel, 10 μl volume of mixture was inserted to give the best sealing 
result.  
The recirculation of cell culture medium was achieved by gravity-induced flow 
(Figure 6.4(a)). Using gravity has several advantages over using an external pump. 
First, removal of an external pump reduces the total space occupied by the device and 
enables a high throughput experiment. Secondly, use of silicone tubing often causes 
adsorption of molecules on the inner surface, and gravity-induced flow eliminates the 
possibility of unwanted binding. Thirdly, using gravity automatically solves the 
problem of air bubble formation, since air bubbles are prevented from entering the 
device due to its buoyancy. The flow rate through the conduits depends on several 
factors, and can be expressed by following equation (Morier et al. 2004). 
 
 Q ൌ   ρ୥π଼η
∆୦Rర
L       (6.1) 
Where Q is the volumetric flow rate (m3•sec-1), ρ is a density (kg•m-3), g is the gravity 
constant (m•s-2), η is a fluid viscosity (Pa•s), Δh is a height difference (m), R is the 
radius of a channel (m), and L is the length of a channel (m). The µCCA device 
consists of several channels connected in parallel, and can be thought as a single 
hypothetical single channel when combined together. The equation (1) indicates that 
the flow rate is linearly proportional to the height difference, and the experimental 
result shown in Figure 6.4 demonstrates that this is true. However, the line does not 
converge to zero intercept, as predicted by the equation. A possible cause for such an 
observation is that after the flow is initiated, the height difference continuously 
changes as the liquid moves from the higher well to the lower well, which could have 
introduced an error in the measured height difference. With a smaller initial height 
difference, the effect of the error would have been greater.   
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Figure 6.3 Sealing of device 
(a) A bright-field picture of the assembled µCCA. A cell culture chamber and 
channels are shown on the left side of the picture (b) A fluorescein solution was 
inserted to visualized the channel and test sealing. Channels are shown in bright green. 
Fluorescein also diffuses into alginate, staining them in light green. (c) A cell culture 
chamber is seen with red fluorescent beads, which were mixed with alginate and 
inserted into a µCCA. 
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Figure 6.4 Gravity-induced flow 
(a) Medium recirculation with gravity-induced flow in a µCCA. Tilting of the device 
causes liquid to flow from one well to the other well. After three minutes, the rocking 
platform changes the angle and medium flows in the opposite direction. (b) A plot of 
measured flow rates against various heights. 
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Using the gravity induced flow, it was possible to operate the device for 
several days with cells maintaining good viability. Figure 6.5 shows the live/dead 
staining result of the three cell types cultured in the device for three days. After three 
days, cells remained quite healthy, although different viability was observed 
depending on the cell type. For example, colon cancer cell line (HCT-116) showed 
viability close to 100%, whereas myeloblast (K-1) and hepatoma cell line 
(HepG2/C3A) showed somewhat lower viability. This difference demonstrates the 
variations in the cell response to the 3-D microfluidic environment. The observed 
trend in the cell viability in Figure 6.5 agrees with the viability measured using 
Trypan-blue exclusion assay, as will be shown later. In addition, it should be noted 
that the result shown in Figure 6.5 is for the case where the cell culture medium was 
recirculated without replenishment. Therefore, eventually a nutrient depletion and 
waste accumulation in the recirculating medium would have caused a loss of cell 
viability. In case where the cell culture medium was replaced every day, cells 
maintained a higher viability for a longer period of time.  
 
6.3.2 Construction of PK-PD model 
 
A PD model for a static hydrogel cell culture was constructed first. In the case 
of a static cell culture, a PK model is not needed, since a single cell type is cultured at 
a time, and no multi-organ interaction is expected to occur. A transit compartment 
model was constructed for each cell type, and the parameters for each cell type were 
fitted to experimental data. A transit compartment model assumes a series of transit 
compartments, representing various cell stages eventually leading to the cell death. It 
has been used for modeling the time-dependent, irreversible effect of a 
chemotherapeutic agent on tumor cells (Lobo and Balthasar 2002). Figure 6.6 shows  
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Figure 6.5 Live/dead staining of cells 
(a) HepG2/C3A (b) HCT-116 (c) Kasumi-1 cells in a µCCA after three days of 
operation with medium recirculation 
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the experimental results with the simulation results of the constructed PD model in 
static condition. Overall, predicted cell viabilities for the three cell types showed a 
good agreement with the experimental data. However, some variations in the trend 
were observed. In case of HepG2/C3A cells, the drop in the viability seemed to be 
slower in day 2 and day 3, compared with a faster drop in the viability in the case of 
other cell types. Kasumi-1 cells, in particular, showed a considerable drop in the 
viability on day 3, when treated with 0.5 mM 5-FU. In general, PD models predicted 
more linear responses than the experimental result. This could imply that an additional 
molecular mechanism might be present, which is not accurately described by the 
transit compartment model. The fitted parameters for the PD model are summarized in 
Table 6.2. 
 A PK model was constructed for the µCCA with three different 5-FU 
concentrations. Figure 6.7(a) shows the concentration profiles of 5-FU in the device 
for the three dosing conditions. Due to the combination of uracil with 5-FU, 
metabolism of 5-FU is prohibited, and almost constant concentrations of 5-FU are 
maintained in all three concentrations. The short residence times in each compartment 
(100, 240, 180 seconds for the liver, tumor and the marrow compartment) ensure that 
all compartments are quickly equilibrated with medium reservoir, and the 
concentration profiles of 5-FU in the liver, tumor and the marrow compartment were 
similar to one another.  
 Once the PK model was constructed, the 5-FU concentration profile in each 
compartment was used as an input for a PD model in the same compartment. The 
parameters for the PD models were fitted to the cell viability result of the 
corresponding cell type, which are summarized in Table 6.3. Interestingly, Figure 6.7 
shows that all cell types showed drastically different responses from one another, and 
also different responses from the static condition. In general, all cells showed a higher 
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sensitivity to 5-FU in a µCCA than in static condition. The high sensitivity of the cells 
in a µCCA was more evident in case of higher 5-FU concentrations in all cells. Also, 
when cells were tested in a µCCA, the differences between the cell types were more 
distinct than when they were tested in static condition. In the case of the static 
condition, shown in Figure 6.6, all three cell types showed similar trends in response 
to 5-FU treatment. In the case of a µCCA, in Figure 6.7, tumor (HCT-116) and 
morrow (Kasumi-1) cell lines were much more sensitive to 5-FU treatment than 
hepatoma (HepG2/C3A) cell line. The behavior of the cells in the absence of drugs 
was markedly different, too. When 5-FU concentration was zero, hepatoma cells 
showed a gradual loss in cell viability. In the case of marrow cell line, cell viability 
was as low as 60% on day 3, even without 5-FU treatment. The tumor cell line 
maintained a high viability throughout the three-day period, about 95% on day 3. On 
the other hand, when the cells were cultured in static condition, the behavior of the 
cells was similar to one another. At zero 5-FU concentration, all cells showed a 
gradual decrease in cell viability over three days, and addition of 5-FU caused a 
similar amount of drop in the cell viability across all three cell types. 
  
6.3.3 Effect of Uracil as a Modulator 
 
The major pathway for the metabolism of 5-FU is known to be through the 
enzyme dihydropyrimidine dehydrogenase (DPD), mainly present in the liver (Van 
Kuilenburg et al. 2002). Uracil inhibits 5-FU metabolism, and is often combined with 
5-FU to enhance the effect of 5-FU (de Bono and Twelves 2001). The effect of uracil 
as a modulator of 5-FU was tested by removing uracil from the drug combination. 
First, using the PK-PD model for a µCCA, the PK profile and the responses of cells to 
the drugs (5-FU only and 5-FU plus uracil), was simulated (Figure 6.8(a)).   
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Figure 6.6 Measured and simulated cell viability in static condition 
(a) HepG2/C3A (b) HCT-116 (c) Kasumi-1 for four different concentrations of 5-FU 
(0, 0.1, 0.2, and 0.5 mM). 
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Figure 6.7 Measured and simulated cell viability in a µCCA 
(a) Predicted concentration profiles of 5-FU in a µCCA for three different dosages. 
Measured and simulated viability of (b) HepG2/C3A (c) HCT-116 (d) Kasumi-1 cells 
in a µCCA treated with four different 5-FU concentrations for three days 
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Table 6.2 Parameters for a PD model in static condition 
 HepG2/C3A HCT-116 Kasumi-1 
Kmax 0.0578 0.0966 0.0992 
KC50 5515.2 8607.9 7409.4 
kd 0.003 0.0029 0.0038 
 
 
 
 
Table 6.3 Parameters for a PD model in a µCCA 
 HepG2/C3A HCT-116 Kasumi-1 
Kmax 0.0470 0.0311 0.0299 
KC50 1665.3 205.3 246.6 
kd 0.0027 0.0002 0.0055 
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Figure 6.8 Effect of uracil as a modulator 
(a) Predicted concentration profiles of 5-FU in a µCCA at two dosing conditions (0.1 
mM 5-FU alone and 0.1 mM 5-FU plus 0.5 mM uracil). (b) Viabilities of three cell 
lines treated with 5-FU alone or 5-FU plus uracil. (c) Viability of three cell lines after 
3-day treatment with 5-FU alone or 5-FU plus uracil. Cells were encapsulated in 2% 
alginate in a µCCA. (d) Predicted concentration profiles of 5-FU in a µCCA at two 
dosing conditions (5-FU alone and 5-FU plus uracil), with the rate of 5-FU 
metabolism reduced three-fold. (e) With the reduced metabolic activity, combination 
of uracil does not enhance the PD profile of 5-FU. (f) Viability of three cell lines after 
3-day treatment with 5-FU alone or 5-FU plus uracil. Cells were encapsulated in 
MatrigelTM in a µCCA.  
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The absence of uracil is predicted to cause faster metabolism of 5-FU, resulting 
in about 80% reduction in 5-FU concentration on day 3. Consequently, all three cell 
types are predicted to have higher cell viabilities when treated with 5-FU only (Figure 
6.8(b)). However, when this was tested experimentally using a µCCA, the difference 
in the cell viability was not significant (Figure 6.8(c)). We hypothesized that this was 
due to an insufficient metabolic activity of liver cells in the device. This was verified 
by a mathematical simulation, where the value of Vmax in the PK-PD model was 
arbitrarily reduced. In this case, metabolism of 5-FU is slower, and absence of uracil 
does not have as much effect on the pharmacokinetics of 5-FU (Figure 6.8(d)). 
Consequently, the predicted cell viabilities in both cases are similar (Figure 6.8(e)). To 
enhance the metabolic function of HepG2/C3A cells, MatrigelTM was used instead of 
alginate as an encapsulating matrix. In this case, shown in Figure 6.8(f), combination 
of uracil with 5-FU showed an enhanced cytotoxic effect compared to 5-FU alone. 
Furthermore, the liver cells showed similar viabilities in both cases, whereas the tumor 
and marrow cells showed significantly lower cell viabilities when they were treated 
with 5-FU plus uracil than 5-FU alone (p < 0.05 for both tumor and marrow cells), 
which was consistent with a model prediction. 
 
6.4 Discussion 
6.4.1 Advantages of Layered Design 
 
One of the aims of this work was to develop a ‘user-friendly’ microfluidic 
device, with a relatively easy device assembly and operation, high throughput 
implementation, and data extraction. These conditions had to be met while still 
enabling multi-organ interaction, which requires culturing multiple cell types in 
separate chambers in a single microfluidic device, and connecting them with fluidic 
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conduits. Having to seed multiple cell types sets a challenge in sealing the device, 
because the device has to be sealed after the cell seeding. The most common way of 
sealing a PDMS microfluidic device is oxygen or air plasma treatment, which would 
kill the cells. Equipping the microfluidic device with a fluidic-control system such as 
pneumatic valves (Unger et al. 2000) would allow to sealing the device before cell 
seeding, but this approach would increase the complexity of the device, which 
contradicts our initial objective. The separate layers for the cell culture chambers and 
fluidic conduits allowed one to seed multiple cell types at a time, and sealing the cell 
culture chamber layer and the channel layer with top and bottom frames provided a 
consistent sealing.  
This design offered another advantage, that the thickness and the shape of the 
cell-encapsulated hydrogel could be changed simply by replacing the cell culture 
chamber layer, without having to modify the whole system. In addition to the 0.2 mm 
thickness layer used in this study, we also tested 0.5 mm and 1 mm thickness layers 
successfully. This feature may become useful in future studies, because the transport 
of oxygen and nutrients inside the system can be controlled by changing the geometry 
of the cell culture chambers. For example, the liver tissue is known to have a 
differential oxygen tension across its length, and the local liver function is known to 
vary depending on the local oxygen concentration, known as liver zonation (Allen and 
Bhatia 2003). A study with different oxygen concentrations in the system can be 
performed easily, simply by replacing the cell culture chamber layer with a different 
thickness, rather than fabricating the whole device. In addition, the use of gravity-
induced convective flow eliminated the use of a pump, which enabled a more high-
throughput implementation at a lower cost. Another, perhaps a more important 
advantage was that air bubble formation inside the device was naturally eliminated. 
The formation of air bubbles is a notorious problem in microfluidic systems, and 
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several attempts have been made to avoid this by using an external or in-line bubble 
trap (Kang et al. 2008; Skelley and Voldman 2008; Sung and Shuler 2009). However, 
the performance of a bubble trap is not always perfect, and it always has a limit in its 
capacity, that is, in the maximum amount of bubbles it can capture. The µCCA device 
could be operated in a bubble-free manner by using a gravity-induced flow, since 
bubbles were prevented from entering the device due to its buoyancy.  
 
6.4.2 Insights from a PK-PD Model of a µCCA  
 
The parameters for a PBPK model of a µCCA were found from the literature 
and from experimental conditions, whereas the parameters for the PD model were 
optimized by fitting to experimental data. It should be noted that the use of gravity-
induced flow and a rocking platform results in a reciprocating mode of recirculation; 
instead of a continuous, closed-loop recirculation, the direction of the flow changes 
every three minutes. The effect of the reciprocating recirculation on the 
pharmacokinetic profiles of drugs was tested by mathematical simulation, and it was 
verified that this mode of recirculation causes a negligible deviation on the 
concentration profiles of both prodrug and metabolite (Figure 6.9). In addition to the 
PK-PD model for a µCCA, a PD model for the cells treated in static condition was 
developed, for comparison with a dynamic condition in a µCCA. The growth of cells 
was assumed to be negligible by setting the growth rate parameter at 0.001, because it 
was observed that the cell growth was negligible during the three-day period when 
encapsulated in alginate matrix. This observation was consistent with previous studies 
by other researchers, where cell growth was poor in alginate due to its inability to 
attach to the negatively-charged polymers (Grandolfo et al. 1993; Lawson et al. 2004).  
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Figure 6.9 Comparison of PK profile for different modes of recirculation 
Pharmacokinetic profiles of a hypothetical prodrug (A), and its metabolite (B) were 
simulated with a mathematical model representing the two modes. Each compartment 
was segregated into five sub-compartments, since using well-mixed assumption for the 
compartment neglects any difference that may be caused the reciprocating 
recirculation. (a) In the first model, a continuous recirculation is shown, where the 
flow coming out of each compartment goes back into the reservoir for recirculation. (b) 
In case of gravity-induced flow, the direction of the flow changes every three minutes. 
(c) Predicted concentration profiles of a prodrug A in both cases. (d) Predicted 
concentration profiles of metabolite B. 
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Comparison of optimized parameters gave a further insight into the behavior of 
cells in various conditions. In the transit compartment model, Kmax shows how fast 
cells progress through the cell death mechanisms, and KC50 shows the concentration 
range of the drug in which they are most sensitive. Comparison the graphs in Figure 
6.6 and 7 shows that in a µCCA cells go through cell death more rapidly in the static 
condition. A quantitative comparison of the parameters in static condition (Table 6.2) 
and the dynamic condition (Table 6.3) demonstrates that the differential response is 
caused by lower values of KC50 in the case of a µCCA, while the values of Kmax were 
not changed as much. This implies that in a µCCA, cells were more sensitive in a 
lower concentration range than in static condition. In addition, differential behaviors 
between cell types could also be observed. In both static and dynamic conditions, the 
liver cells (HepG2/C3A) were most resistant to 5-FU, demonstrated by a lower value 
of Kmax or a higher value of KC50 than other cell types. This observation is consistent 
with previous clinical findings, where hematological toxicity was the dose-limiting 
toxicity, and hepatotoxicity was less serious than other toxicities with 5-FU (van 
Kuilenburg 2004; Testart-Paillet et al. 2007). The value of kd reveals the ‘natural’ 
death rate, of how fast cells die when drugs are not present. In static condition, the 
values of kd were similar in all three cell types, whereas in a µCCA, the values varied 
widely between the cell types, implying that cells have differential adaptability to the 
microfluidic environment. For example, tumor cells (HCT-116, kd = 0.0002) showed 
excellent cell viability for the three days in the device, while the viability of marrow 
cells (Kasumi-1, kd = 0.0055) dropped down to about 60% on day 3 even in the 
absence of drugs.       
 In Figure 6.8, we showed the pharmacokinetic profile of 5-FU with two dosing 
strategies, administration of 5-FU alone or in combination with uracil. A mathematical 
simulation for the two dosing strategies was performed under two conditions, one with 
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a normal rate of 5-FU metabolism, and one with a low rate of 5-FU metabolism. In all 
cases, combination of uracil resulted in a higher concentration of 5-FU than the 
administration of 5-FU alone, but the amount of improvement was significantly higher 
only in the case where the metabolizing rate was normal (Figure 6.8(a) and (c)). As a 
consequence, combination of uracil enhanced the efficacy of 5-FU, that is, cells died 
more quickly, only when the metabolism rate of 5-FU was normal. Also, it is 
interesting to note that the difference in the resulting cell viabilities on day 3 is much 
smaller than the difference in the predicted 5-FU concentrations. This is because the 
mechanism of cell death due to a chemotherapeutic agent is time-dependent, and often 
the response of tumor cells is observed in a time-delayed manner (Lobo and Balthasar 
2002). This is consistent with experimental observation in Figure 6.8(f), where the 
differences in the cell viability on day 3 were about 20% to 30%. We speculate that a 
longer experiment than three days would yield a greater difference in the cell 
viabilities, which we are planning to pursue in future studies. 
  
6.4.3 Effect of Encapsulating Matrix on Cell Function 
  
HepG2/C3A is a derivative cell line of HepG2, which is originated from the 
liver and is the most commonly used cell line for assessing the liver function. 
However, it is known to retain only minimal liver-metabolic activity (Wilkening et al. 
2003). Furthermore, it is possible that culturing hepatoma cell in alginate matrix 
would reduce the metabolic function of the cells, since alginate polymers contain 
negative charges, which prevent attachment of cells, and do not provide functional 
groups necessary for proper cell signaling and function (Grandolfo et al. 1993; 
Lawson et al. 2004). It has been demonstrated that HepG2 cells can aggregate into a 
spheroid-like structure when encapsulated in alginate and cultured for over seven days 
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(Elkayam et al. 2006), but this was not observed during the three-day culture period in 
our experiment. It has been reported that the hepatic function of cultured hepatocytes 
can be enhanced by culturing them in a more naturally-derived hydrogel such as 
collagen or MatrigelTM (Brandon et al. 2003; Wang et al. 2008). In this study, a 
comparative study of encapsulating cells in alginate or Matrigel, and treating them 
with 5-FU alone or 5-FU plus uracil indicated that the metabolism of 5-FU may be 
slower in alginate than in Matrigel. We plan to verify this further in the future studies, 
by analyzing the metabolites in the recirculating medium, and comparing the rate of 5-
FU metabolism and other metabolic activities of the liver cells in different conditions. 
In a preliminary study, it was shown that the P450 1A1/1A2 activity of HepG2/C3A 
cells can be enhanced when they are cultured in Matrigel, in the presence of flow 
(Sung et al. 2009). A further in-depth study into the contributing factors of a 
microfluidic environment with 3-D hydrogel cell cultures to authentic cell functions 
can yield valuable information about how to retain the liver-specific functions of 
cultured liver cells in vitro.  
 
6.5  Conclusion 
 
A microfluidic device based on a mathematical PK-PD model was developed. 
The layer-by-layer design and the use of gravity-induced flow allowed an easy 
assembly and operation of the device for several days. A mathematical model 
describing the pharmacokinetics (PK) and pharmacodynamics (PD) of 5-FU in the 
device was constructed, and the optimization of parameters provided an insight into 
the differential responses of cells to the drug in various environments. Combination of 
PK-PD modeling and a µCCA can provide a novel in vitro/in silico platform for 
testing the effect of drugs in a physiologically realistic manner. 
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CHAPTER 7 
FINAL CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
The overall goal of this thesis work was to develop an in vitro platform to 
predict the toxicity of drugs better, using a combined approach of mathematical 
modeling and microfluidics technology. A PK-PD model was developed to describe 
tumor growth in a rat and its response to the administration of UFT. Various dosing 
strategies and the effect of metabolizing enzyme were simulated. The mathematical 
model revealed that the 5-FU chemotherapy can be optimized depending the level of 
metabolizing enzyme, and the efficacy can be further enhanced by optimizing the 
dosing schedule and the mode of administration. Based on the previous μCCA works, 
the μCCA was modified to enable 3-D hydrogel cell culture, which improved the cell 
functions in the device and allowed studies to reproduce metabolism-dependent 
toxicity of Tegafur. Among several improvements made over the previous versions, a 
PDMS microscale bubble trap significantly enhanced the consistency and success rate 
of device operation. In addition, in situ fluorescence optical detection system enabled 
a real-time monitoring of a μCCA, and it was demonstrated that the viability and the 
P450 activity of a hepatoma cell line (HepG2/C3A) can be observed and parameters 
extracted. A novel design of a μCCA was developed, which allowed easier high-
throughput implementation. Utilization of a mathematical model to analyze the 
experimental results from the μCCA gave an insight into the behaviors of different 
cells in the μCCA or in static condition.  
 Ultimately, we envision that the μCCA combined with mathematical modeling 
will be able to supplement animal studies and human clinical trials. Given the high 
cost of animal/human studies, the ability to obtain prior information about the drug 
toxicity to allow more efficient design of animal/human studies will contribute 
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significantly to reducing the overall cost of drug development. Recently, the notion of 
personalized-medicine has been gaining a wider acceptance as it has become clear that 
individual variations in patients, whether genotypic or phenotypic, can contribute to 
differential reactions to the same dosing regimen. Research efforts are directed toward 
predicting how individuals will respond to a certain therapeutic regimen, and 
optimizing the regimen correspondingly. The ‘body-on-a-chip’ approach, described in 
this thesis work, paves the way towards achieving this goal. It will be possible to 
observe the response of tissue biopsy samples obtained from individual patients, and 
optimize dosing regimen on patient-specific basis.  
To achieve this goal, several obstacles need to be overcome. The most critical 
of these is to reproduce authentic cell functions in vitro, such as the liver function for 
drug metabolism or the kidney for elimination of drugs and toxic wastes. Currently, 
there have been many research efforts to realize such ‘artificial organs’ in vitro, but 
this has not realized to a satisfactory level. Fortunately, with the advent of 
microfluidics and cells-on-a-chip technology, novel microscale ‘organ’ models are 
beginning to appear (Baudoin et al. 2007; Borenstein et al. 2007; Nahmias et al. 2007). 
In this perspective, characterization of the effect of microfluidic environment on the 
behavior of cells can provide important information. From our preliminary results, 
factors such as the encapsulating matrix, flow rate, and transport process seem to 
affect the behavior of cells, such as metabolic activity and response to drugs. Richer 
information about the effect of microfluidic environment on the cell behavior will 
foster the development of a more realistic μCCA, or ‘body-on-a-chip’.  
Secondly, high-throughput implementation of a μCCA will enable data 
collection at statistically meaningful level. However, a critical issue in microfluidic 
devices is the difficulty in the operation and high-throughput experimentation. What is 
particularly pertinent to a μCCA is that multiple cell types need to be seeded into a 
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device and the device must be sealed. This makes it impossible to seal the device with 
irreversible plasma bonding, the most commonly used method for sealing a 
microfluidic device. One solution is to incorporate a valve system, for example a 
pneumatic valve system, which will enable sealing the device first, and injecting the 
cell suspension. However, this approach will increase the complexity of the device and 
will render high-throughput operation difficult. A novel μCCA design is required, 
which will enable easier assembly and operation of multiple devices simultaneously. 
The new design described in chapter 6 partially addresses this issue, but more 
improvement is necessary to realize a true high-throughput implementation.  
Finally, the μCCA device allows novel experiments which would be 
impossible to perform in static, conventional in vitro systems. For example, PK-PD 
modeling described in chapter 2 showed that a pharmacokinetic modulating 
chemotherapy (PMC) can significantly enhance the effectiveness of 5-FU 
chemotherapy, simply by controlling the dosing strategy of the drugs. This has also 
been demonstrated in clinical studies (Muneoka et al., 2005). Further optimization of 
the dosing strategy would be costly and time consuming, because it would be difficult 
to reproduce such dosing schemes in vitro, and can be tested only in vivo. The ability 
of microfluidic systems such as a μCCA to precisely control the flow pattern would 
allow one to test even complex dosing schemes, such as time-dependent dosing of 
multiple drugs. Such an attempt would be more successful if combined with a 
mathematical modeling approach. In that perspective, information about the drugs and 
metabolites concentration from HPLC or MS analysis would allow construction of a 
more detailed mathematical model of the μCCA.  
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APPENDIX 
 
1. Equations for a PBPK model (chapter 2) 
 
Vi: Volume of organ i 
Qi: Flow rate out of organ i 
Cji: Concentration of a chemical j (FT, 5-FU or uracil) in organ i 
Pji: Partition coefficient of chemical j in organ i 
kabs,j: Absorption rate constant for a chemical j 
Vm,k,i: Maximum rate for enzyme k (CYP or DPD) in organ i 
Km,k,i: Michaelis-Menten kinetics constant for enzyme k in organ i 
CLj: Renal clearance rate of a chemical j 
Ki: Inhibition constant for degradation reaction of DPD by uracil in liver 
Ki_T: Inhibition constant for degradation reaction of DPD by uracil in tumor 
Ki_u: Inhibition constant for degradation reaction of DPD by 5-FU 
fb_i: Unbound free fraction of i in tissue 
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2. Equations for PD model (chapter 2) 
C: Number of cells 
CS: Number of sensitive cells  
CR: Number of resistant cells  
Css: Maximum cell number that can be reached 
kg: Cell growth rate 
kd: Cell death rate 
ksr: Rate of change of cell population from sensitive to resistant group 
krs: Rate of change of cell population from resistant to sensitive group 
Kmax: Maximum cell kill rate 
EC50: Michaelis constant 
τ: Mean transit time 
FU: Concentration of 5-FU 
Kn: nth transit compartment of the first set of transit compartments 
 
Ln: nth transit compartment of the second set of transit compartments 
 
Phase specific model 
SRSSSSS
S CCC)C/C1(C
dt
dC  Kkkk rssrg  
RRS
R CCC
dt
dC  drssr kkk  
 
  
Transit compartment model 
C)C/C1(C
dt
dC
SS  ng Kk  
FU
FU
50
max


EC
KK
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dt
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dt
d
32
3 KKK   
 ….. 
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1 nn
n KKK    
  
 
 
Dual transit compartment model 
CC)C/C1(C
dt
dC
SS  nng LKk  
11
1 /)(
dt
d KKK    
21
1 /)(
dt
d LLL   
1/)(dt
d
21
2 KKK    
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2 /)(
dt
d LLL   
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11 /)(dt
d nnn KKK     
21 /)(dt
d nnn LLL    
FU
FU
50
max


EC
KK  
FU
FU
'
50
'
max


EC
KL  
FU
FU
50
max


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3. Equations for a PBPK model (chapter 6) 
 
FU: 5-FU, U: uracil, B: blood, L: liver, T: tumor, M: marrow 
Ca,b: Concentration of a in compartment b.  
Va: Volume of compartment a 
Qa: Flow rate into compartment a   
 
VB · dCFU,Bdt ൌ QL · CFU,L ൅ QT · CFU,T ൅ QM · CFU,M െ QB · CFU,B 
VL · dCFU,Ldt ൌ QL · CFU,BെQL · CFU,L െ
V୫,FU · CFU,L · VL
K୫,FU · ሺ1 ൅ CU,LK୧,Uሻ ൅ CFU,L
 
VT · dCFU,Tdt ൌ QT · CFU,BെQT · CFU,T 
VM · dCFU,Mdt ൌ QM · CFU,BെQM · CFU,M 
VB · dCU,Bdt ൌ QL · CU,L ൅ QT · CU,T ൅ QM · CU,M െ QB · CU,B 
VL · dCU,Ldt ൌ QL · CU,BെQL · CU,L െ
V୫,U · CU,L · VL
K୫,U · ሺ1 ൅ CU,LK୧,FUሻ ൅ CU,L
 
VT · dCU,Tdt ൌ QT · CU,BെQT · CU,T 
VM · dCU,Mdt ൌ QM · CU,BെQM · CU,M 
 
 
4. Equations for a PD Model (chapter 6) 
 
dC1
dt ൌ k୥ · C1 · ൬1 െ
C1
CSS൰ െ C4 · C1 െ kୢ · C1 
dC2
dt ൌ ሺ
K୫ୟ୶ · FU
KCହ଴ ൅ FU െ C2ሻ/tau 
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dC3
dt ൌ ሺC2 െ C3ሻ/tau 
dC4
dt ൌ ሺC3 െ C4ሻ/tau 
 
Cn: Number of cells in the nth transit compartment. 
Kmax: Maximum rate of cell death progression 
KC50: Saturation constant  
FU: 5-FU 
tau: Time constant for cell death progression    
kd: Natural cell death rate 
CSS: Maximum cell number that can be reached 
Kg: Cell proliferation rate 
 
